#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Brain structural and functional dissociated patterns in schizophrenia
#Text=Background
#Text=Although previous studies found that aberrations in gray matter volume (GMV) and global functional connectivity density (gFCD) are important characteristics of schizophrenia, to the best of our knowledge no study to date has investigated the associations between the spatial distribution patterns of GMV and gFCD alterations.
1-1	0-5	Brain	_	
1-2	6-16	structural	_	
1-3	17-20	and	_	
1-4	21-31	functional	_	
1-5	32-43	dissociated	_	
1-6	44-52	patterns	_	
1-7	53-55	in	_	
1-8	56-69	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-9	70-80	Background	_	
1-10	81-89	Although	_	
1-11	90-98	previous	_	
1-12	99-106	studies	_	
1-13	107-112	found	_	
1-14	113-117	that	_	
1-15	118-129	aberrations	_	
1-16	130-132	in	_	
1-17	133-137	gray	_	
1-18	138-144	matter	_	
1-19	145-151	volume	_	
1-20	152-153	(	_	
1-21	153-156	GMV	_	
1-22	156-157	)	_	
1-23	158-161	and	_	
1-24	162-168	global	_	
1-25	169-179	functional	_	
1-26	180-192	connectivity	_	
1-27	193-200	density	_	
1-28	201-202	(	_	
1-29	202-206	gFCD	_	
1-30	206-207	)	_	
1-31	208-211	are	_	
1-32	212-221	important	_	
1-33	222-237	characteristics	_	
1-34	238-240	of	_	
1-35	241-254	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-36	254-255	,	_	
1-37	256-258	to	_	
1-38	259-262	the	_	
1-39	263-267	best	_	
1-40	268-270	of	_	
1-41	271-274	our	_	
1-42	275-284	knowledge	_	
1-43	285-287	no	_	
1-44	288-293	study	_	
1-45	294-296	to	_	
1-46	297-301	date	_	
1-47	302-305	has	_	
1-48	306-318	investigated	_	
1-49	319-322	the	_	
1-50	323-335	associations	_	
1-51	336-343	between	_	
1-52	344-347	the	_	
1-53	348-355	spatial	_	
1-54	356-368	distribution	_	
1-55	369-377	patterns	_	
1-56	378-380	of	_	
1-57	381-384	GMV	_	
1-58	385-388	and	_	
1-59	389-393	gFCD	_	
1-60	394-405	alterations	_	
1-61	405-406	.	_	

#Text=We investigated pattern changes in gFCD and GMV among patients with schizophrenia and their associated spatial distributions.
2-1	407-409	We	_	
2-2	410-422	investigated	_	
2-3	423-430	pattern	_	
2-4	431-438	changes	_	
2-5	439-441	in	_	
2-6	442-446	gFCD	_	
2-7	447-450	and	_	
2-8	451-454	GMV	_	
2-9	455-460	among	_	
2-10	461-469	patients	_	
2-11	470-474	with	_	
2-12	475-488	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
2-13	489-492	and	_	
2-14	493-498	their	_	
2-15	499-509	associated	_	
2-16	510-517	spatial	_	
2-17	518-531	distributions	_	
2-18	531-532	.	_	

#Text=Methods
#Text=Ninety-five patients with schizophrenia and 93 matched healthy controls underwent structural and resting-state functional MRI scanning to assess gFCD and GMV.
3-1	533-540	Methods	_	
3-2	541-552	Ninety-five	_	
3-3	553-561	patients	_	
3-4	562-566	with	_	
3-5	567-580	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
3-6	581-584	and	_	
3-7	585-587	93	_	
3-8	588-595	matched	_	
3-9	596-603	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-10	604-612	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-11	613-622	underwent	_	
3-12	623-633	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	
3-13	634-637	and	_	
3-14	638-651	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-15	652-662	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-16	663-666	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-17	667-675	scanning	_	
3-18	676-678	to	_	
3-19	679-685	assess	_	
3-20	686-690	gFCD	_	
3-21	691-694	and	_	
3-22	695-698	GMV	_	
3-23	698-699	.	_	

#Text=Results
#Text=We found that gFCD increased in the subcortical regions (caudate, pallidum, putamen, and thalami) and limbic system (left hippocampus and parahippocampus), and decreased in the posterior parieto-occipito-temporal cortices (postcentral gyri, occipital cortex, temporo-occipital conjunction, and inferior parietal lobule), in patients with schizophrenia.
4-1	700-707	Results	_	
4-2	708-710	We	_	
4-3	711-716	found	_	
4-4	717-721	that	_	
4-5	722-726	gFCD	_	
4-6	727-736	increased	_	
4-7	737-739	in	_	
4-8	740-743	the	_	
4-9	744-755	subcortical	_	
4-10	756-763	regions	_	
4-11	764-765	(	_	
4-12	765-772	caudate	_	
4-13	772-773	,	_	
4-14	774-782	pallidum	_	
4-15	782-783	,	_	
4-16	784-791	putamen	_	
4-17	791-792	,	_	
4-18	793-796	and	_	
4-19	797-804	thalami	_	
4-20	804-805	)	_	
4-21	806-809	and	_	
4-22	810-816	limbic	_	
4-23	817-823	system	_	
4-24	824-825	(	_	
4-25	825-829	left	_	
4-26	830-841	hippocampus	_	
4-27	842-845	and	_	
4-28	846-861	parahippocampus	_	
4-29	861-862	)	_	
4-30	862-863	,	_	
4-31	864-867	and	_	
4-32	868-877	decreased	_	
4-33	878-880	in	_	
4-34	881-884	the	_	
4-35	885-894	posterior	_	
4-36	895-920	parieto-occipito-temporal	_	
4-37	921-929	cortices	_	
4-38	930-931	(	_	
4-39	931-942	postcentral	_	
4-40	943-947	gyri	_	
4-41	947-948	,	_	
4-42	949-958	occipital	_	
4-43	959-965	cortex	_	
4-44	965-966	,	_	
4-45	967-984	temporo-occipital	_	
4-46	985-996	conjunction	_	
4-47	996-997	,	_	
4-48	998-1001	and	_	
4-49	1002-1010	inferior	_	
4-50	1011-1019	parietal	_	
4-51	1020-1026	lobule	_	
4-52	1026-1027	)	_	
4-53	1027-1028	,	_	
4-54	1029-1031	in	_	
4-55	1032-1040	patients	_	
4-56	1041-1045	with	_	
4-57	1046-1059	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
4-58	1059-1060	.	_	

#Text=By contrast, we found decreased GMV in brain regions including the frontal, parietal, temporal, occipital, cingulate cortices, and the insular, striatum, thalamus in these patients.
5-1	1061-1063	By	_	
5-2	1064-1072	contrast	_	
5-3	1072-1073	,	_	
5-4	1074-1076	we	_	
5-5	1077-1082	found	_	
5-6	1083-1092	decreased	_	
5-7	1093-1096	GMV	_	
5-8	1097-1099	in	_	
5-9	1100-1105	brain	_	
5-10	1106-1113	regions	_	
5-11	1114-1123	including	_	
5-12	1124-1127	the	_	
5-13	1128-1135	frontal	_	
5-14	1135-1136	,	_	
5-15	1137-1145	parietal	_	
5-16	1145-1146	,	_	
5-17	1147-1155	temporal	_	
5-18	1155-1156	,	_	
5-19	1157-1166	occipital	_	
5-20	1166-1167	,	_	
5-21	1168-1177	cingulate	_	
5-22	1178-1186	cortices	_	
5-23	1186-1187	,	_	
5-24	1188-1191	and	_	
5-25	1192-1195	the	_	
5-26	1196-1203	insular	_	
5-27	1203-1204	,	_	
5-28	1205-1213	striatum	_	
5-29	1213-1214	,	_	
5-30	1215-1223	thalamus	_	
5-31	1224-1226	in	_	
5-32	1227-1232	these	_	
5-33	1233-1241	patients	_	
5-34	1241-1242	.	_	

#Text=Increased gFCD primarily occurred in subcortical regions including the basal ganglia and some regions of the limbic system.
6-1	1243-1252	Increased	_	
6-2	1253-1257	gFCD	_	
6-3	1258-1267	primarily	_	
6-4	1268-1276	occurred	_	
6-5	1277-1279	in	_	
6-6	1280-1291	subcortical	_	
6-7	1292-1299	regions	_	
6-8	1300-1309	including	_	
6-9	1310-1313	the	_	
6-10	1314-1319	basal	_	
6-11	1320-1327	ganglia	_	
6-12	1328-1331	and	_	
6-13	1332-1336	some	_	
6-14	1337-1344	regions	_	
6-15	1345-1347	of	_	
6-16	1348-1351	the	_	
6-17	1352-1358	limbic	_	
6-18	1359-1365	system	_	
6-19	1365-1366	.	_	

#Text=Decreased gFCD appeared primarily in the cortical regions.
7-1	1367-1376	Decreased	_	
7-2	1377-1381	gFCD	_	
7-3	1382-1390	appeared	_	
7-4	1391-1400	primarily	_	
7-5	1401-1403	in	_	
7-6	1404-1407	the	_	
7-7	1408-1416	cortical	_	
7-8	1417-1424	regions	_	
7-9	1424-1425	.	_	

#Text=There were no statistically significant correlations between changes in gFCD and GMV, and their spatial distribution patterns, in different regions.
8-1	1426-1431	There	_	
8-2	1432-1436	were	_	
8-3	1437-1439	no	_	
8-4	1440-1453	statistically	_	
8-5	1454-1465	significant	_	
8-6	1466-1478	correlations	_	
8-7	1479-1486	between	_	
8-8	1487-1494	changes	_	
8-9	1495-1497	in	_	
8-10	1498-1502	gFCD	_	
8-11	1503-1506	and	_	
8-12	1507-1510	GMV	_	
8-13	1510-1511	,	_	
8-14	1512-1515	and	_	
8-15	1516-1521	their	_	
8-16	1522-1529	spatial	_	
8-17	1530-1542	distribution	_	
8-18	1543-1551	patterns	_	
8-19	1551-1552	,	_	
8-20	1553-1555	in	_	
8-21	1556-1565	different	_	
8-22	1566-1573	regions	_	
8-23	1573-1574	.	_	

#Text=Conclusions
#Text=Our findings indicate that gFCD and GMV are both perturbed in multiple brain regions in schizophrenia. gFCD and GMV consistently decreased in the cortical regions, with the exception of the Supplementary Motor Area (SMA).
9-1	1575-1586	Conclusions	_	
9-2	1587-1590	Our	_	
9-3	1591-1599	findings	_	
9-4	1600-1608	indicate	_	
9-5	1609-1613	that	_	
9-6	1614-1618	gFCD	_	
9-7	1619-1622	and	_	
9-8	1623-1626	GMV	_	
9-9	1627-1630	are	_	
9-10	1631-1635	both	_	
9-11	1636-1645	perturbed	_	
9-12	1646-1648	in	_	
9-13	1649-1657	multiple	_	
9-14	1658-1663	brain	_	
9-15	1664-1671	regions	_	
9-16	1672-1674	in	_	
9-17	1675-1688	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
9-18	1688-1689	.	_	
9-19	1690-1694	gFCD	_	
9-20	1695-1698	and	_	
9-21	1699-1702	GMV	_	
9-22	1703-1715	consistently	_	
9-23	1716-1725	decreased	_	
9-24	1726-1728	in	_	
9-25	1729-1732	the	_	
9-26	1733-1741	cortical	_	
9-27	1742-1749	regions	_	
9-28	1749-1750	,	_	
9-29	1751-1755	with	_	
9-30	1756-1759	the	_	
9-31	1760-1769	exception	_	
9-32	1770-1772	of	_	
9-33	1773-1776	the	_	
9-34	1777-1790	Supplementary	_	
9-35	1791-1796	Motor	_	
9-36	1797-1801	Area	_	
9-37	1802-1803	(	_	
9-38	1803-1806	SMA	_	
9-39	1806-1807	)	_	
9-40	1807-1808	.	_	

#Text=However, in the sub-cortical regions, the alterations of gFCD and GMV showed the opposite pattern, with increased gFCD and decreased GMV simultaneously observed in these regions.
10-1	1809-1816	However	_	
10-2	1816-1817	,	_	
10-3	1818-1820	in	_	
10-4	1821-1824	the	_	
10-5	1825-1837	sub-cortical	_	
10-6	1838-1845	regions	_	
10-7	1845-1846	,	_	
10-8	1847-1850	the	_	
10-9	1851-1862	alterations	_	
10-10	1863-1865	of	_	
10-11	1866-1870	gFCD	_	
10-12	1871-1874	and	_	
10-13	1875-1878	GMV	_	
10-14	1879-1885	showed	_	
10-15	1886-1889	the	_	
10-16	1890-1898	opposite	_	
10-17	1899-1906	pattern	_	
10-18	1906-1907	,	_	
10-19	1908-1912	with	_	
10-20	1913-1922	increased	_	
10-21	1923-1927	gFCD	_	
10-22	1928-1931	and	_	
10-23	1932-1941	decreased	_	
10-24	1942-1945	GMV	_	
10-25	1946-1960	simultaneously	_	
10-26	1961-1969	observed	_	
10-27	1970-1972	in	_	
10-28	1973-1978	these	_	
10-29	1979-1986	regions	_	
10-30	1986-1987	.	_	

#Text=Overall, our findings suggest that structural and functional alterations appear to contribute independently to the neurobiology of schizophrenia.
11-1	1988-1995	Overall	_	
11-2	1995-1996	,	_	
11-3	1997-2000	our	_	
11-4	2001-2009	findings	_	
11-5	2010-2017	suggest	_	
11-6	2018-2022	that	_	
11-7	2023-2033	structural	_	
11-8	2034-2037	and	_	
11-9	2038-2048	functional	_	
11-10	2049-2060	alterations	_	
11-11	2061-2067	appear	_	
11-12	2068-2070	to	_	
11-13	2071-2081	contribute	_	
11-14	2082-2095	independently	_	
11-15	2096-2098	to	_	
11-16	2099-2102	the	_	
11-17	2103-2115	neurobiology	_	
11-18	2116-2118	of	_	
11-19	2119-2132	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
11-20	2132-2133	.	_	

#Text=Background
#Text=In the past few decades, numerous MRI studies have reported that schizophrenia is associated with widespread brain structural and functional alterations.
12-1	2134-2144	Background	_	
12-2	2145-2147	In	_	
12-3	2148-2151	the	_	
12-4	2152-2156	past	_	
12-5	2157-2160	few	_	
12-6	2161-2168	decades	_	
12-7	2168-2169	,	_	
12-8	2170-2178	numerous	_	
12-9	2179-2182	MRI	_	
12-10	2183-2190	studies	_	
12-11	2191-2195	have	_	
12-12	2196-2204	reported	_	
12-13	2205-2209	that	_	
12-14	2210-2223	schizophrenia	_	
12-15	2224-2226	is	_	
12-16	2227-2237	associated	_	
12-17	2238-2242	with	_	
12-18	2243-2253	widespread	_	
12-19	2254-2259	brain	_	
12-20	2260-2270	structural	_	
12-21	2271-2274	and	_	
12-22	2275-2285	functional	_	
12-23	2286-2297	alterations	_	
12-24	2297-2298	.	_	

#Text=Previous studies have consistently confirmed that patients with schizophrenia have a diffused gray matter volume (GMV) decreases and that this is predominantly located in various cortical and subcortical brain regions.
13-1	2299-2307	Previous	_	
13-2	2308-2315	studies	_	
13-3	2316-2320	have	_	
13-4	2321-2333	consistently	_	
13-5	2334-2343	confirmed	_	
13-6	2344-2348	that	_	
13-7	2349-2357	patients	_	
13-8	2358-2362	with	_	
13-9	2363-2376	schizophrenia	_	
13-10	2377-2381	have	_	
13-11	2382-2383	a	_	
13-12	2384-2392	diffused	_	
13-13	2393-2397	gray	_	
13-14	2398-2404	matter	_	
13-15	2405-2411	volume	_	
13-16	2412-2413	(	_	
13-17	2413-2416	GMV	_	
13-18	2416-2417	)	_	
13-19	2418-2427	decreases	_	
13-20	2428-2431	and	_	
13-21	2432-2436	that	_	
13-22	2437-2441	this	_	
13-23	2442-2444	is	_	
13-24	2445-2458	predominantly	_	
13-25	2459-2466	located	_	
13-26	2467-2469	in	_	
13-27	2470-2477	various	_	
13-28	2478-2486	cortical	_	
13-29	2487-2490	and	_	
13-30	2491-2502	subcortical	_	
13-31	2503-2508	brain	_	
13-32	2509-2516	regions	_	
13-33	2516-2517	.	_	

#Text=The overwhelming majority of studies have demonstrated that the frontal, temporal, and parietal lobes, cingulate cortex, hippocampus, thalami, and basal ganglia are key regions of GMV decrease in schizophrenia.
14-1	2518-2521	The	_	
14-2	2522-2534	overwhelming	_	
14-3	2535-2543	majority	_	
14-4	2544-2546	of	_	
14-5	2547-2554	studies	_	
14-6	2555-2559	have	_	
14-7	2560-2572	demonstrated	_	
14-8	2573-2577	that	_	
14-9	2578-2581	the	_	
14-10	2582-2589	frontal	_	
14-11	2589-2590	,	_	
14-12	2591-2599	temporal	_	
14-13	2599-2600	,	_	
14-14	2601-2604	and	_	
14-15	2605-2613	parietal	_	
14-16	2614-2619	lobes	_	
14-17	2619-2620	,	_	
14-18	2621-2630	cingulate	_	
14-19	2631-2637	cortex	_	
14-20	2637-2638	,	_	
14-21	2639-2650	hippocampus	_	
14-22	2650-2651	,	_	
14-23	2652-2659	thalami	_	
14-24	2659-2660	,	_	
14-25	2661-2664	and	_	
14-26	2665-2670	basal	_	
14-27	2671-2678	ganglia	_	
14-28	2679-2682	are	_	
14-29	2683-2686	key	_	
14-30	2687-2694	regions	_	
14-31	2695-2697	of	_	
14-32	2698-2701	GMV	_	
14-33	2702-2710	decrease	_	
14-34	2711-2713	in	_	
14-35	2714-2727	schizophrenia	_	
14-36	2727-2728	.	_	

#Text=Echoing the alterations in brain structure in schizophrenia, considerable fMRI evidence suggests that functional alterations characterized by hyper-functional activity in sub-cortical regions (mainly in the basal ganglia and some regions of limbic system) with coexistent hypo- or hyper-functional activity in cortical regions occur in schizophrenia.
15-1	2729-2736	Echoing	_	
15-2	2737-2740	the	_	
15-3	2741-2752	alterations	_	
15-4	2753-2755	in	_	
15-5	2756-2761	brain	_	
15-6	2762-2771	structure	_	
15-7	2772-2774	in	_	
15-8	2775-2788	schizophrenia	_	
15-9	2788-2789	,	_	
15-10	2790-2802	considerable	_	
15-11	2803-2807	fMRI	_	
15-12	2808-2816	evidence	_	
15-13	2817-2825	suggests	_	
15-14	2826-2830	that	_	
15-15	2831-2841	functional	_	
15-16	2842-2853	alterations	_	
15-17	2854-2867	characterized	_	
15-18	2868-2870	by	_	
15-19	2871-2887	hyper-functional	_	
15-20	2888-2896	activity	_	
15-21	2897-2899	in	_	
15-22	2900-2912	sub-cortical	_	
15-23	2913-2920	regions	_	
15-24	2921-2922	(	_	
15-25	2922-2928	mainly	_	
15-26	2929-2931	in	_	
15-27	2932-2935	the	_	
15-28	2936-2941	basal	_	
15-29	2942-2949	ganglia	_	
15-30	2950-2953	and	_	
15-31	2954-2958	some	_	
15-32	2959-2966	regions	_	
15-33	2967-2969	of	_	
15-34	2970-2976	limbic	_	
15-35	2977-2983	system	_	
15-36	2983-2984	)	_	
15-37	2985-2989	with	_	
15-38	2990-3000	coexistent	_	
15-39	3001-3005	hypo	_	
15-40	3005-3006	-	_	
15-41	3007-3009	or	_	
15-42	3010-3026	hyper-functional	_	
15-43	3027-3035	activity	_	
15-44	3036-3038	in	_	
15-45	3039-3047	cortical	_	
15-46	3048-3055	regions	_	
15-47	3056-3061	occur	_	
15-48	3062-3064	in	_	
15-49	3065-3078	schizophrenia	_	
15-50	3078-3079	.	_	

#Text=The frontal, temporal and parietal lobes, cingulate gyrus, occipital gyrus, hippocampus, and thalami are key regions of functional alteration in schizophrenia.
16-1	3080-3083	The	_	
16-2	3084-3091	frontal	_	
16-3	3091-3092	,	_	
16-4	3093-3101	temporal	_	
16-5	3102-3105	and	_	
16-6	3106-3114	parietal	_	
16-7	3115-3120	lobes	_	
16-8	3120-3121	,	_	
16-9	3122-3131	cingulate	_	
16-10	3132-3137	gyrus	_	
16-11	3137-3138	,	_	
16-12	3139-3148	occipital	_	
16-13	3149-3154	gyrus	_	
16-14	3154-3155	,	_	
16-15	3156-3167	hippocampus	_	
16-16	3167-3168	,	_	
16-17	3169-3172	and	_	
16-18	3173-3180	thalami	_	
16-19	3181-3184	are	_	
16-20	3185-3188	key	_	
16-21	3189-3196	regions	_	
16-22	3197-3199	of	_	
16-23	3200-3210	functional	_	
16-24	3211-3221	alteration	_	
16-25	3222-3224	in	_	
16-26	3225-3238	schizophrenia	_	
16-27	3238-3239	.	_	

#Text=According to previous studies, whole-brain measurement (VBM) is an unbiased and fully automated method used to investigate GMV alterations, which can be used as structural biomarkers for clinical and research applications in psychiatric disorders.
17-1	3240-3249	According	_	
17-2	3250-3252	to	_	
17-3	3253-3261	previous	_	
17-4	3262-3269	studies	_	
17-5	3269-3270	,	_	
17-6	3271-3282	whole-brain	_	
17-7	3283-3294	measurement	_	
17-8	3295-3296	(	_	
17-9	3296-3299	VBM	_	
17-10	3299-3300	)	_	
17-11	3301-3303	is	_	
17-12	3304-3306	an	_	
17-13	3307-3315	unbiased	_	
17-14	3316-3319	and	_	
17-15	3320-3325	fully	_	
17-16	3326-3335	automated	_	
17-17	3336-3342	method	_	
17-18	3343-3347	used	_	
17-19	3348-3350	to	_	
17-20	3351-3362	investigate	_	
17-21	3363-3366	GMV	_	
17-22	3367-3378	alterations	_	
17-23	3378-3379	,	_	
17-24	3380-3385	which	_	
17-25	3386-3389	can	_	
17-26	3390-3392	be	_	
17-27	3393-3397	used	_	
17-28	3398-3400	as	_	
17-29	3401-3411	structural	_	
17-30	3412-3422	biomarkers	_	
17-31	3423-3426	for	_	
17-32	3427-3435	clinical	_	
17-33	3436-3439	and	_	
17-34	3440-3448	research	_	
17-35	3449-3461	applications	_	
17-36	3462-3464	in	_	
17-37	3465-3476	psychiatric	_	
17-38	3477-3486	disorders	_	
17-39	3486-3487	.	_	

#Text=Functional connectivity density mapping (FCDM) is a voxel-wise data-driven method that measures the number of functional connections between a given voxel and other voxels in the whole brain, producing a measure of global functional connectivity density (gFCD). gFCD has been developed to measure the number of resting-state functional connections of a given voxel with all other voxels in the entire brain and reflects a one-to-many relationship.
18-1	3488-3498	Functional	_	
18-2	3499-3511	connectivity	_	
18-3	3512-3519	density	_	
18-4	3520-3527	mapping	_	
18-5	3528-3529	(	_	
18-6	3529-3533	FCDM	_	
18-7	3533-3534	)	_	
18-8	3535-3537	is	_	
18-9	3538-3539	a	_	
18-10	3540-3550	voxel-wise	_	
18-11	3551-3562	data-driven	_	
18-12	3563-3569	method	_	
18-13	3570-3574	that	_	
18-14	3575-3583	measures	_	
18-15	3584-3587	the	_	
18-16	3588-3594	number	_	
18-17	3595-3597	of	_	
18-18	3598-3608	functional	_	
18-19	3609-3620	connections	_	
18-20	3621-3628	between	_	
18-21	3629-3630	a	_	
18-22	3631-3636	given	_	
18-23	3637-3642	voxel	_	
18-24	3643-3646	and	_	
18-25	3647-3652	other	_	
18-26	3653-3659	voxels	_	
18-27	3660-3662	in	_	
18-28	3663-3666	the	_	
18-29	3667-3672	whole	_	
18-30	3673-3678	brain	_	
18-31	3678-3679	,	_	
18-32	3680-3689	producing	_	
18-33	3690-3691	a	_	
18-34	3692-3699	measure	_	
18-35	3700-3702	of	_	
18-36	3703-3709	global	_	
18-37	3710-3720	functional	_	
18-38	3721-3733	connectivity	_	
18-39	3734-3741	density	_	
18-40	3742-3743	(	_	
18-41	3743-3747	gFCD	_	
18-42	3747-3748	)	_	
18-43	3748-3749	.	_	
18-44	3750-3754	gFCD	_	
18-45	3755-3758	has	_	
18-46	3759-3763	been	_	
18-47	3764-3773	developed	_	
18-48	3774-3776	to	_	
18-49	3777-3784	measure	_	
18-50	3785-3788	the	_	
18-51	3789-3795	number	_	
18-52	3796-3798	of	_	
18-53	3799-3812	resting-state	_	
18-54	3813-3823	functional	_	
18-55	3824-3835	connections	_	
18-56	3836-3838	of	_	
18-57	3839-3840	a	_	
18-58	3841-3846	given	_	
18-59	3847-3852	voxel	_	
18-60	3853-3857	with	_	
18-61	3858-3861	all	_	
18-62	3862-3867	other	_	
18-63	3868-3874	voxels	_	
18-64	3875-3877	in	_	
18-65	3878-3881	the	_	
18-66	3882-3888	entire	_	
18-67	3889-3894	brain	_	
18-68	3895-3898	and	_	
18-69	3899-3907	reflects	_	
18-70	3908-3909	a	_	
18-71	3910-3921	one-to-many	_	
18-72	3922-3934	relationship	_	
18-73	3934-3935	.	_	

#Text=While traditional functional connectivity mainly measures the connectivity (FC) strength between two voxels or regions or networks, which reflects a one-to-one relationship.
19-1	3936-3941	While	_	
19-2	3942-3953	traditional	_	
19-3	3954-3964	functional	_	
19-4	3965-3977	connectivity	_	
19-5	3978-3984	mainly	_	
19-6	3985-3993	measures	_	
19-7	3994-3997	the	_	
19-8	3998-4010	connectivity	_	
19-9	4011-4012	(	_	
19-10	4012-4014	FC	_	
19-11	4014-4015	)	_	
19-12	4016-4024	strength	_	
19-13	4025-4032	between	_	
19-14	4033-4036	two	_	
19-15	4037-4043	voxels	_	
19-16	4044-4046	or	_	
19-17	4047-4054	regions	_	
19-18	4055-4057	or	_	
19-19	4058-4066	networks	_	
19-20	4066-4067	,	_	
19-21	4068-4073	which	_	
19-22	4074-4082	reflects	_	
19-23	4083-4084	a	_	
19-24	4085-4095	one-to-one	_	
19-25	4096-4108	relationship	_	
19-26	4108-4109	.	_	

#Text=Compared to traditional FC, gFCD can reflect the functional activity aberrant from another perspectives, a recent study have shown that gFCD is also a biomarker for psychiatric disorders.
20-1	4110-4118	Compared	_	
20-2	4119-4121	to	_	
20-3	4122-4133	traditional	_	
20-4	4134-4136	FC	_	
20-5	4136-4137	,	_	
20-6	4138-4142	gFCD	_	
20-7	4143-4146	can	_	
20-8	4147-4154	reflect	_	
20-9	4155-4158	the	_	
20-10	4159-4169	functional	_	
20-11	4170-4178	activity	_	
20-12	4179-4187	aberrant	_	
20-13	4188-4192	from	_	
20-14	4193-4200	another	_	
20-15	4201-4213	perspectives	_	
20-16	4213-4214	,	_	
20-17	4215-4216	a	_	
20-18	4217-4223	recent	_	
20-19	4224-4229	study	_	
20-20	4230-4234	have	_	
20-21	4235-4240	shown	_	
20-22	4241-4245	that	_	
20-23	4246-4250	gFCD	_	
20-24	4251-4253	is	_	
20-25	4254-4258	also	_	
20-26	4259-4260	a	_	
20-27	4261-4270	biomarker	_	
20-28	4271-4274	for	_	
20-29	4275-4286	psychiatric	_	
20-30	4287-4296	disorders	_	
20-31	4296-4297	.	_	

#Text=Although previous studies found that aberrations in GMV and gFCD are important characteristics of schizophrenia, to the best of our knowledge no study to date has investigated the associations between the spatial distribution patterns of GMV and gFCD alterations.
21-1	4298-4306	Although	_	
21-2	4307-4315	previous	_	
21-3	4316-4323	studies	_	
21-4	4324-4329	found	_	
21-5	4330-4334	that	_	
21-6	4335-4346	aberrations	_	
21-7	4347-4349	in	_	
21-8	4350-4353	GMV	_	
21-9	4354-4357	and	_	
21-10	4358-4362	gFCD	_	
21-11	4363-4366	are	_	
21-12	4367-4376	important	_	
21-13	4377-4392	characteristics	_	
21-14	4393-4395	of	_	
21-15	4396-4409	schizophrenia	_	
21-16	4409-4410	,	_	
21-17	4411-4413	to	_	
21-18	4414-4417	the	_	
21-19	4418-4422	best	_	
21-20	4423-4425	of	_	
21-21	4426-4429	our	_	
21-22	4430-4439	knowledge	_	
21-23	4440-4442	no	_	
21-24	4443-4448	study	_	
21-25	4449-4451	to	_	
21-26	4452-4456	date	_	
21-27	4457-4460	has	_	
21-28	4461-4473	investigated	_	
21-29	4474-4477	the	_	
21-30	4478-4490	associations	_	
21-31	4491-4498	between	_	
21-32	4499-4502	the	_	
21-33	4503-4510	spatial	_	
21-34	4511-4523	distribution	_	
21-35	4524-4532	patterns	_	
21-36	4533-4535	of	_	
21-37	4536-4539	GMV	_	
21-38	4540-4543	and	_	
21-39	4544-4548	gFCD	_	
21-40	4549-4560	alterations	_	
21-41	4560-4561	.	_	

#Text=Therefore, in the present study we aimed to investigate the alterations in GMV and gFCD, and their spatial distribution patterns in patients with schizophrenia, using VBM and FCDM.
22-1	4562-4571	Therefore	_	
22-2	4571-4572	,	_	
22-3	4573-4575	in	_	
22-4	4576-4579	the	_	
22-5	4580-4587	present	_	
22-6	4588-4593	study	_	
22-7	4594-4596	we	_	
22-8	4597-4602	aimed	_	
22-9	4603-4605	to	_	
22-10	4606-4617	investigate	_	
22-11	4618-4621	the	_	
22-12	4622-4633	alterations	_	
22-13	4634-4636	in	_	
22-14	4637-4640	GMV	_	
22-15	4641-4644	and	_	
22-16	4645-4649	gFCD	_	
22-17	4649-4650	,	_	
22-18	4651-4654	and	_	
22-19	4655-4660	their	_	
22-20	4661-4668	spatial	_	
22-21	4669-4681	distribution	_	
22-22	4682-4690	patterns	_	
22-23	4691-4693	in	_	
22-24	4694-4702	patients	_	
22-25	4703-4707	with	_	
22-26	4708-4721	schizophrenia	_	
22-27	4721-4722	,	_	
22-28	4723-4728	using	_	
22-29	4729-4732	VBM	_	
22-30	4733-4736	and	_	
22-31	4737-4741	FCDM	_	
22-32	4741-4742	.	_	

#Text=Several previous studies reported that anatomical and functional brain aberrant are significantly dissociated with schizophrenia, anatomical aberrant has been most robust within thalamo-cortical regions, while functional aberrant has been most pronounced in fronto-parietal and default-mode networks regions.
23-1	4743-4750	Several	_	
23-2	4751-4759	previous	_	
23-3	4760-4767	studies	_	
23-4	4768-4776	reported	_	
23-5	4777-4781	that	_	
23-6	4782-4792	anatomical	_	
23-7	4793-4796	and	_	
23-8	4797-4807	functional	_	
23-9	4808-4813	brain	_	
23-10	4814-4822	aberrant	_	
23-11	4823-4826	are	_	
23-12	4827-4840	significantly	_	
23-13	4841-4852	dissociated	_	
23-14	4853-4857	with	_	
23-15	4858-4871	schizophrenia	_	
23-16	4871-4872	,	_	
23-17	4873-4883	anatomical	_	
23-18	4884-4892	aberrant	_	
23-19	4893-4896	has	_	
23-20	4897-4901	been	_	
23-21	4902-4906	most	_	
23-22	4907-4913	robust	_	
23-23	4914-4920	within	_	
23-24	4921-4937	thalamo-cortical	_	
23-25	4938-4945	regions	_	
23-26	4945-4946	,	_	
23-27	4947-4952	while	_	
23-28	4953-4963	functional	_	
23-29	4964-4972	aberrant	_	
23-30	4973-4976	has	_	
23-31	4977-4981	been	_	
23-32	4982-4986	most	_	
23-33	4987-4997	pronounced	_	
23-34	4998-5000	in	_	
23-35	5001-5016	fronto-parietal	_	
23-36	5017-5020	and	_	
23-37	5021-5033	default-mode	_	
23-38	5034-5042	networks	_	
23-39	5043-5050	regions	_	
23-40	5050-5051	.	_	

#Text=More importantly, the spatial and temporal distributions of anatomical and functional alterations are uncorrelated and the aberrant patterns are also inconsistent or even contradictory, demonstrate a “distinct patterns”.
24-1	5052-5056	More	_	
24-2	5057-5068	importantly	_	
24-3	5068-5069	,	_	
24-4	5070-5073	the	_	
24-5	5074-5081	spatial	_	
24-6	5082-5085	and	_	
24-7	5086-5094	temporal	_	
24-8	5095-5108	distributions	_	
24-9	5109-5111	of	_	
24-10	5112-5122	anatomical	_	
24-11	5123-5126	and	_	
24-12	5127-5137	functional	_	
24-13	5138-5149	alterations	_	
24-14	5150-5153	are	_	
24-15	5154-5166	uncorrelated	_	
24-16	5167-5170	and	_	
24-17	5171-5174	the	_	
24-18	5175-5183	aberrant	_	
24-19	5184-5192	patterns	_	
24-20	5193-5196	are	_	
24-21	5197-5201	also	_	
24-22	5202-5214	inconsistent	_	
24-23	5215-5217	or	_	
24-24	5218-5222	even	_	
24-25	5223-5236	contradictory	_	
24-26	5236-5237	,	_	
24-27	5238-5249	demonstrate	_	
24-28	5250-5251	a	_	
24-29	5252-5253	“	_	
24-30	5253-5261	distinct	_	
24-31	5262-5270	patterns	_	
24-32	5270-5271	”	_	
24-33	5271-5272	.	_	

#Text=Based on these findings, we hypothesized that gFCD and GMV would be altered in patients with schizophrenia compared with matched healthy controls.
25-1	5273-5278	Based	_	
25-2	5279-5281	on	_	
25-3	5282-5287	these	_	
25-4	5288-5296	findings	_	
25-5	5296-5297	,	_	
25-6	5298-5300	we	_	
25-7	5301-5313	hypothesized	_	
25-8	5314-5318	that	_	
25-9	5319-5323	gFCD	_	
25-10	5324-5327	and	_	
25-11	5328-5331	GMV	_	
25-12	5332-5337	would	_	
25-13	5338-5340	be	_	
25-14	5341-5348	altered	_	
25-15	5349-5351	in	_	
25-16	5352-5360	patients	_	
25-17	5361-5365	with	_	
25-18	5366-5379	schizophrenia	_	
25-19	5380-5388	compared	_	
25-20	5389-5393	with	_	
25-21	5394-5401	matched	_	
25-22	5402-5409	healthy	_	
25-23	5410-5418	controls	_	
25-24	5418-5419	.	_	

#Text=We also hypothesized that gFCD and GMV would both be affected in particular brain regions but that their spatial distributions and aberrant patterns (increased or decreased) are also unrelated, or even more complex.
26-1	5420-5422	We	_	
26-2	5423-5427	also	_	
26-3	5428-5440	hypothesized	_	
26-4	5441-5445	that	_	
26-5	5446-5450	gFCD	_	
26-6	5451-5454	and	_	
26-7	5455-5458	GMV	_	
26-8	5459-5464	would	_	
26-9	5465-5469	both	_	
26-10	5470-5472	be	_	
26-11	5473-5481	affected	_	
26-12	5482-5484	in	_	
26-13	5485-5495	particular	_	
26-14	5496-5501	brain	_	
26-15	5502-5509	regions	_	
26-16	5510-5513	but	_	
26-17	5514-5518	that	_	
26-18	5519-5524	their	_	
26-19	5525-5532	spatial	_	
26-20	5533-5546	distributions	_	
26-21	5547-5550	and	_	
26-22	5551-5559	aberrant	_	
26-23	5560-5568	patterns	_	
26-24	5569-5570	(	_	
26-25	5570-5579	increased	_	
26-26	5580-5582	or	_	
26-27	5583-5592	decreased	_	
26-28	5592-5593	)	_	
26-29	5594-5597	are	_	
26-30	5598-5602	also	_	
26-31	5603-5612	unrelated	_	
26-32	5612-5613	,	_	
26-33	5614-5616	or	_	
26-34	5617-5621	even	_	
26-35	5622-5626	more	_	
26-36	5627-5634	complex	_	
26-37	5634-5635	.	_	

#Text=Methods
#Text=Subjects
#Text=Flow chart of the participants
#Text=A total of 200 right-handed subjects participated in the study, including 98 patients with schizophrenia and 102 healthy controls.
27-1	5636-5643	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
27-2	5644-5652	Subjects	_	
27-3	5653-5657	Flow	_	
27-4	5658-5663	chart	_	
27-5	5664-5666	of	_	
27-6	5667-5670	the	_	
27-7	5671-5683	participants	_	
27-8	5684-5685	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-9	5686-5691	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-10	5692-5694	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-11	5695-5698	200	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-12	5699-5711	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-13	5712-5720	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-14	5721-5733	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-15	5734-5736	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-16	5737-5740	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-17	5741-5746	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-18	5746-5747	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-19	5748-5757	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-20	5758-5760	98	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-21	5761-5769	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-22	5770-5774	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-23	5775-5788	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
27-24	5789-5792	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-25	5793-5796	102	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-26	5797-5804	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
27-27	5805-5813	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
27-28	5813-5814	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	

#Text=The patients were recruited from Tianjin Aning Hospital and Tianjn Anding Hospital and the healthy controls were recruited from the hospital staff or community residents.
28-1	5815-5818	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-2	5819-5827	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-3	5828-5832	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-4	5833-5842	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-5	5843-5847	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-6	5848-5855	Tianjin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-7	5856-5861	Aning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-8	5862-5870	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-9	5871-5874	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-10	5875-5881	Tianjn	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-11	5882-5888	Anding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-12	5889-5897	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-13	5898-5901	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-14	5902-5905	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-15	5906-5913	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
28-16	5914-5922	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
28-17	5923-5927	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-18	5928-5937	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-19	5938-5942	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-20	5943-5946	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-21	5947-5955	hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-22	5956-5961	staff	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-23	5962-5964	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-24	5965-5974	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-25	5975-5984	residents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
28-26	5984-5985	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=Patient diagnoses and illness duration were determined by the consensus of two senior psychiatrists using the Structured Interview for DSM-IV Axis I Disorder (SCID).
29-1	5986-5993	Patient	_	
29-2	5994-6003	diagnoses	_	
29-3	6004-6007	and	_	
29-4	6008-6015	illness	_	
29-5	6016-6024	duration	_	
29-6	6025-6029	were	_	
29-7	6030-6040	determined	_	
29-8	6041-6043	by	_	
29-9	6044-6047	the	_	
29-10	6048-6057	consensus	_	
29-11	6058-6060	of	_	
29-12	6061-6064	two	_	
29-13	6065-6071	senior	_	
29-14	6072-6085	psychiatrists	_	
29-15	6086-6091	using	_	
29-16	6092-6095	the	_	
29-17	6096-6106	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
29-18	6107-6116	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
29-19	6117-6120	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
29-20	6121-6127	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
29-21	6128-6132	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
29-22	6133-6134	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
29-23	6135-6143	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
29-24	6144-6145	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
29-25	6145-6149	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
29-26	6149-6150	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
29-27	6150-6151	.	_	

#Text=All healthy controls were screened using the non-patient edition of the SCID to confirm a lifetime absence of psychiatric illnesses.
30-1	6152-6155	All	_	
30-2	6156-6163	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
30-3	6164-6172	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
30-4	6173-6177	were	_	
30-5	6178-6186	screened	_	
30-6	6187-6192	using	_	
30-7	6193-6196	the	_	
30-8	6197-6208	non-patient	_	
30-9	6209-6216	edition	_	
30-10	6217-6219	of	_	
30-11	6220-6223	the	_	
30-12	6224-6228	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	
30-13	6229-6231	to	_	
30-14	6232-6239	confirm	_	
30-15	6240-6241	a	_	
30-16	6242-6250	lifetime	_	
30-17	6251-6258	absence	_	
30-18	6259-6261	of	_	
30-19	6262-6273	psychiatric	_	
30-20	6274-6283	illnesses	_	
30-21	6283-6284	.	_	

#Text=Healthy controls were interviewed to exclude individuals with a known history of psychiatric illness in first-degree relatives.
31-1	6285-6292	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
31-2	6293-6301	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
31-3	6302-6306	were	_	
31-4	6307-6318	interviewed	_	
31-5	6319-6321	to	_	
31-6	6322-6329	exclude	_	
31-7	6330-6341	individuals	_	
31-8	6342-6346	with	_	
31-9	6347-6348	a	_	
31-10	6349-6354	known	_	
31-11	6355-6362	history	_	
31-12	6363-6365	of	_	
31-13	6366-6377	psychiatric	_	
31-14	6378-6385	illness	_	
31-15	6386-6388	in	_	
31-16	6389-6401	first-degree	_	
31-17	6402-6411	relatives	_	
31-18	6411-6412	.	_	

#Text=Exclusion criteria for all subjects were a history of head trauma with consciousness disturbances lasting more than 5 min, a history of substance abuse, pregnancy, or any physical illness, such as cardiovascular disease and neurological disorders, as diagnosed by interview or a review of their medical records.
32-1	6413-6422	Exclusion	_	
32-2	6423-6431	criteria	_	
32-3	6432-6435	for	_	
32-4	6436-6439	all	_	
32-5	6440-6448	subjects	_	
32-6	6449-6453	were	_	
32-7	6454-6455	a	_	
32-8	6456-6463	history	_	
32-9	6464-6466	of	_	
32-10	6467-6471	head	_	
32-11	6472-6478	trauma	_	
32-12	6479-6483	with	_	
32-13	6484-6497	consciousness	_	
32-14	6498-6510	disturbances	_	
32-15	6511-6518	lasting	_	
32-16	6519-6523	more	_	
32-17	6524-6528	than	_	
32-18	6529-6530	5	_	
32-19	6530-6531	 	_	
32-20	6531-6534	min	_	
32-21	6534-6535	,	_	
32-22	6536-6537	a	_	
32-23	6538-6545	history	_	
32-24	6546-6548	of	_	
32-25	6549-6558	substance	_	
32-26	6559-6564	abuse	_	
32-27	6564-6565	,	_	
32-28	6566-6575	pregnancy	_	
32-29	6575-6576	,	_	
32-30	6577-6579	or	_	
32-31	6580-6583	any	_	
32-32	6584-6592	physical	_	
32-33	6593-6600	illness	_	
32-34	6600-6601	,	_	
32-35	6602-6606	such	_	
32-36	6607-6609	as	_	
32-37	6610-6624	cardiovascular	_	
32-38	6625-6632	disease	_	
32-39	6633-6636	and	_	
32-40	6637-6649	neurological	_	
32-41	6650-6659	disorders	_	
32-42	6659-6660	,	_	
32-43	6661-6663	as	_	
32-44	6664-6673	diagnosed	_	
32-45	6674-6676	by	_	
32-46	6677-6686	interview	_	
32-47	6687-6689	or	_	
32-48	6690-6691	a	_	
32-49	6692-6698	review	_	
32-50	6699-6701	of	_	
32-51	6702-6707	their	_	
32-52	6708-6715	medical	_	
32-53	6716-6723	records	_	
32-54	6723-6724	.	_	

#Text=A professional radiologist assessed the MRIs slice-by-slice, and three patients and nine healthy controls were excluded owing to poor image quality.
33-1	6725-6726	A	_	
33-2	6727-6739	professional	_	
33-3	6740-6751	radiologist	_	
33-4	6752-6760	assessed	_	
33-5	6761-6764	the	_	
33-6	6765-6769	MRIs	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
33-7	6770-6784	slice-by-slice	_	
33-8	6784-6785	,	_	
33-9	6786-6789	and	_	
33-10	6790-6795	three	_	
33-11	6796-6804	patients	_	
33-12	6805-6808	and	_	
33-13	6809-6813	nine	_	
33-14	6814-6821	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
33-15	6822-6830	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
33-16	6831-6835	were	_	
33-17	6836-6844	excluded	_	
33-18	6845-6850	owing	_	
33-19	6851-6853	to	_	
33-20	6854-6858	poor	_	
33-21	6859-6864	image	_	
33-22	6865-6872	quality	_	
33-23	6872-6873	.	_	

#Text=Consequently, the results for 95 patients with schizophrenia and 93 controls were analyzed (Fig. 1).
34-1	6874-6886	Consequently	_	
34-2	6886-6887	,	_	
34-3	6888-6891	the	_	
34-4	6892-6899	results	_	
34-5	6900-6903	for	_	
34-6	6904-6906	95	_	
34-7	6907-6915	patients	_	
34-8	6916-6920	with	_	
34-9	6921-6934	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
34-10	6935-6938	and	_	
34-11	6939-6941	93	_	
34-12	6942-6950	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
34-13	6951-6955	were	_	
34-14	6956-6964	analyzed	_	
34-15	6965-6966	(	_	
34-16	6966-6969	Fig	_	
34-17	6969-6970	.	_	
34-18	6970-6971	 	_	
34-19	6971-6972	1	_	
34-20	6972-6973	)	_	
34-21	6973-6974	.	_	

#Text=The Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of patients’ psychotic symptoms.
35-1	6975-6978	The	_	
35-2	6979-6987	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
35-3	6988-6991	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
35-4	6992-7000	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
35-5	7001-7009	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
35-6	7010-7015	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
35-7	7016-7017	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
35-8	7017-7022	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
35-9	7022-7023	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
35-10	7024-7027	was	_	
35-11	7028-7032	used	_	
35-12	7033-7035	to	_	
35-13	7036-7042	assess	_	
35-14	7043-7046	the	_	
35-15	7047-7055	severity	_	
35-16	7056-7058	of	_	
35-17	7059-7067	patients	_	
35-18	7067-7068	’	_	
35-19	7069-7078	psychotic	_	
35-20	7079-7087	symptoms	_	
35-21	7087-7088	.	_	

#Text=The Medical Research Ethics Committee of Tianjin Medical University General Hospital approved this study.
36-1	7089-7092	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-2	7093-7100	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-3	7101-7109	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-4	7110-7116	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-5	7117-7126	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-6	7127-7129	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-7	7130-7137	Tianjin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-8	7138-7145	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-9	7146-7156	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-10	7157-7164	General	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-11	7165-7173	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-12	7174-7182	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-13	7183-7187	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-14	7188-7193	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-15	7193-7194	.	_	

#Text=Written informed consent was gained from each participant following a complete description of the study.
37-1	7195-7202	Written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-2	7203-7211	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-3	7212-7219	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-4	7220-7223	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-5	7224-7230	gained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-6	7231-7235	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-7	7236-7240	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-8	7241-7252	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-9	7253-7262	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-10	7263-7264	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-11	7265-7273	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-12	7274-7285	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-13	7286-7288	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-14	7289-7292	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-15	7293-7298	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-16	7298-7299	.	_	

#Text=MRI data acquisition
#Text=MRI was performed using a 3.0-Tesla MR system (Discovery MR750, General Electric, Milwaukee, WI, USA).
38-1	7301-7304	MRI	_	
38-2	7305-7309	data	_	
38-3	7310-7321	acquisition	_	
38-4	7322-7325	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
38-5	7326-7329	was	_	
38-6	7330-7339	performed	_	
38-7	7340-7345	using	_	
38-8	7346-7347	a	_	
38-9	7348-7351	3.0	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
38-10	7351-7352	-	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
38-11	7352-7357	Tesla	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
38-12	7358-7360	MR	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
38-13	7361-7367	system	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
38-14	7368-7369	(	_	
38-15	7369-7378	Discovery	_	
38-16	7379-7384	MR750	_	
38-17	7384-7385	,	_	
38-18	7386-7393	General	_	
38-19	7394-7402	Electric	_	
38-20	7402-7403	,	_	
38-21	7404-7413	Milwaukee	_	
38-22	7413-7414	,	_	
38-23	7415-7417	WI	_	
38-24	7417-7418	,	_	
38-25	7419-7422	USA	_	
38-26	7422-7423	)	_	
38-27	7423-7424	.	_	

#Text=Tight, but comfortable, foam padding was used to minimize head motion, and earplugs were used to reduce scanner noise.
39-1	7425-7430	Tight	_	
39-2	7430-7431	,	_	
39-3	7432-7435	but	_	
39-4	7436-7447	comfortable	_	
39-5	7447-7448	,	_	
39-6	7449-7453	foam	_	
39-7	7454-7461	padding	_	
39-8	7462-7465	was	_	
39-9	7466-7470	used	_	
39-10	7471-7473	to	_	
39-11	7474-7482	minimize	_	
39-12	7483-7487	head	_	
39-13	7488-7494	motion	_	
39-14	7494-7495	,	_	
39-15	7496-7499	and	_	
39-16	7500-7508	earplugs	_	
39-17	7509-7513	were	_	
39-18	7514-7518	used	_	
39-19	7519-7521	to	_	
39-20	7522-7528	reduce	_	
39-21	7529-7536	scanner	_	
39-22	7537-7542	noise	_	
39-23	7542-7543	.	_	

#Text=Sagittal 3D T1-weighted images were acquired using a brain volume sequence with the following parameters: repetition time (TR) = 8.2 ms; echo time (TE) = 3.2 ms; inversion time (TI) = 450 ms; flip angle (FA) = 12°; field of view (FOV) = 256 mm × 256 mm; matrix = 256 × 256; slice thickness = 1 mm, no gap; and 188 sagittal slices).
40-1	7544-7552	Sagittal	_	
40-2	7553-7555	3D	_	
40-3	7556-7558	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[16]	
40-4	7558-7559	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[16]	
40-5	7559-7567	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[16]	
40-6	7568-7574	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[16]	
40-7	7575-7579	were	_	
40-8	7580-7588	acquired	_	
40-9	7589-7594	using	_	
40-10	7595-7596	a	_	
40-11	7597-7602	brain	_	
40-12	7603-7609	volume	_	
40-13	7610-7618	sequence	_	
40-14	7619-7623	with	_	
40-15	7624-7627	the	_	
40-16	7628-7637	following	_	
40-17	7638-7648	parameters	_	
40-18	7648-7649	:	_	
40-19	7650-7660	repetition	_	
40-20	7661-7665	time	_	
40-21	7666-7667	(	_	
40-22	7667-7669	TR	_	
40-23	7669-7670	)	_	
40-24	7671-7672	=	_	
40-25	7673-7676	8.2	_	
40-26	7676-7677	 	_	
40-27	7677-7679	ms	_	
40-28	7679-7680	;	_	
40-29	7681-7685	echo	_	
40-30	7686-7690	time	_	
40-31	7691-7692	(	_	
40-32	7692-7694	TE	_	
40-33	7694-7695	)	_	
40-34	7696-7697	=	_	
40-35	7698-7701	3.2	_	
40-36	7701-7702	 	_	
40-37	7702-7704	ms	_	
40-38	7704-7705	;	_	
40-39	7706-7715	inversion	_	
40-40	7716-7720	time	_	
40-41	7721-7722	(	_	
40-42	7722-7724	TI	_	
40-43	7724-7725	)	_	
40-44	7726-7727	=	_	
40-45	7728-7731	450	_	
40-46	7731-7732	 	_	
40-47	7732-7734	ms	_	
40-48	7734-7735	;	_	
40-49	7736-7740	flip	_	
40-50	7741-7746	angle	_	
40-51	7747-7748	(	_	
40-52	7748-7750	FA	_	
40-53	7750-7751	)	_	
40-54	7752-7753	=	_	
40-55	7754-7756	12	_	
40-56	7756-7757	°	_	
40-57	7757-7758	;	_	
40-58	7759-7764	field	_	
40-59	7765-7767	of	_	
40-60	7768-7772	view	_	
40-61	7773-7774	(	_	
40-62	7774-7777	FOV	_	
40-63	7777-7778	)	_	
40-64	7779-7780	=	_	
40-65	7781-7784	256	_	
40-66	7784-7785	 	_	
40-67	7785-7787	mm	_	
40-68	7788-7789	×	_	
40-69	7790-7793	256	_	
40-70	7793-7794	 	_	
40-71	7794-7796	mm	_	
40-72	7796-7797	;	_	
40-73	7798-7804	matrix	_	
40-74	7805-7806	=	_	
40-75	7807-7810	256	_	
40-76	7811-7812	×	_	
40-77	7813-7816	256	_	
40-78	7816-7817	;	_	
40-79	7818-7823	slice	_	
40-80	7824-7833	thickness	_	
40-81	7834-7835	=	_	
40-82	7836-7837	1	_	
40-83	7837-7838	 	_	
40-84	7838-7840	mm	_	
40-85	7840-7841	,	_	
40-86	7842-7844	no	_	
40-87	7845-7848	gap	_	
40-88	7848-7849	;	_	
40-89	7850-7853	and	_	
40-90	7854-7857	188	_	
40-91	7858-7866	sagittal	_	
40-92	7867-7873	slices	_	
40-93	7873-7874	)	_	
40-94	7874-7875	.	_	

#Text=Resting-state fMRI data were acquired using a gradient-echo single-short Echo planar imaging sequence with the following parameters: TR/TE = 2000/45 ms; FOV = 220 mm × 220 mm; matrix = 64 × 64; FA = 90°; slice thickness = 4 mm; gap = 0.5 mm; 32 interleaved transverse slices; and 180 volumes.
41-1	7876-7889	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[17]	
41-2	7890-7894	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[17]	
41-3	7895-7899	data	_	
41-4	7900-7904	were	_	
41-5	7905-7913	acquired	_	
41-6	7914-7919	using	_	
41-7	7920-7921	a	_	
41-8	7922-7935	gradient-echo	_	
41-9	7936-7948	single-short	_	
41-10	7949-7953	Echo	_	
41-11	7954-7960	planar	_	
41-12	7961-7968	imaging	_	
41-13	7969-7977	sequence	_	
41-14	7978-7982	with	_	
41-15	7983-7986	the	_	
41-16	7987-7996	following	_	
41-17	7997-8007	parameters	_	
41-18	8007-8008	:	_	
41-19	8009-8011	TR	_	
41-20	8011-8012	/	_	
41-21	8012-8014	TE	_	
41-22	8015-8016	=	_	
41-23	8017-8021	2000	_	
41-24	8021-8022	/	_	
41-25	8022-8024	45	_	
41-26	8024-8025	 	_	
41-27	8025-8027	ms	_	
41-28	8027-8028	;	_	
41-29	8029-8032	FOV	_	
41-30	8033-8034	=	_	
41-31	8035-8038	220	_	
41-32	8038-8039	 	_	
41-33	8039-8041	mm	_	
41-34	8042-8043	×	_	
41-35	8044-8047	220	_	
41-36	8047-8048	 	_	
41-37	8048-8050	mm	_	
41-38	8050-8051	;	_	
41-39	8052-8058	matrix	_	
41-40	8059-8060	=	_	
41-41	8061-8063	64	_	
41-42	8064-8065	×	_	
41-43	8066-8068	64	_	
41-44	8068-8069	;	_	
41-45	8070-8072	FA	_	
41-46	8073-8074	=	_	
41-47	8075-8077	90	_	
41-48	8077-8078	°	_	
41-49	8078-8079	;	_	
41-50	8080-8085	slice	_	
41-51	8086-8095	thickness	_	
41-52	8096-8097	=	_	
41-53	8098-8099	4	_	
41-54	8099-8100	 	_	
41-55	8100-8102	mm	_	
41-56	8102-8103	;	_	
41-57	8104-8107	gap	_	
41-58	8108-8109	=	_	
41-59	8110-8113	0.5	_	
41-60	8113-8114	 	_	
41-61	8114-8116	mm	_	
41-62	8116-8117	;	_	
41-63	8118-8120	32	_	
41-64	8121-8132	interleaved	_	
41-65	8133-8143	transverse	_	
41-66	8144-8150	slices	_	
41-67	8150-8151	;	_	
41-68	8152-8155	and	_	
41-69	8156-8159	180	_	
41-70	8160-8167	volumes	_	
41-71	8167-8168	.	_	

#Text=All subjects were requested to keep their eyes closed, relax, move as little as possible, think of nothing in particular, and not fall asleep during the scanning period.
#Text=fMRI data preprocessing
#Text=Resting-state fMRI data were preprocessed using Statistical Parametric Mapping software (SPM8; http://www.fil.ion.ucl.ac.uk/spm).
42-1	8169-8172	All	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-2	8173-8181	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-3	8182-8186	were	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-4	8187-8196	requested	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-5	8197-8199	to	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-6	8200-8204	keep	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-7	8205-8210	their	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-8	8211-8215	eyes	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-9	8216-8222	closed	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-10	8222-8223	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-11	8224-8229	relax	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-12	8229-8230	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-13	8231-8235	move	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-14	8236-8238	as	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-15	8239-8245	little	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-16	8246-8248	as	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-17	8249-8257	possible	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-18	8257-8258	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-19	8259-8264	think	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-20	8265-8267	of	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-21	8268-8275	nothing	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-22	8276-8278	in	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-23	8279-8289	particular	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-24	8289-8290	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-25	8291-8294	and	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-26	8295-8298	not	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-27	8299-8303	fall	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-28	8304-8310	asleep	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-29	8311-8317	during	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-30	8318-8321	the	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-31	8322-8330	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-32	8331-8337	period	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-33	8337-8338	.	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[18]	
42-34	8339-8343	fMRI	_	
42-35	8344-8348	data	_	
42-36	8349-8362	preprocessing	_	
42-37	8363-8376	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[19]	
42-38	8377-8381	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[19]	
42-39	8382-8386	data	_	
42-40	8387-8391	were	_	
42-41	8392-8404	preprocessed	_	
42-42	8405-8410	using	_	
42-43	8411-8422	Statistical	_	
42-44	8423-8433	Parametric	_	
42-45	8434-8441	Mapping	_	
42-46	8442-8450	software	_	
42-47	8451-8452	(	_	
42-48	8452-8456	SPM8	_	
42-49	8456-8457	;	_	
42-50	8458-8462	http	_	
42-51	8462-8463	:	_	
42-52	8463-8464	/	_	
42-53	8464-8465	/	_	
42-54	8465-8486	www.fil.ion.ucl.ac.uk	_	
42-55	8486-8487	/	_	
42-56	8487-8490	spm	_	
42-57	8490-8491	)	_	
42-58	8491-8492	.	_	

#Text=The first 10 volumes for each subject were discarded to allow the signal to reach equilibrium and the participants to adapt to the scanning noise.
43-1	8493-8496	The	_	
43-2	8497-8502	first	_	
43-3	8503-8505	10	_	
43-4	8506-8513	volumes	_	
43-5	8514-8517	for	_	
43-6	8518-8522	each	_	
43-7	8523-8530	subject	_	
43-8	8531-8535	were	_	
43-9	8536-8545	discarded	_	
43-10	8546-8548	to	_	
43-11	8549-8554	allow	_	
43-12	8555-8558	the	_	
43-13	8559-8565	signal	_	
43-14	8566-8568	to	_	
43-15	8569-8574	reach	_	
43-16	8575-8586	equilibrium	_	
43-17	8587-8590	and	_	
43-18	8591-8594	the	_	
43-19	8595-8607	participants	_	
43-20	8608-8610	to	_	
43-21	8611-8616	adapt	_	
43-22	8617-8619	to	_	
43-23	8620-8623	the	_	
43-24	8624-8632	scanning	_	
43-25	8633-8638	noise	_	
43-26	8638-8639	.	_	

#Text=The remaining volumes were corrected for the acquisition time delay between slices.
44-1	8640-8643	The	_	
44-2	8644-8653	remaining	_	
44-3	8654-8661	volumes	_	
44-4	8662-8666	were	_	
44-5	8667-8676	corrected	_	
44-6	8677-8680	for	_	
44-7	8681-8684	the	_	
44-8	8685-8696	acquisition	_	
44-9	8697-8701	time	_	
44-10	8702-8707	delay	_	
44-11	8708-8715	between	_	
44-12	8716-8722	slices	_	
44-13	8722-8723	.	_	

#Text=Realignment was then performed to correct for motion between time points.
45-1	8724-8735	Realignment	_	
45-2	8736-8739	was	_	
45-3	8740-8744	then	_	
45-4	8745-8754	performed	_	
45-5	8755-8757	to	_	
45-6	8758-8765	correct	_	
45-7	8766-8769	for	_	
45-8	8770-8776	motion	_	
45-9	8777-8784	between	_	
45-10	8785-8789	time	_	
45-11	8790-8796	points	_	
45-12	8796-8797	.	_	

#Text=All subjects’ fMRI data were within defined motion thresholds (i.e., translational or rotational motion parameters less than 2 mm or 2°).
46-1	8798-8801	All	_	
46-2	8802-8810	subjects	_	
46-3	8810-8811	’	_	
46-4	8812-8816	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
46-5	8817-8821	data	_	
46-6	8822-8826	were	_	
46-7	8827-8833	within	_	
46-8	8834-8841	defined	_	
46-9	8842-8848	motion	_	
46-10	8849-8859	thresholds	_	
46-11	8860-8861	(	_	
46-12	8861-8864	i.e	_	
46-13	8864-8865	.	_	
46-14	8865-8866	,	_	
46-15	8867-8880	translational	_	
46-16	8881-8883	or	_	
46-17	8884-8894	rotational	_	
46-18	8895-8901	motion	_	
46-19	8902-8912	parameters	_	
46-20	8913-8917	less	_	
46-21	8918-8922	than	_	
46-22	8923-8924	2	_	
46-23	8924-8925	 	_	
46-24	8925-8927	mm	_	
46-25	8928-8930	or	_	
46-26	8931-8932	2	_	
46-27	8932-8933	°	_	
46-28	8933-8934	)	_	
46-29	8934-8935	.	_	

#Text=We also calculated frame-wise displacement, which indexes volume-to-volume changes in head position.
47-1	8936-8938	We	_	
47-2	8939-8943	also	_	
47-3	8944-8954	calculated	_	
47-4	8955-8965	frame-wise	_	
47-5	8966-8978	displacement	_	
47-6	8978-8979	,	_	
47-7	8980-8985	which	_	
47-8	8986-8993	indexes	_	
47-9	8994-9010	volume-to-volume	_	
47-10	9011-9018	changes	_	
47-11	9019-9021	in	_	
47-12	9022-9026	head	_	
47-13	9027-9035	position	_	
47-14	9035-9036	.	_	

#Text=Several nuisance covariates (six motion parameters, their first time derivations, and average BOLD signals of the ventricular and white matter) were regressed from the data.
48-1	9037-9044	Several	_	
48-2	9045-9053	nuisance	_	
48-3	9054-9064	covariates	_	
48-4	9065-9066	(	_	
48-5	9066-9069	six	_	
48-6	9070-9076	motion	_	
48-7	9077-9087	parameters	_	
48-8	9087-9088	,	_	
48-9	9089-9094	their	_	
48-10	9095-9100	first	_	
48-11	9101-9105	time	_	
48-12	9106-9117	derivations	_	
48-13	9117-9118	,	_	
48-14	9119-9122	and	_	
48-15	9123-9130	average	_	
48-16	9131-9135	BOLD	_	
48-17	9136-9143	signals	_	
48-18	9144-9146	of	_	
48-19	9147-9150	the	_	
48-20	9151-9162	ventricular	_	
48-21	9163-9166	and	_	
48-22	9167-9172	white	_	
48-23	9173-9179	matter	_	
48-24	9179-9180	)	_	
48-25	9181-9185	were	_	
48-26	9186-9195	regressed	_	
48-27	9196-9200	from	_	
48-28	9201-9204	the	_	
48-29	9205-9209	data	_	
48-30	9209-9210	.	_	

#Text=Recent study have reported that the signal spike caused by head motion significantly contaminates the final resting-state fMRI results even after regressing out the six motion parameters.
49-1	9211-9217	Recent	_	
49-2	9218-9223	study	_	
49-3	9224-9228	have	_	
49-4	9229-9237	reported	_	
49-5	9238-9242	that	_	
49-6	9243-9246	the	_	
49-7	9247-9253	signal	_	
49-8	9254-9259	spike	_	
49-9	9260-9266	caused	_	
49-10	9267-9269	by	_	
49-11	9270-9274	head	_	
49-12	9275-9281	motion	_	
49-13	9282-9295	significantly	_	
49-14	9296-9308	contaminates	_	
49-15	9309-9312	the	_	
49-16	9313-9318	final	_	
49-17	9319-9332	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[20]	
49-18	9333-9337	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[20]	
49-19	9338-9345	results	_	
49-20	9346-9350	even	_	
49-21	9351-9356	after	_	
49-22	9357-9367	regressing	_	
49-23	9368-9371	out	_	
49-24	9372-9375	the	_	
49-25	9376-9379	six	_	
49-26	9380-9386	motion	_	
49-27	9387-9397	parameters	_	
49-28	9397-9398	.	_	

#Text=Therefore, we further regressed out spike volumes when the frame-wise displacement of the specific volume exceeded 0.5.
50-1	9399-9408	Therefore	_	
50-2	9408-9409	,	_	
50-3	9410-9412	we	_	
50-4	9413-9420	further	_	
50-5	9421-9430	regressed	_	
50-6	9431-9434	out	_	
50-7	9435-9440	spike	_	
50-8	9441-9448	volumes	_	
50-9	9449-9453	when	_	
50-10	9454-9457	the	_	
50-11	9458-9468	frame-wise	_	
50-12	9469-9481	displacement	_	
50-13	9482-9484	of	_	
50-14	9485-9488	the	_	
50-15	9489-9497	specific	_	
50-16	9498-9504	volume	_	
50-17	9505-9513	exceeded	_	
50-18	9514-9517	0.5	_	
50-19	9517-9518	.	_	

#Text=The datasets were then band-pass filtered in a frequency range of 0.01 to 0.08 Hz.
51-1	9519-9522	The	_	
51-2	9523-9531	datasets	_	
51-3	9532-9536	were	_	
51-4	9537-9541	then	_	
51-5	9542-9551	band-pass	_	
51-6	9552-9560	filtered	_	
51-7	9561-9563	in	_	
51-8	9564-9565	a	_	
51-9	9566-9575	frequency	_	
51-10	9576-9581	range	_	
51-11	9582-9584	of	_	
51-12	9585-9589	0.01	_	
51-13	9590-9592	to	_	
51-14	9593-9597	0.08	_	
51-15	9597-9598	 	_	
51-16	9598-9600	Hz	_	
51-17	9600-9601	.	_	

#Text=In the normalization step, individual structural images were linearly co-registered with the mean functional image, and then linearly co-registered to the Montreal Neurological Institute (MNI) space.
52-1	9602-9604	In	_	
52-2	9605-9608	the	_	
52-3	9609-9622	normalization	_	
52-4	9623-9627	step	_	
52-5	9627-9628	,	_	
52-6	9629-9639	individual	_	
52-7	9640-9650	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[21]	
52-8	9651-9657	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[21]	
52-9	9658-9662	were	_	
52-10	9663-9671	linearly	_	
52-11	9672-9685	co-registered	_	
52-12	9686-9690	with	_	
52-13	9691-9694	the	_	
52-14	9695-9699	mean	_	
52-15	9700-9710	functional	_	
52-16	9711-9716	image	_	
52-17	9716-9717	,	_	
52-18	9718-9721	and	_	
52-19	9722-9726	then	_	
52-20	9727-9735	linearly	_	
52-21	9736-9749	co-registered	_	
52-22	9750-9752	to	_	
52-23	9753-9756	the	_	
52-24	9757-9765	Montreal	_	
52-25	9766-9778	Neurological	_	
52-26	9779-9788	Institute	_	
52-27	9789-9790	(	_	
52-28	9790-9793	MNI	_	
52-29	9793-9794	)	_	
52-30	9795-9800	space	_	
52-31	9800-9801	.	_	

#Text=Finally, each filtered functional volume was spatially normalized to the MNI space using the co-registration parameters and were resampled into a 3-mm cubic voxel.
53-1	9802-9809	Finally	_	
53-2	9809-9810	,	_	
53-3	9811-9815	each	_	
53-4	9816-9824	filtered	_	
53-5	9825-9835	functional	_	
53-6	9836-9842	volume	_	
53-7	9843-9846	was	_	
53-8	9847-9856	spatially	_	
53-9	9857-9867	normalized	_	
53-10	9868-9870	to	_	
53-11	9871-9874	the	_	
53-12	9875-9878	MNI	_	
53-13	9879-9884	space	_	
53-14	9885-9890	using	_	
53-15	9891-9894	the	_	
53-16	9895-9910	co-registration	_	
53-17	9911-9921	parameters	_	
53-18	9922-9925	and	_	
53-19	9926-9930	were	_	
53-20	9931-9940	resampled	_	
53-21	9941-9945	into	_	
53-22	9946-9947	a	_	
53-23	9948-9949	3	_	
53-24	9949-9950	-	_	
53-25	9950-9952	mm	_	
53-26	9953-9958	cubic	_	
53-27	9959-9964	voxel	_	
53-28	9964-9965	.	_	

#Text=GMV calculation
#Text=The GMV of each voxel was calculated using SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/).
54-1	9966-9969	GMV	_	
54-2	9970-9981	calculation	_	
54-3	9982-9985	The	_	
54-4	9986-9989	GMV	_	
54-5	9990-9992	of	_	
54-6	9993-9997	each	_	
54-7	9998-10003	voxel	_	
54-8	10004-10007	was	_	
54-9	10008-10018	calculated	_	
54-10	10019-10024	using	_	
54-11	10025-10029	SPM8	_	
54-12	10030-10031	(	_	
54-13	10031-10035	http	_	
54-14	10035-10036	:	_	
54-15	10036-10037	/	_	
54-16	10037-10038	/	_	
54-17	10038-10059	www.fil.ion.ucl.ac.uk	_	
54-18	10059-10060	/	_	
54-19	10060-10063	spm	_	
54-20	10063-10064	/	_	
54-21	10064-10072	software	_	
54-22	10072-10073	/	_	
54-23	10073-10077	spm8	_	
54-24	10077-10078	/	_	
54-25	10078-10079	)	_	
54-26	10079-10080	.	_	

#Text=Structural MR images were segmented into gray matter (GM), white matter and cerebrospinal fluid using the standard unified segmentation model.
55-1	10081-10091	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[22]	
55-2	10092-10094	MR	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[22]	
55-3	10095-10101	images	_	
55-4	10102-10106	were	_	
55-5	10107-10116	segmented	_	
55-6	10117-10121	into	_	
55-7	10122-10126	gray	_	
55-8	10127-10133	matter	_	
55-9	10134-10135	(	_	
55-10	10135-10137	GM	_	
55-11	10137-10138	)	_	
55-12	10138-10139	,	_	
55-13	10140-10145	white	_	
55-14	10146-10152	matter	_	
55-15	10153-10156	and	_	
55-16	10157-10170	cerebrospinal	_	
55-17	10171-10176	fluid	_	
55-18	10177-10182	using	_	
55-19	10183-10186	the	_	
55-20	10187-10195	standard	_	
55-21	10196-10203	unified	_	
55-22	10204-10216	segmentation	_	
55-23	10217-10222	model	_	
55-24	10222-10223	.	_	

#Text=After an initial affine registration of the GM concentration map into the MNI space, GM concentration images were nonlinearly warped using the diffeomorphic anatomical registration through exponentiated lie algebra technique, and the results resampled to a voxel size of 3 mm × 3 mm × 3 mm.
56-1	10224-10229	After	_	
56-2	10230-10232	an	_	
56-3	10233-10240	initial	_	
56-4	10241-10247	affine	_	
56-5	10248-10260	registration	_	
56-6	10261-10263	of	_	
56-7	10264-10267	the	_	
56-8	10268-10270	GM	_	
56-9	10271-10284	concentration	_	
56-10	10285-10288	map	_	
56-11	10289-10293	into	_	
56-12	10294-10297	the	_	
56-13	10298-10301	MNI	_	
56-14	10302-10307	space	_	
56-15	10307-10308	,	_	
56-16	10309-10311	GM	_	
56-17	10312-10325	concentration	_	
56-18	10326-10332	images	_	
56-19	10333-10337	were	_	
56-20	10338-10349	nonlinearly	_	
56-21	10350-10356	warped	_	
56-22	10357-10362	using	_	
56-23	10363-10366	the	_	
56-24	10367-10380	diffeomorphic	_	
56-25	10381-10391	anatomical	_	
56-26	10392-10404	registration	_	
56-27	10405-10412	through	_	
56-28	10413-10426	exponentiated	_	
56-29	10427-10430	lie	_	
56-30	10431-10438	algebra	_	
56-31	10439-10448	technique	_	
56-32	10448-10449	,	_	
56-33	10450-10453	and	_	
56-34	10454-10457	the	_	
56-35	10458-10465	results	_	
56-36	10466-10475	resampled	_	
56-37	10476-10478	to	_	
56-38	10479-10480	a	_	
56-39	10481-10486	voxel	_	
56-40	10487-10491	size	_	
56-41	10492-10494	of	_	
56-42	10495-10496	3	_	
56-43	10496-10497	 	_	
56-44	10497-10499	mm	_	
56-45	10500-10501	×	_	
56-46	10502-10503	3	_	
56-47	10503-10504	 	_	
56-48	10504-10506	mm	_	
56-49	10507-10508	×	_	
56-50	10509-10510	3	_	
56-51	10510-10511	 	_	
56-52	10511-10513	mm	_	
56-53	10513-10514	.	_	

#Text=The GMV of each voxel was obtained by multiplying the GM concentration map by the non-linear determinants derived from the spatial normalization step.
57-1	10515-10518	The	_	
57-2	10519-10522	GMV	_	
57-3	10523-10525	of	_	
57-4	10526-10530	each	_	
57-5	10531-10536	voxel	_	
57-6	10537-10540	was	_	
57-7	10541-10549	obtained	_	
57-8	10550-10552	by	_	
57-9	10553-10564	multiplying	_	
57-10	10565-10568	the	_	
57-11	10569-10571	GM	_	
57-12	10572-10585	concentration	_	
57-13	10586-10589	map	_	
57-14	10590-10592	by	_	
57-15	10593-10596	the	_	
57-16	10597-10607	non-linear	_	
57-17	10608-10620	determinants	_	
57-18	10621-10628	derived	_	
57-19	10629-10633	from	_	
57-20	10634-10637	the	_	
57-21	10638-10645	spatial	_	
57-22	10646-10659	normalization	_	
57-23	10660-10664	step	_	
57-24	10664-10665	.	_	

#Text=Finally, the GMV images were smoothed using a Gaussian kernel of 6 mm × 6 mm × 6 mm full-width at half maximum.
58-1	10666-10673	Finally	_	
58-2	10673-10674	,	_	
58-3	10675-10678	the	_	
58-4	10679-10682	GMV	_	
58-5	10683-10689	images	_	
58-6	10690-10694	were	_	
58-7	10695-10703	smoothed	_	
58-8	10704-10709	using	_	
58-9	10710-10711	a	_	
58-10	10712-10720	Gaussian	_	
58-11	10721-10727	kernel	_	
58-12	10728-10730	of	_	
58-13	10731-10732	6	_	
58-14	10732-10733	 	_	
58-15	10733-10735	mm	_	
58-16	10736-10737	×	_	
58-17	10738-10739	6	_	
58-18	10739-10740	 	_	
58-19	10740-10742	mm	_	
58-20	10743-10744	×	_	
58-21	10745-10746	6	_	
58-22	10746-10747	 	_	
58-23	10747-10749	mm	_	
58-24	10750-10760	full-width	_	
58-25	10761-10763	at	_	
58-26	10764-10768	half	_	
58-27	10769-10776	maximum	_	
58-28	10776-10777	.	_	

#Text=After spatial preprocessing, the smoothed GMV maps were used for statistical analyses.
59-1	10778-10783	After	_	
59-2	10784-10791	spatial	_	
59-3	10792-10805	preprocessing	_	
59-4	10805-10806	,	_	
59-5	10807-10810	the	_	
59-6	10811-10819	smoothed	_	
59-7	10820-10823	GMV	_	
59-8	10824-10828	maps	_	
59-9	10829-10833	were	_	
59-10	10834-10838	used	_	
59-11	10839-10842	for	_	
59-12	10843-10854	statistical	_	
59-13	10855-10863	analyses	_	
59-14	10863-10864	.	_	

#Text=FCD calculation
#Text=The FCD of each voxel was calculated using an in-house Linux script according to the method described by Tomasi and Volkow.
60-1	10865-10868	FCD	_	
60-2	10869-10880	calculation	_	
60-3	10881-10884	The	_	
60-4	10885-10888	FCD	_	
60-5	10889-10891	of	_	
60-6	10892-10896	each	_	
60-7	10897-10902	voxel	_	
60-8	10903-10906	was	_	
60-9	10907-10917	calculated	_	
60-10	10918-10923	using	_	
60-11	10924-10926	an	_	
60-12	10927-10935	in-house	_	
60-13	10936-10941	Linux	_	
60-14	10942-10948	script	_	
60-15	10949-10958	according	_	
60-16	10959-10961	to	_	
60-17	10962-10965	the	_	
60-18	10966-10972	method	_	
60-19	10973-10982	described	_	
60-20	10983-10985	by	_	
60-21	10986-10992	Tomasi	_	
60-22	10993-10996	and	_	
60-23	10997-11003	Volkow	_	
60-24	11003-11004	.	_	

#Text=Pearson’s linear correlation evaluated the strength of the functional connectivity between voxels.
61-1	11005-11012	Pearson	_	
61-2	11012-11013	’	_	
61-3	11013-11014	s	_	
61-4	11015-11021	linear	_	
61-5	11022-11033	correlation	_	
61-6	11034-11043	evaluated	_	
61-7	11044-11047	the	_	
61-8	11048-11056	strength	_	
61-9	11057-11059	of	_	
61-10	11060-11063	the	_	
61-11	11064-11074	functional	_	
61-12	11075-11087	connectivity	_	
61-13	11088-11095	between	_	
61-14	11096-11102	voxels	_	
61-15	11102-11103	.	_	

#Text=According to the most of the previous studies, voxel pairs with a correlation coefficient of R > 0.6 were considered significantly connected, thereafter, in current study, we also adopted R > 0.6 as the cut-off point., FCD calculations were restricted to the cerebral gray matter mask regions.
62-1	11104-11113	According	_	
62-2	11114-11116	to	_	
62-3	11117-11120	the	_	
62-4	11121-11125	most	_	
62-5	11126-11128	of	_	
62-6	11129-11132	the	_	
62-7	11133-11141	previous	_	
62-8	11142-11149	studies	_	
62-9	11149-11150	,	_	
62-10	11151-11156	voxel	_	
62-11	11157-11162	pairs	_	
62-12	11163-11167	with	_	
62-13	11168-11169	a	_	
62-14	11170-11181	correlation	_	
62-15	11182-11193	coefficient	_	
62-16	11194-11196	of	_	
62-17	11197-11198	R	_	
62-18	11199-11200	>	_	
62-19	11201-11204	0.6	_	
62-20	11205-11209	were	_	
62-21	11210-11220	considered	_	
62-22	11221-11234	significantly	_	
62-23	11235-11244	connected	_	
62-24	11244-11245	,	_	
62-25	11246-11256	thereafter	_	
62-26	11256-11257	,	_	
62-27	11258-11260	in	_	
62-28	11261-11268	current	_	
62-29	11269-11274	study	_	
62-30	11274-11275	,	_	
62-31	11276-11278	we	_	
62-32	11279-11283	also	_	
62-33	11284-11291	adopted	_	
62-34	11292-11293	R	_	
62-35	11294-11295	>	_	
62-36	11296-11299	0.6	_	
62-37	11300-11302	as	_	
62-38	11303-11306	the	_	
62-39	11307-11314	cut-off	_	
62-40	11315-11320	point	_	
62-41	11320-11321	.	_	
62-42	11321-11322	,	_	
62-43	11323-11326	FCD	_	
62-44	11327-11339	calculations	_	
62-45	11340-11344	were	_	
62-46	11345-11355	restricted	_	
62-47	11356-11358	to	_	
62-48	11359-11362	the	_	
62-49	11363-11371	cerebral	_	
62-50	11372-11376	gray	_	
62-51	11377-11383	matter	_	
62-52	11384-11388	mask	_	
62-53	11389-11396	regions	_	
62-54	11396-11397	.	_	

#Text=The gFCD at a given voxel, x0, was computed as the global number of functional connections, k(x0), between x0 and all other voxels.
63-1	11398-11401	The	_	
63-2	11402-11406	gFCD	_	
63-3	11407-11409	at	_	
63-4	11410-11411	a	_	
63-5	11412-11417	given	_	
63-6	11418-11423	voxel	_	
63-7	11423-11424	,	_	
63-8	11425-11427	x0	_	
63-9	11427-11428	,	_	
63-10	11429-11432	was	_	
63-11	11433-11441	computed	_	
63-12	11442-11444	as	_	
63-13	11445-11448	the	_	
63-14	11449-11455	global	_	
63-15	11456-11462	number	_	
63-16	11463-11465	of	_	
63-17	11466-11476	functional	_	
63-18	11477-11488	connections	_	
63-19	11488-11489	,	_	
63-20	11490-11491	k	_	
63-21	11491-11492	(	_	
63-22	11492-11494	x0	_	
63-23	11494-11495	)	_	
63-24	11495-11496	,	_	
63-25	11497-11504	between	_	
63-26	11505-11507	x0	_	
63-27	11508-11511	and	_	
63-28	11512-11515	all	_	
63-29	11516-11521	other	_	
63-30	11522-11528	voxels	_	
63-31	11528-11529	.	_	

#Text=This calculation was repeated for all x0 voxels in the brain.
64-1	11530-11534	This	_	
64-2	11535-11546	calculation	_	
64-3	11547-11550	was	_	
64-4	11551-11559	repeated	_	
64-5	11560-11563	for	_	
64-6	11564-11567	all	_	
64-7	11568-11570	x0	_	
64-8	11571-11577	voxels	_	
64-9	11578-11580	in	_	
64-10	11581-11584	the	_	
64-11	11585-11590	brain	_	
64-12	11590-11591	.	_	

#Text=The FCD maps were spatially smoothed using a 6 mm × 6 mm × 6 mm Gaussian kernel to minimize differences in the functional brain anatomy across subjects.
65-1	11592-11595	The	_	
65-2	11596-11599	FCD	_	
65-3	11600-11604	maps	_	
65-4	11605-11609	were	_	
65-5	11610-11619	spatially	_	
65-6	11620-11628	smoothed	_	
65-7	11629-11634	using	_	
65-8	11635-11636	a	_	
65-9	11637-11638	6	_	
65-10	11638-11639	 	_	
65-11	11639-11641	mm	_	
65-12	11642-11643	×	_	
65-13	11644-11645	6	_	
65-14	11645-11646	 	_	
65-15	11646-11648	mm	_	
65-16	11649-11650	×	_	
65-17	11651-11652	6	_	
65-18	11652-11653	 	_	
65-19	11653-11655	mm	_	
65-20	11656-11664	Gaussian	_	
65-21	11665-11671	kernel	_	
65-22	11672-11674	to	_	
65-23	11675-11683	minimize	_	
65-24	11684-11695	differences	_	
65-25	11696-11698	in	_	
65-26	11699-11702	the	_	
65-27	11703-11713	functional	_	
65-28	11714-11719	brain	_	
65-29	11720-11727	anatomy	_	
65-30	11728-11734	across	_	
65-31	11735-11743	subjects	_	
65-32	11743-11744	.	_	

#Text=Statistical analysis
#Text=Group differences in GMV and gFCD were compared in a voxel-wise manner using a two-sample t-test with age and sex as nuisance variables.
66-1	11745-11756	Statistical	_	
66-2	11757-11765	analysis	_	
66-3	11766-11771	Group	_	
66-4	11772-11783	differences	_	
66-5	11784-11786	in	_	
66-6	11787-11790	GMV	_	
66-7	11791-11794	and	_	
66-8	11795-11799	gFCD	_	
66-9	11800-11804	were	_	
66-10	11805-11813	compared	_	
66-11	11814-11816	in	_	
66-12	11817-11818	a	_	
66-13	11819-11829	voxel-wise	_	
66-14	11830-11836	manner	_	
66-15	11837-11842	using	_	
66-16	11843-11844	a	_	
66-17	11845-11855	two-sample	_	
66-18	11856-11862	t-test	_	
66-19	11863-11867	with	_	
66-20	11868-11871	age	_	
66-21	11872-11875	and	_	
66-22	11876-11879	sex	_	
66-23	11880-11882	as	_	
66-24	11883-11891	nuisance	_	
66-25	11892-11901	variables	_	
66-26	11901-11902	.	_	

#Text=Multiple comparisons were corrected using a false discovery rate method with a corrected threshold of P < 0.05.
67-1	11903-11911	Multiple	_	
67-2	11912-11923	comparisons	_	
67-3	11924-11928	were	_	
67-4	11929-11938	corrected	_	
67-5	11939-11944	using	_	
67-6	11945-11946	a	_	
67-7	11947-11952	false	_	
67-8	11953-11962	discovery	_	
67-9	11963-11967	rate	_	
67-10	11968-11974	method	_	
67-11	11975-11979	with	_	
67-12	11980-11981	a	_	
67-13	11982-11991	corrected	_	
67-14	11992-12001	threshold	_	
67-15	12002-12004	of	_	
67-16	12005-12006	P	_	
67-17	12007-12008	<	_	
67-18	12009-12013	0.05	_	
67-19	12013-12014	.	_	

#Text=The mean gFCD and GMV values of each cluster, with significant group differences in gFCD, were extracted for each subject and used for region of interest (ROI)-based group comparisons.
68-1	12015-12018	The	_	
68-2	12019-12023	mean	_	
68-3	12024-12028	gFCD	_	
68-4	12029-12032	and	_	
68-5	12033-12036	GMV	_	
68-6	12037-12043	values	_	
68-7	12044-12046	of	_	
68-8	12047-12051	each	_	
68-9	12052-12059	cluster	_	
68-10	12059-12060	,	_	
68-11	12061-12065	with	_	
68-12	12066-12077	significant	_	
68-13	12078-12083	group	_	
68-14	12084-12095	differences	_	
68-15	12096-12098	in	_	
68-16	12099-12103	gFCD	_	
68-17	12103-12104	,	_	
68-18	12105-12109	were	_	
68-19	12110-12119	extracted	_	
68-20	12120-12123	for	_	
68-21	12124-12128	each	_	
68-22	12129-12136	subject	_	
68-23	12137-12140	and	_	
68-24	12141-12145	used	_	
68-25	12146-12149	for	_	
68-26	12150-12156	region	_	
68-27	12157-12159	of	_	
68-28	12160-12168	interest	_	
68-29	12169-12170	(	_	
68-30	12170-12173	ROI	_	
68-31	12173-12174	)	_	
68-32	12174-12175	-	_	
68-33	12175-12180	based	_	
68-34	12181-12186	group	_	
68-35	12187-12198	comparisons	_	
68-36	12198-12199	.	_	

#Text=To clarify if the regions with altered gFCD also showed structural impairment, we first tested the group differences in GMV for each ROI using two-sample t-tests after controlling for age and sex.
69-1	12200-12202	To	_	
69-2	12203-12210	clarify	_	
69-3	12211-12213	if	_	
69-4	12214-12217	the	_	
69-5	12218-12225	regions	_	
69-6	12226-12230	with	_	
69-7	12231-12238	altered	_	
69-8	12239-12243	gFCD	_	
69-9	12244-12248	also	_	
69-10	12249-12255	showed	_	
69-11	12256-12266	structural	_	
69-12	12267-12277	impairment	_	
69-13	12277-12278	,	_	
69-14	12279-12281	we	_	
69-15	12282-12287	first	_	
69-16	12288-12294	tested	_	
69-17	12295-12298	the	_	
69-18	12299-12304	group	_	
69-19	12305-12316	differences	_	
69-20	12317-12319	in	_	
69-21	12320-12323	GMV	_	
69-22	12324-12327	for	_	
69-23	12328-12332	each	_	
69-24	12333-12336	ROI	_	
69-25	12337-12342	using	_	
69-26	12343-12353	two-sample	_	
69-27	12354-12361	t-tests	_	
69-28	12362-12367	after	_	
69-29	12368-12379	controlling	_	
69-30	12380-12383	for	_	
69-31	12384-12387	age	_	
69-32	12388-12391	and	_	
69-33	12392-12395	sex	_	
69-34	12395-12396	.	_	

#Text=The group differences in gFCD were then tested using two-sample t-tests, after further regressing out the GMV influences, to investigate their separate contributions to functional aberrances in schizophrenia.
70-1	12397-12400	The	_	
70-2	12401-12406	group	_	
70-3	12407-12418	differences	_	
70-4	12419-12421	in	_	
70-5	12422-12426	gFCD	_	
70-6	12427-12431	were	_	
70-7	12432-12436	then	_	
70-8	12437-12443	tested	_	
70-9	12444-12449	using	_	
70-10	12450-12460	two-sample	_	
70-11	12461-12468	t-tests	_	
70-12	12468-12469	,	_	
70-13	12470-12475	after	_	
70-14	12476-12483	further	_	
70-15	12484-12494	regressing	_	
70-16	12495-12498	out	_	
70-17	12499-12502	the	_	
70-18	12503-12506	GMV	_	
70-19	12507-12517	influences	_	
70-20	12517-12518	,	_	
70-21	12519-12521	to	_	
70-22	12522-12533	investigate	_	
70-23	12534-12539	their	_	
70-24	12540-12548	separate	_	
70-25	12549-12562	contributions	_	
70-26	12563-12565	to	_	
70-27	12566-12576	functional	_	
70-28	12577-12587	aberrances	_	
70-29	12588-12590	in	_	
70-30	12591-12604	schizophrenia	_	
70-31	12604-12605	.	_	

#Text=Finally, a partial correlation coefficient was used to test the relationship between gFCD and GMV in each group, and to test the associations between gFCD and clinical variables, including antipsychotic dose (chlorpromazine equivalents), illness duration, and PANSS scores.
71-1	12606-12613	Finally	_	
71-2	12613-12614	,	_	
71-3	12615-12616	a	_	
71-4	12617-12624	partial	_	
71-5	12625-12636	correlation	_	
71-6	12637-12648	coefficient	_	
71-7	12649-12652	was	_	
71-8	12653-12657	used	_	
71-9	12658-12660	to	_	
71-10	12661-12665	test	_	
71-11	12666-12669	the	_	
71-12	12670-12682	relationship	_	
71-13	12683-12690	between	_	
71-14	12691-12695	gFCD	_	
71-15	12696-12699	and	_	
71-16	12700-12703	GMV	_	
71-17	12704-12706	in	_	
71-18	12707-12711	each	_	
71-19	12712-12717	group	_	
71-20	12717-12718	,	_	
71-21	12719-12722	and	_	
71-22	12723-12725	to	_	
71-23	12726-12730	test	_	
71-24	12731-12734	the	_	
71-25	12735-12747	associations	_	
71-26	12748-12755	between	_	
71-27	12756-12760	gFCD	_	
71-28	12761-12764	and	_	
71-29	12765-12773	clinical	_	
71-30	12774-12783	variables	_	
71-31	12783-12784	,	_	
71-32	12785-12794	including	_	
71-33	12795-12808	antipsychotic	_	
71-34	12809-12813	dose	_	
71-35	12814-12815	(	_	
71-36	12815-12829	chlorpromazine	_	
71-37	12830-12841	equivalents	_	
71-38	12841-12842	)	_	
71-39	12842-12843	,	_	
71-40	12844-12851	illness	_	
71-41	12852-12860	duration	_	
71-42	12860-12861	,	_	
71-43	12862-12865	and	_	
71-44	12866-12871	PANSS	_	
71-45	12872-12878	scores	_	
71-46	12878-12879	.	_	

#Text=Age and sex effects were regressed out and multiple comparisons were corrected using the Bonferroni method (P < 0.05).
72-1	12880-12883	Age	_	
72-2	12884-12887	and	_	
72-3	12888-12891	sex	_	
72-4	12892-12899	effects	_	
72-5	12900-12904	were	_	
72-6	12905-12914	regressed	_	
72-7	12915-12918	out	_	
72-8	12919-12922	and	_	
72-9	12923-12931	multiple	_	
72-10	12932-12943	comparisons	_	
72-11	12944-12948	were	_	
72-12	12949-12958	corrected	_	
72-13	12959-12964	using	_	
72-14	12965-12968	the	_	
72-15	12969-12979	Bonferroni	_	
72-16	12980-12986	method	_	
72-17	12987-12988	(	_	
72-18	12988-12989	P	_	
72-19	12990-12991	<	_	
72-20	12992-12996	0.05	_	
72-21	12996-12997	)	_	
72-22	12997-12998	.	_	

#Text=Results
#Text=Subject demographics and clinical characteristics
#Text=Demographic and clinical characteristics of the participants
#Text=Characteristics\tSchizophrenia Patients\tHealthy Controls\tP value\t \tNumber of subjects\t95\t93\tNA\t \tAge (years)\t33.6 (7.8)\t33.0 (10.2)\t0.633\t \tGender (female/male)\t41/54\t48/45\t0.246\t \tAntipsychotic dosage (mg/d) (chlorpromazine equivalents)\t446.5 (341.6)\t–\tNA\t \tDuration of illness (months)\t121.4 (92.8)\t\tNA\t \tPANSS\t\t–\tNA\t \t Positive score\t17.1 (7.9)\t–\t\t \t Negative score\t20.3 (9.1)\t–\t\t \t General psychopathologyscore\t34.1 (10.8)\t–\t\t \t Total score\t71.5 (23.2)\t–\t\t \t
#Text=Data are shown as the mean (standard deviation).
73-1	12999-13006	Results	_	
73-2	13007-13014	Subject	_	
73-3	13015-13027	demographics	_	
73-4	13028-13031	and	_	
73-5	13032-13040	clinical	_	
73-6	13041-13056	characteristics	_	
73-7	13057-13068	Demographic	_	
73-8	13069-13072	and	_	
73-9	13073-13081	clinical	_	
73-10	13082-13097	characteristics	_	
73-11	13098-13100	of	_	
73-12	13101-13104	the	_	
73-13	13105-13117	participants	_	
73-14	13118-13133	Characteristics	_	
73-15	13134-13147	Schizophrenia	_	
73-16	13148-13156	Patients	_	
73-17	13157-13164	Healthy	_	
73-18	13165-13173	Controls	_	
73-19	13174-13175	P	_	
73-20	13176-13181	value	_	
73-21	13184-13190	Number	_	
73-22	13191-13193	of	_	
73-23	13194-13202	subjects	_	
73-24	13203-13205	95	_	
73-25	13206-13208	93	_	
73-26	13209-13211	NA	_	
73-27	13214-13217	Age	_	
73-28	13218-13219	(	_	
73-29	13219-13224	years	_	
73-30	13224-13225	)	_	
73-31	13226-13230	33.6	_	
73-32	13231-13232	(	_	
73-33	13232-13235	7.8	_	
73-34	13235-13236	)	_	
73-35	13237-13241	33.0	_	
73-36	13242-13243	(	_	
73-37	13243-13247	10.2	_	
73-38	13247-13248	)	_	
73-39	13249-13254	0.633	_	
73-40	13257-13263	Gender	_	
73-41	13264-13265	(	_	
73-42	13265-13271	female	_	
73-43	13271-13272	/	_	
73-44	13272-13276	male	_	
73-45	13276-13277	)	_	
73-46	13278-13280	41	_	
73-47	13280-13281	/	_	
73-48	13281-13283	54	_	
73-49	13284-13286	48	_	
73-50	13286-13287	/	_	
73-51	13287-13289	45	_	
73-52	13290-13295	0.246	_	
73-53	13298-13311	Antipsychotic	_	
73-54	13312-13318	dosage	_	
73-55	13319-13320	(	_	
73-56	13320-13322	mg	_	
73-57	13322-13323	/	_	
73-58	13323-13324	d	_	
73-59	13324-13325	)	_	
73-60	13326-13327	(	_	
73-61	13327-13341	chlorpromazine	_	
73-62	13342-13353	equivalents	_	
73-63	13353-13354	)	_	
73-64	13355-13360	446.5	_	
73-65	13361-13362	(	_	
73-66	13362-13367	341.6	_	
73-67	13367-13368	)	_	
73-68	13369-13370	–	_	
73-69	13371-13373	NA	_	
73-70	13376-13384	Duration	_	
73-71	13385-13387	of	_	
73-72	13388-13395	illness	_	
73-73	13396-13397	(	_	
73-74	13397-13403	months	_	
73-75	13403-13404	)	_	
73-76	13405-13410	121.4	_	
73-77	13411-13412	(	_	
73-78	13412-13416	92.8	_	
73-79	13416-13417	)	_	
73-80	13419-13421	NA	_	
73-81	13424-13429	PANSS	_	
73-82	13431-13432	–	_	
73-83	13433-13435	NA	_	
73-84	13439-13447	Positive	_	
73-85	13448-13453	score	_	
73-86	13454-13458	17.1	_	
73-87	13459-13460	(	_	
73-88	13460-13463	7.9	_	
73-89	13463-13464	)	_	
73-90	13465-13466	–	_	
73-91	13471-13479	Negative	_	
73-92	13480-13485	score	_	
73-93	13486-13490	20.3	_	
73-94	13491-13492	(	_	
73-95	13492-13495	9.1	_	
73-96	13495-13496	)	_	
73-97	13497-13498	–	_	
73-98	13503-13510	General	_	
73-99	13511-13531	psychopathologyscore	_	
73-100	13532-13536	34.1	_	
73-101	13537-13538	(	_	
73-102	13538-13542	10.8	_	
73-103	13542-13543	)	_	
73-104	13544-13545	–	_	
73-105	13550-13555	Total	_	
73-106	13556-13561	score	_	
73-107	13562-13566	71.5	_	
73-108	13567-13568	(	_	
73-109	13568-13572	23.2	_	
73-110	13572-13573	)	_	
73-111	13574-13575	–	_	
73-112	13580-13584	Data	_	
73-113	13585-13588	are	_	
73-114	13589-13594	shown	_	
73-115	13595-13597	as	_	
73-116	13598-13601	the	_	
73-117	13602-13606	mean	_	
73-118	13607-13608	(	_	
73-119	13608-13616	standard	_	
73-120	13617-13626	deviation	_	
73-121	13626-13627	)	_	
73-122	13627-13628	.	_	

#Text=PANSS The Positive and Negative Syndrome Scale
#Text=The demographic and clinical characteristics of the subjects are summarized in Table 1.
74-1	13629-13634	PANSS	_	
74-2	13635-13638	The	_	
74-3	13639-13647	Positive	_	
74-4	13648-13651	and	_	
74-5	13652-13660	Negative	_	
74-6	13661-13669	Syndrome	_	
74-7	13670-13675	Scale	_	
74-8	13676-13679	The	_	
74-9	13680-13691	demographic	_	
74-10	13692-13695	and	_	
74-11	13696-13704	clinical	_	
74-12	13705-13720	characteristics	_	
74-13	13721-13723	of	_	
74-14	13724-13727	the	_	
74-15	13728-13736	subjects	_	
74-16	13737-13740	are	_	
74-17	13741-13751	summarized	_	
74-18	13752-13754	in	_	
74-19	13755-13760	Table	_	
74-20	13760-13761	 	_	
74-21	13761-13762	1	_	
74-22	13762-13763	.	_	

#Text=There were no significant group differences in sex (χ2 = 1.35, P = 0.25) or age (t = 0.48, P = 0.63).
75-1	13764-13769	There	_	
75-2	13770-13774	were	_	
75-3	13775-13777	no	_	
75-4	13778-13789	significant	_	
75-5	13790-13795	group	_	
75-6	13796-13807	differences	_	
75-7	13808-13810	in	_	
75-8	13811-13814	sex	_	
75-9	13815-13816	(	_	
75-10	13816-13818	χ2	_	
75-11	13819-13820	=	_	
75-12	13821-13825	1.35	_	
75-13	13825-13826	,	_	
75-14	13827-13828	P	_	
75-15	13829-13830	=	_	
75-16	13831-13835	0.25	_	
75-17	13835-13836	)	_	
75-18	13837-13839	or	_	
75-19	13840-13843	age	_	
75-20	13844-13845	(	_	
75-21	13845-13846	t	_	
75-22	13847-13848	=	_	
75-23	13849-13853	0.48	_	
75-24	13853-13854	,	_	
75-25	13855-13856	P	_	
75-26	13857-13858	=	_	
75-27	13859-13863	0.63	_	
75-28	13863-13864	)	_	
75-29	13864-13865	.	_	

#Text=Eighty-seven patients received medication during the MRI examinations, with the remaining eight patients being treatment naïve.
76-1	13866-13878	Eighty-seven	_	
76-2	13879-13887	patients	_	
76-3	13888-13896	received	_	
76-4	13897-13907	medication	_	
76-5	13908-13914	during	_	
76-6	13915-13918	the	_	
76-7	13919-13922	MRI	_	
76-8	13923-13935	examinations	_	
76-9	13935-13936	,	_	
76-10	13937-13941	with	_	
76-11	13942-13945	the	_	
76-12	13946-13955	remaining	_	
76-13	13956-13961	eight	_	
76-14	13962-13970	patients	_	
76-15	13971-13976	being	_	
76-16	13977-13986	treatment	_	
76-17	13987-13992	naïve	_	
76-18	13992-13993	.	_	

#Text=The mean antipsychotic dose (cholorpromazin equivalents) was 446.5 ± 341.6 mg/d for the patients with schizophrenia.
77-1	13994-13997	The	_	
77-2	13998-14002	mean	_	
77-3	14003-14016	antipsychotic	_	
77-4	14017-14021	dose	_	
77-5	14022-14023	(	_	
77-6	14023-14037	cholorpromazin	_	
77-7	14038-14049	equivalents	_	
77-8	14049-14050	)	_	
77-9	14051-14054	was	_	
77-10	14055-14060	446.5	_	
77-11	14061-14062	±	_	
77-12	14063-14068	341.6	_	
77-13	14068-14069	 	_	
77-14	14069-14071	mg	_	
77-15	14071-14072	/	_	
77-16	14072-14073	d	_	
77-17	14074-14077	for	_	
77-18	14078-14081	the	_	
77-19	14082-14090	patients	_	
77-20	14091-14095	with	_	
77-21	14096-14109	schizophrenia	_	
77-22	14109-14110	.	_	

#Text=The mean duration of illness was 121.4 ± 92.8 months.
78-1	14111-14114	The	_	
78-2	14115-14119	mean	_	
78-3	14120-14128	duration	_	
78-4	14129-14131	of	_	
78-5	14132-14139	illness	_	
78-6	14140-14143	was	_	
78-7	14144-14149	121.4	_	
78-8	14150-14151	±	_	
78-9	14152-14156	92.8	_	
78-10	14156-14157	 	_	
78-11	14157-14163	months	_	
78-12	14163-14164	.	_	

#Text=Mean scores on the PANSS positive, negative, and general psychopathology subscales were 17.1 ± 7.9, 20.3 ± 9.1, and 34.1 ± 10.8, respectively.
79-1	14165-14169	Mean	_	
79-2	14170-14176	scores	_	
79-3	14177-14179	on	_	
79-4	14180-14183	the	_	
79-5	14184-14189	PANSS	_	
79-6	14190-14198	positive	_	
79-7	14198-14199	,	_	
79-8	14200-14208	negative	_	
79-9	14208-14209	,	_	
79-10	14210-14213	and	_	
79-11	14214-14221	general	_	
79-12	14222-14237	psychopathology	_	
79-13	14238-14247	subscales	_	
79-14	14248-14252	were	_	
79-15	14253-14257	17.1	_	
79-16	14258-14259	±	_	
79-17	14260-14263	7.9	_	
79-18	14263-14264	,	_	
79-19	14265-14269	20.3	_	
79-20	14270-14271	±	_	
79-21	14272-14275	9.1	_	
79-22	14275-14276	,	_	
79-23	14277-14280	and	_	
79-24	14281-14285	34.1	_	
79-25	14286-14287	±	_	
79-26	14288-14292	10.8	_	
79-27	14292-14293	,	_	
79-28	14294-14306	respectively	_	
79-29	14306-14307	.	_	

#Text=Distributed specificity of gFCD hubs in patients and controls
#Text=Spatial distributions of the average rescaled gFCD hubs between patients with schizophrenia and controls.
80-1	14309-14320	Distributed	_	
80-2	14321-14332	specificity	_	
80-3	14333-14335	of	_	
80-4	14336-14340	gFCD	_	
80-5	14341-14345	hubs	_	
80-6	14346-14348	in	_	
80-7	14349-14357	patients	_	
80-8	14358-14361	and	_	
80-9	14362-14370	controls	_	
80-10	14371-14378	Spatial	_	
80-11	14379-14392	distributions	_	
80-12	14393-14395	of	_	
80-13	14396-14399	the	_	
80-14	14400-14407	average	_	
80-15	14408-14416	rescaled	_	
80-16	14417-14421	gFCD	_	
80-17	14422-14426	hubs	_	
80-18	14427-14434	between	_	
80-19	14435-14443	patients	_	
80-20	14444-14448	with	_	
80-21	14449-14462	schizophrenia	_	
80-22	14463-14466	and	_	
80-23	14467-14475	controls	_	
80-24	14475-14476	.	_	

#Text=Abbreviations: gFCD, global FCD; HC, healthy controls; SZ, patients with schizophrenia
#Text=Our results revealed that the strongest gFCD hubs were consistently located in the precuneus, inferior parietal lobe, superior temporal gyrus, medial prefrontal cortex, and dorsal lateral prefrontal cortex in our two groups.
81-1	14477-14490	Abbreviations	_	
81-2	14490-14491	:	_	
81-3	14492-14496	gFCD	_	
81-4	14496-14497	,	_	
81-5	14498-14504	global	_	
81-6	14505-14508	FCD	_	
81-7	14508-14509	;	_	
81-8	14510-14512	HC	_	
81-9	14512-14513	,	_	
81-10	14514-14521	healthy	_	
81-11	14522-14530	controls	_	
81-12	14530-14531	;	_	
81-13	14532-14534	SZ	_	
81-14	14534-14535	,	_	
81-15	14536-14544	patients	_	
81-16	14545-14549	with	_	
81-17	14550-14563	schizophrenia	_	
81-18	14564-14567	Our	_	
81-19	14568-14575	results	_	
81-20	14576-14584	revealed	_	
81-21	14585-14589	that	_	
81-22	14590-14593	the	_	
81-23	14594-14603	strongest	_	
81-24	14604-14608	gFCD	_	
81-25	14609-14613	hubs	_	
81-26	14614-14618	were	_	
81-27	14619-14631	consistently	_	
81-28	14632-14639	located	_	
81-29	14640-14642	in	_	
81-30	14643-14646	the	_	
81-31	14647-14656	precuneus	_	
81-32	14656-14657	,	_	
81-33	14658-14666	inferior	_	
81-34	14667-14675	parietal	_	
81-35	14676-14680	lobe	_	
81-36	14680-14681	,	_	
81-37	14682-14690	superior	_	
81-38	14691-14699	temporal	_	
81-39	14700-14705	gyrus	_	
81-40	14705-14706	,	_	
81-41	14707-14713	medial	_	
81-42	14714-14724	prefrontal	_	
81-43	14725-14731	cortex	_	
81-44	14731-14732	,	_	
81-45	14733-14736	and	_	
81-46	14737-14743	dorsal	_	
81-47	14744-14751	lateral	_	
81-48	14752-14762	prefrontal	_	
81-49	14763-14769	cortex	_	
81-50	14770-14772	in	_	
81-51	14773-14776	our	_	
81-52	14777-14780	two	_	
81-53	14781-14787	groups	_	
81-54	14787-14788	.	_	

#Text=Most of the gFCD hubs are located in the default mode network and sensory cortices (Fig. 2).
82-1	14789-14793	Most	_	
82-2	14794-14796	of	_	
82-3	14797-14800	the	_	
82-4	14801-14805	gFCD	_	
82-5	14806-14810	hubs	_	
82-6	14811-14814	are	_	
82-7	14815-14822	located	_	
82-8	14823-14825	in	_	
82-9	14826-14829	the	_	
82-10	14830-14837	default	_	
82-11	14838-14842	mode	_	
82-12	14843-14850	network	_	
82-13	14851-14854	and	_	
82-14	14855-14862	sensory	_	
82-15	14863-14871	cortices	_	
82-16	14872-14873	(	_	
82-17	14873-14876	Fig	_	
82-18	14876-14877	.	_	
82-19	14877-14878	 	_	
82-20	14878-14879	2	_	
82-21	14879-14880	)	_	
82-22	14880-14881	.	_	

#Text=The distribution of the gFCD hubs did not differ between the two groups and was also consistent with the results of Tomasi et al..
83-1	14882-14885	The	_	
83-2	14886-14898	distribution	_	
83-3	14899-14901	of	_	
83-4	14902-14905	the	_	
83-5	14906-14910	gFCD	_	
83-6	14911-14915	hubs	_	
83-7	14916-14919	did	_	
83-8	14920-14923	not	_	
83-9	14924-14930	differ	_	
83-10	14931-14938	between	_	
83-11	14939-14942	the	_	
83-12	14943-14946	two	_	
83-13	14947-14953	groups	_	
83-14	14954-14957	and	_	
83-15	14958-14961	was	_	
83-16	14962-14966	also	_	
83-17	14967-14977	consistent	_	
83-18	14978-14982	with	_	
83-19	14983-14986	the	_	
83-20	14987-14994	results	_	
83-21	14995-14997	of	_	
83-22	14998-15004	Tomasi	_	
83-23	15005-15007	et	_	
83-24	15008-15010	al	_	
83-25	15010-15011	.	_	
83-26	15011-15012	.	_	

#Text=gFCD changes in patients with schizophrenia
#Text=ROI-based gFCD and GMV comparisons in regions exhibiting group differences in gFCD voxel-based analysis.
84-1	15014-15018	gFCD	_	
84-2	15019-15026	changes	_	
84-3	15027-15029	in	_	
84-4	15030-15038	patients	_	
84-5	15039-15043	with	_	
84-6	15044-15057	schizophrenia	_	
84-7	15058-15067	ROI-based	_	
84-8	15068-15072	gFCD	_	
84-9	15073-15076	and	_	
84-10	15077-15080	GMV	_	
84-11	15081-15092	comparisons	_	
84-12	15093-15095	in	_	
84-13	15096-15103	regions	_	
84-14	15104-15114	exhibiting	_	
84-15	15115-15120	group	_	
84-16	15121-15132	differences	_	
84-17	15133-15135	in	_	
84-18	15136-15140	gFCD	_	
84-19	15141-15152	voxel-based	_	
84-20	15153-15161	analysis	_	
84-21	15161-15162	.	_	

#Text=Note: Error bars indicate the standard deviations of the means.
85-1	15163-15167	Note	_	
85-2	15167-15168	:	_	
85-3	15169-15174	Error	_	
85-4	15175-15179	bars	_	
85-5	15180-15188	indicate	_	
85-6	15189-15192	the	_	
85-7	15193-15201	standard	_	
85-8	15202-15212	deviations	_	
85-9	15213-15215	of	_	
85-10	15216-15219	the	_	
85-11	15220-15225	means	_	
85-12	15225-15226	.	_	

#Text=*P < 0.05, Bonferroni corrected.
86-1	15227-15228	*	_	
86-2	15228-15229	P	_	
86-3	15230-15231	<	_	
86-4	15232-15236	0.05	_	
86-5	15236-15237	,	_	
86-6	15238-15248	Bonferroni	_	
86-7	15249-15258	corrected	_	
86-8	15258-15259	.	_	

#Text=Cal, calcarine gyrus; Cau, caudate; FCD, functional connectivity density; HC, healthy controls; HP, hippocampus; IPL, parietal inferior lobule; ITG, inferior temporal gyrus; PH, parahippocampal gyrus; Post CG, postcentral gyrus; Put, putamen; SMA, supplementary motor area; SZ, patients with schizophrenia; Th, thalamus.
87-1	15260-15263	Cal	_	
87-2	15263-15264	,	_	
87-3	15265-15274	calcarine	_	
87-4	15275-15280	gyrus	_	
87-5	15280-15281	;	_	
87-6	15282-15285	Cau	_	
87-7	15285-15286	,	_	
87-8	15287-15294	caudate	_	
87-9	15294-15295	;	_	
87-10	15296-15299	FCD	_	
87-11	15299-15300	,	_	
87-12	15301-15311	functional	_	
87-13	15312-15324	connectivity	_	
87-14	15325-15332	density	_	
87-15	15332-15333	;	_	
87-16	15334-15336	HC	_	
87-17	15336-15337	,	_	
87-18	15338-15345	healthy	_	
87-19	15346-15354	controls	_	
87-20	15354-15355	;	_	
87-21	15356-15358	HP	_	
87-22	15358-15359	,	_	
87-23	15360-15371	hippocampus	_	
87-24	15371-15372	;	_	
87-25	15373-15376	IPL	_	
87-26	15376-15377	,	_	
87-27	15378-15386	parietal	_	
87-28	15387-15395	inferior	_	
87-29	15396-15402	lobule	_	
87-30	15402-15403	;	_	
87-31	15404-15407	ITG	_	
87-32	15407-15408	,	_	
87-33	15409-15417	inferior	_	
87-34	15418-15426	temporal	_	
87-35	15427-15432	gyrus	_	
87-36	15432-15433	;	_	
87-37	15434-15436	PH	_	
87-38	15436-15437	,	_	
87-39	15438-15453	parahippocampal	_	
87-40	15454-15459	gyrus	_	
87-41	15459-15460	;	_	
87-42	15461-15465	Post	_	
87-43	15466-15468	CG	_	
87-44	15468-15469	,	_	
87-45	15470-15481	postcentral	_	
87-46	15482-15487	gyrus	_	
87-47	15487-15488	;	_	
87-48	15489-15492	Put	_	
87-49	15492-15493	,	_	
87-50	15494-15501	putamen	_	
87-51	15501-15502	;	_	
87-52	15503-15506	SMA	_	
87-53	15506-15507	,	_	
87-54	15508-15521	supplementary	_	
87-55	15522-15527	motor	_	
87-56	15528-15532	area	_	
87-57	15532-15533	;	_	
87-58	15534-15536	SZ	_	
87-59	15536-15537	,	_	
87-60	15538-15546	patients	_	
87-61	15547-15551	with	_	
87-62	15552-15565	schizophrenia	_	
87-63	15565-15566	;	_	
87-64	15567-15569	Th	_	
87-65	15569-15570	,	_	
87-66	15571-15579	thalamus	_	
87-67	15579-15580	.	_	

#Text=(a) Schizophrenia patient's gFCD is increased compareded to healthy controls in sub-cortical regions (with an exception of supplementary motor area) (b) Schizophrenia patient's gFCD is decreased compareded to healthy controls in cortical regions (c) Schizophrenia patient's GMV is decreased compareded to healthy controls in sub-cortical regions (d) Schizophrenia patient's GMV is decreased compareded to healthy controls in cortical regions
#Text=Global FCD changes in patients with schizophrenia relative to healthy controls
#Text=Regions\tBrodmann areas\tCluster size (Voxels)\tPeak t values\tCoordinates in MNI (x, y, z)\t \tSchizophrenia patients > Healthy controls\t \t Left putamen\t–\t218\t4.87\t−12, 3, −6\t \t Right putamen\t–\t177\t5.09\t12, 12, −9\t \t Left caudate\t–\t77\t3.75\t−15, −18, 18\t \t Left hippocampus\t–\t59\t4.35\t−27, −33, −6\t \t Left parahippocampal gyrus\t–\t47\t4.47\t−27, −24, −18\t \t Left supplementary motor area\t6\t28\t4.52\t−3, 0, 72\t \t Left thalamus\t–\t31\t3.94\t−6, −27, 0\t \t Right thalamus\t–\t42\t4.18\t9, −24, −3\t \tSchizophrenia patients < Healthy controls\t \t Right calcarine gyrus\t18\t132\t−4.67\t18, −87, 12\t \t Left parietal inferior lobule\t40\t31\t−4.12\t−39, −33, 36\t \t Right inferior temporal gyrus\t37\t46\t−4.67\t42, −66, −6\t \t Left postcentral gyrus\t4, 6\t110\t−4.81\t−54, −12, 36\t \t Right postcentral gyrus\t2, 3, 4\t90\t−4.32\t48, −24, 45\t \t
#Text=
#Text=FCD functional connectivity density, MNI Montreal Neurological Institute
#Text=Voxel-wise analysis showed increased gFCD in the sub-cortical and limbic system areas (including the bilateral putamen, caudate, pallidum, and thalami), the hippocampal/parahippocampal complex, and the supplementary motor area (SMA) (Fig. 3a, Table 2).
88-1	15581-15582	(	_	
88-2	15582-15583	a	_	
88-3	15583-15584	)	_	
88-4	15585-15598	Schizophrenia	_	
88-5	15599-15608	patient's	_	
88-6	15609-15613	gFCD	_	
88-7	15614-15616	is	_	
88-8	15617-15626	increased	_	
88-9	15627-15637	compareded	_	
88-10	15638-15640	to	_	
88-11	15641-15648	healthy	_	
88-12	15649-15657	controls	_	
88-13	15658-15660	in	_	
88-14	15661-15673	sub-cortical	_	
88-15	15674-15681	regions	_	
88-16	15682-15683	(	_	
88-17	15683-15687	with	_	
88-18	15688-15690	an	_	
88-19	15691-15700	exception	_	
88-20	15701-15703	of	_	
88-21	15704-15717	supplementary	_	
88-22	15718-15723	motor	_	
88-23	15724-15728	area	_	
88-24	15728-15729	)	_	
88-25	15730-15731	(	_	
88-26	15731-15732	b	_	
88-27	15732-15733	)	_	
88-28	15734-15747	Schizophrenia	_	
88-29	15748-15757	patient's	_	
88-30	15758-15762	gFCD	_	
88-31	15763-15765	is	_	
88-32	15766-15775	decreased	_	
88-33	15776-15786	compareded	_	
88-34	15787-15789	to	_	
88-35	15790-15797	healthy	_	
88-36	15798-15806	controls	_	
88-37	15807-15809	in	_	
88-38	15810-15818	cortical	_	
88-39	15819-15826	regions	_	
88-40	15827-15828	(	_	
88-41	15828-15829	c	_	
88-42	15829-15830	)	_	
88-43	15831-15844	Schizophrenia	_	
88-44	15845-15854	patient's	_	
88-45	15855-15858	GMV	_	
88-46	15859-15861	is	_	
88-47	15862-15871	decreased	_	
88-48	15872-15882	compareded	_	
88-49	15883-15885	to	_	
88-50	15886-15893	healthy	_	
88-51	15894-15902	controls	_	
88-52	15903-15905	in	_	
88-53	15906-15918	sub-cortical	_	
88-54	15919-15926	regions	_	
88-55	15927-15928	(	_	
88-56	15928-15929	d	_	
88-57	15929-15930	)	_	
88-58	15931-15944	Schizophrenia	_	
88-59	15945-15954	patient's	_	
88-60	15955-15958	GMV	_	
88-61	15959-15961	is	_	
88-62	15962-15971	decreased	_	
88-63	15972-15982	compareded	_	
88-64	15983-15985	to	_	
88-65	15986-15993	healthy	_	
88-66	15994-16002	controls	_	
88-67	16003-16005	in	_	
88-68	16006-16014	cortical	_	
88-69	16015-16022	regions	_	
88-70	16023-16029	Global	_	
88-71	16030-16033	FCD	_	
88-72	16034-16041	changes	_	
88-73	16042-16044	in	_	
88-74	16045-16053	patients	_	
88-75	16054-16058	with	_	
88-76	16059-16072	schizophrenia	_	
88-77	16073-16081	relative	_	
88-78	16082-16084	to	_	
88-79	16085-16092	healthy	_	
88-80	16093-16101	controls	_	
88-81	16102-16109	Regions	_	
88-82	16110-16118	Brodmann	_	
88-83	16119-16124	areas	_	
88-84	16125-16132	Cluster	_	
88-85	16133-16137	size	_	
88-86	16138-16139	(	_	
88-87	16139-16145	Voxels	_	
88-88	16145-16146	)	_	
88-89	16147-16151	Peak	_	
88-90	16152-16153	t	_	
88-91	16154-16160	values	_	
88-92	16161-16172	Coordinates	_	
88-93	16173-16175	in	_	
88-94	16176-16179	MNI	_	
88-95	16180-16181	(	_	
88-96	16181-16182	x	_	
88-97	16182-16183	,	_	
88-98	16184-16185	y	_	
88-99	16185-16186	,	_	
88-100	16187-16188	z	_	
88-101	16188-16189	)	_	
88-102	16192-16205	Schizophrenia	_	
88-103	16206-16214	patients	_	
88-104	16215-16216	>	_	
88-105	16217-16224	Healthy	_	
88-106	16225-16233	controls	_	
88-107	16237-16241	Left	_	
88-108	16242-16249	putamen	_	
88-109	16250-16251	–	_	
88-110	16252-16255	218	_	
88-111	16256-16260	4.87	_	
88-112	16261-16262	−	_	
88-113	16262-16264	12	_	
88-114	16264-16265	,	_	
88-115	16266-16267	3	_	
88-116	16267-16268	,	_	
88-117	16269-16270	−	_	
88-118	16270-16271	6	_	
88-119	16275-16280	Right	_	
88-120	16281-16288	putamen	_	
88-121	16289-16290	–	_	
88-122	16291-16294	177	_	
88-123	16295-16299	5.09	_	
88-124	16300-16302	12	_	
88-125	16302-16303	,	_	
88-126	16304-16306	12	_	
88-127	16306-16307	,	_	
88-128	16308-16309	−	_	
88-129	16309-16310	9	_	
88-130	16314-16318	Left	_	
88-131	16319-16326	caudate	_	
88-132	16327-16328	–	_	
88-133	16329-16331	77	_	
88-134	16332-16336	3.75	_	
88-135	16337-16338	−	_	
88-136	16338-16340	15	_	
88-137	16340-16341	,	_	
88-138	16342-16343	−	_	
88-139	16343-16345	18	_	
88-140	16345-16346	,	_	
88-141	16347-16349	18	_	
88-142	16353-16357	Left	_	
88-143	16358-16369	hippocampus	_	
88-144	16370-16371	–	_	
88-145	16372-16374	59	_	
88-146	16375-16379	4.35	_	
88-147	16380-16381	−	_	
88-148	16381-16383	27	_	
88-149	16383-16384	,	_	
88-150	16385-16386	−	_	
88-151	16386-16388	33	_	
88-152	16388-16389	,	_	
88-153	16390-16391	−	_	
88-154	16391-16392	6	_	
88-155	16396-16400	Left	_	
88-156	16401-16416	parahippocampal	_	
88-157	16417-16422	gyrus	_	
88-158	16423-16424	–	_	
88-159	16425-16427	47	_	
88-160	16428-16432	4.47	_	
88-161	16433-16434	−	_	
88-162	16434-16436	27	_	
88-163	16436-16437	,	_	
88-164	16438-16439	−	_	
88-165	16439-16441	24	_	
88-166	16441-16442	,	_	
88-167	16443-16444	−	_	
88-168	16444-16446	18	_	
88-169	16450-16454	Left	_	
88-170	16455-16468	supplementary	_	
88-171	16469-16474	motor	_	
88-172	16475-16479	area	_	
88-173	16480-16481	6	_	
88-174	16482-16484	28	_	
88-175	16485-16489	4.52	_	
88-176	16490-16491	−	_	
88-177	16491-16492	3	_	
88-178	16492-16493	,	_	
88-179	16494-16495	0	_	
88-180	16495-16496	,	_	
88-181	16497-16499	72	_	
88-182	16503-16507	Left	_	
88-183	16508-16516	thalamus	_	
88-184	16517-16518	–	_	
88-185	16519-16521	31	_	
88-186	16522-16526	3.94	_	
88-187	16527-16528	−	_	
88-188	16528-16529	6	_	
88-189	16529-16530	,	_	
88-190	16531-16532	−	_	
88-191	16532-16534	27	_	
88-192	16534-16535	,	_	
88-193	16536-16537	0	_	
88-194	16541-16546	Right	_	
88-195	16547-16555	thalamus	_	
88-196	16556-16557	–	_	
88-197	16558-16560	42	_	
88-198	16561-16565	4.18	_	
88-199	16566-16567	9	_	
88-200	16567-16568	,	_	
88-201	16569-16570	−	_	
88-202	16570-16572	24	_	
88-203	16572-16573	,	_	
88-204	16574-16575	−	_	
88-205	16575-16576	3	_	
88-206	16579-16592	Schizophrenia	_	
88-207	16593-16601	patients	_	
88-208	16602-16603	<	_	
88-209	16604-16611	Healthy	_	
88-210	16612-16620	controls	_	
88-211	16624-16629	Right	_	
88-212	16630-16639	calcarine	_	
88-213	16640-16645	gyrus	_	
88-214	16646-16648	18	_	
88-215	16649-16652	132	_	
88-216	16653-16654	−	_	
88-217	16654-16658	4.67	_	
88-218	16659-16661	18	_	
88-219	16661-16662	,	_	
88-220	16663-16664	−	_	
88-221	16664-16666	87	_	
88-222	16666-16667	,	_	
88-223	16668-16670	12	_	
88-224	16674-16678	Left	_	
88-225	16679-16687	parietal	_	
88-226	16688-16696	inferior	_	
88-227	16697-16703	lobule	_	
88-228	16704-16706	40	_	
88-229	16707-16709	31	_	
88-230	16710-16711	−	_	
88-231	16711-16715	4.12	_	
88-232	16716-16717	−	_	
88-233	16717-16719	39	_	
88-234	16719-16720	,	_	
88-235	16721-16722	−	_	
88-236	16722-16724	33	_	
88-237	16724-16725	,	_	
88-238	16726-16728	36	_	
88-239	16732-16737	Right	_	
88-240	16738-16746	inferior	_	
88-241	16747-16755	temporal	_	
88-242	16756-16761	gyrus	_	
88-243	16762-16764	37	_	
88-244	16765-16767	46	_	
88-245	16768-16769	−	_	
88-246	16769-16773	4.67	_	
88-247	16774-16776	42	_	
88-248	16776-16777	,	_	
88-249	16778-16779	−	_	
88-250	16779-16781	66	_	
88-251	16781-16782	,	_	
88-252	16783-16784	−	_	
88-253	16784-16785	6	_	
88-254	16789-16793	Left	_	
88-255	16794-16805	postcentral	_	
88-256	16806-16811	gyrus	_	
88-257	16812-16813	4	_	
88-258	16813-16814	,	_	
88-259	16815-16816	6	_	
88-260	16817-16820	110	_	
88-261	16821-16822	−	_	
88-262	16822-16826	4.81	_	
88-263	16827-16828	−	_	
88-264	16828-16830	54	_	
88-265	16830-16831	,	_	
88-266	16832-16833	−	_	
88-267	16833-16835	12	_	
88-268	16835-16836	,	_	
88-269	16837-16839	36	_	
88-270	16843-16848	Right	_	
88-271	16849-16860	postcentral	_	
88-272	16861-16866	gyrus	_	
88-273	16867-16868	2	_	
88-274	16868-16869	,	_	
88-275	16870-16871	3	_	
88-276	16871-16872	,	_	
88-277	16873-16874	4	_	
88-278	16875-16877	90	_	
88-279	16878-16879	−	_	
88-280	16879-16883	4.32	_	
88-281	16884-16886	48	_	
88-282	16886-16887	,	_	
88-283	16888-16889	−	_	
88-284	16889-16891	24	_	
88-285	16891-16892	,	_	
88-286	16893-16895	45	_	
88-287	16900-16903	FCD	_	
88-288	16904-16914	functional	_	
88-289	16915-16927	connectivity	_	
88-290	16928-16935	density	_	
88-291	16935-16936	,	_	
88-292	16937-16940	MNI	_	
88-293	16941-16949	Montreal	_	
88-294	16950-16962	Neurological	_	
88-295	16963-16972	Institute	_	
88-296	16973-16983	Voxel-wise	_	
88-297	16984-16992	analysis	_	
88-298	16993-16999	showed	_	
88-299	17000-17009	increased	_	
88-300	17010-17014	gFCD	_	
88-301	17015-17017	in	_	
88-302	17018-17021	the	_	
88-303	17022-17034	sub-cortical	_	
88-304	17035-17038	and	_	
88-305	17039-17045	limbic	_	
88-306	17046-17052	system	_	
88-307	17053-17058	areas	_	
88-308	17059-17060	(	_	
88-309	17060-17069	including	_	
88-310	17070-17073	the	_	
88-311	17074-17083	bilateral	_	
88-312	17084-17091	putamen	_	
88-313	17091-17092	,	_	
88-314	17093-17100	caudate	_	
88-315	17100-17101	,	_	
88-316	17102-17110	pallidum	_	
88-317	17110-17111	,	_	
88-318	17112-17115	and	_	
88-319	17116-17123	thalami	_	
88-320	17123-17124	)	_	
88-321	17124-17125	,	_	
88-322	17126-17129	the	_	
88-323	17130-17141	hippocampal	_	
88-324	17141-17142	/	_	
88-325	17142-17157	parahippocampal	_	
88-326	17158-17165	complex	_	
88-327	17165-17166	,	_	
88-328	17167-17170	and	_	
88-329	17171-17174	the	_	
88-330	17175-17188	supplementary	_	
88-331	17189-17194	motor	_	
88-332	17195-17199	area	_	
88-333	17200-17201	(	_	
88-334	17201-17204	SMA	_	
88-335	17204-17205	)	_	
88-336	17206-17207	(	_	
88-337	17207-17210	Fig	_	
88-338	17210-17211	.	_	
88-339	17211-17212	 	_	
88-340	17212-17214	3a	_	
88-341	17214-17215	,	_	
88-342	17216-17221	Table	_	
88-343	17221-17222	 	_	
88-344	17222-17223	2	_	
88-345	17223-17224	)	_	
88-346	17224-17225	.	_	

#Text=Decreased gFCD was seen in the posterior cortices, including the bilateral postcentral gyri, precentral gyri, right calcarine sulcus, and the left inferior occipital gyrus lobule in patients with schizophrenia (Fig. 3b, Table 2).
89-1	17226-17235	Decreased	_	
89-2	17236-17240	gFCD	_	
89-3	17241-17244	was	_	
89-4	17245-17249	seen	_	
89-5	17250-17252	in	_	
89-6	17253-17256	the	_	
89-7	17257-17266	posterior	_	
89-8	17267-17275	cortices	_	
89-9	17275-17276	,	_	
89-10	17277-17286	including	_	
89-11	17287-17290	the	_	
89-12	17291-17300	bilateral	_	
89-13	17301-17312	postcentral	_	
89-14	17313-17317	gyri	_	
89-15	17317-17318	,	_	
89-16	17319-17329	precentral	_	
89-17	17330-17334	gyri	_	
89-18	17334-17335	,	_	
89-19	17336-17341	right	_	
89-20	17342-17351	calcarine	_	
89-21	17352-17358	sulcus	_	
89-22	17358-17359	,	_	
89-23	17360-17363	and	_	
89-24	17364-17367	the	_	
89-25	17368-17372	left	_	
89-26	17373-17381	inferior	_	
89-27	17382-17391	occipital	_	
89-28	17392-17397	gyrus	_	
89-29	17398-17404	lobule	_	
89-30	17405-17407	in	_	
89-31	17408-17416	patients	_	
89-32	17417-17421	with	_	
89-33	17422-17435	schizophrenia	_	
89-34	17436-17437	(	_	
89-35	17437-17440	Fig	_	
89-36	17440-17441	.	_	
89-37	17441-17442	 	_	
89-38	17442-17444	3b	_	
89-39	17444-17445	,	_	
89-40	17446-17451	Table	_	
89-41	17451-17452	 	_	
89-42	17452-17453	2	_	
89-43	17453-17454	)	_	
89-44	17454-17455	.	_	

#Text=ROI-based analyses showed that the differences in gFCD between schizophrenia patients and controls persisted even further regress out the GMV effect, suggesting that gFCD alterations in these ROIs are relatively independent characteristics of schizophrenia.
90-1	17456-17465	ROI-based	_	
90-2	17466-17474	analyses	_	
90-3	17475-17481	showed	_	
90-4	17482-17486	that	_	
90-5	17487-17490	the	_	
90-6	17491-17502	differences	_	
90-7	17503-17505	in	_	
90-8	17506-17510	gFCD	_	
90-9	17511-17518	between	_	
90-10	17519-17532	schizophrenia	_	
90-11	17533-17541	patients	_	
90-12	17542-17545	and	_	
90-13	17546-17554	controls	_	
90-14	17555-17564	persisted	_	
90-15	17565-17569	even	_	
90-16	17570-17577	further	_	
90-17	17578-17585	regress	_	
90-18	17586-17589	out	_	
90-19	17590-17593	the	_	
90-20	17594-17597	GMV	_	
90-21	17598-17604	effect	_	
90-22	17604-17605	,	_	
90-23	17606-17616	suggesting	_	
90-24	17617-17621	that	_	
90-25	17622-17626	gFCD	_	
90-26	17627-17638	alterations	_	
90-27	17639-17641	in	_	
90-28	17642-17647	these	_	
90-29	17648-17652	ROIs	_	
90-30	17653-17656	are	_	
90-31	17657-17667	relatively	_	
90-32	17668-17679	independent	_	
90-33	17680-17695	characteristics	_	
90-34	17696-17698	of	_	
90-35	17699-17712	schizophrenia	_	
90-36	17712-17713	.	_	

#Text=Gray matter volume changes in patients with schizophrenia
#Text=Group differences in GMV between patients with schizophrenia and controls
#Text=\tHC\tSZ\tF\tSig.
91-1	17716-17720	Gray	_	
91-2	17721-17727	matter	_	
91-3	17728-17734	volume	_	
91-4	17735-17742	changes	_	
91-5	17743-17745	in	_	
91-6	17746-17754	patients	_	
91-7	17755-17759	with	_	
91-8	17760-17773	schizophrenia	_	
91-9	17774-17779	Group	_	
91-10	17780-17791	differences	_	
91-11	17792-17794	in	_	
91-12	17795-17798	GMV	_	
91-13	17799-17806	between	_	
91-14	17807-17815	patients	_	
91-15	17816-17820	with	_	
91-16	17821-17834	schizophrenia	_	
91-17	17835-17838	and	_	
91-18	17839-17847	controls	_	
91-19	17849-17851	HC	_	
91-20	17852-17854	SZ	_	
91-21	17855-17856	F	_	
91-22	17857-17860	Sig	_	
91-23	17860-17861	.	_	

#Text=Striatum_L\t0.520 ± 0.059\t0.482 ± 0.066\t17.778\t<0.001\t \tStriatum_R\t0.552 ± 0.062\t0.499 ± 0.064\t35.410\t<0.001\t \tCau_L\t0.306 ± 0.030\t0.299 ± 0.034\t2.436\t0.120\t \tHP_L\t0.522 ± 0.043\t0.493 ± 0.048\t17.063\t<0.001\t \tPH_L\t0.709 ± 0.049\t0.682 ± 0.055\t11.519\t0.001\t \tSMA_L\t0.338 ± 0.049\t0.330 ± 0.056\t.726\t0.395\t \tTh_L\t0.553 ± 0.067\t0.508 ± 0.071\t17.739\t<0.001\t \tTh_R\t0.596 ± 0.070\t0.551 ± 0.082\t13.913\t<0.001\t \tCal_R\t0.387 ± 0.045\t0.353 ± 0.047\t22.458\t<0.001\t \tIPL_L\t0.528 ± 0.089\t0.496 ± 0.082\t5.438\t0.021\t \tITG_R\t0.611 ± 0.077\t0.569 ± 0.078\t14.333\t<0.001\t \tPost_CG_L\t0.448 ± 0.055\t0.419 ± 0.056\t11.270\t0.001\t \tPost_CG_R\t0.572 ± 0.067\t0.535 ± 0.058\t14.566\t<0.001\t \t
#Text=age and sex effects were regressed out
#Text=Decreased GMV was seen only in the bilateral frontal, parietal, temporal, occipital lobule, cingulate cortex, insular, striatum and thalamus in patients with schizophrenia (Fig. 3c and d and Table 3).
92-1	17864-17874	Striatum_L	_	
92-2	17875-17880	0.520	_	
92-3	17881-17882	±	_	
92-4	17883-17888	0.059	_	
92-5	17889-17894	0.482	_	
92-6	17895-17896	±	_	
92-7	17897-17902	0.066	_	
92-8	17903-17909	17.778	_	
92-9	17910-17911	<	_	
92-10	17911-17916	0.001	_	
92-11	17919-17929	Striatum_R	_	
92-12	17930-17935	0.552	_	
92-13	17936-17937	±	_	
92-14	17938-17943	0.062	_	
92-15	17944-17949	0.499	_	
92-16	17950-17951	±	_	
92-17	17952-17957	0.064	_	
92-18	17958-17964	35.410	_	
92-19	17965-17966	<	_	
92-20	17966-17971	0.001	_	
92-21	17974-17979	Cau_L	_	
92-22	17980-17985	0.306	_	
92-23	17986-17987	±	_	
92-24	17988-17993	0.030	_	
92-25	17994-17999	0.299	_	
92-26	18000-18001	±	_	
92-27	18002-18007	0.034	_	
92-28	18008-18013	2.436	_	
92-29	18014-18019	0.120	_	
92-30	18022-18026	HP_L	_	
92-31	18027-18032	0.522	_	
92-32	18033-18034	±	_	
92-33	18035-18040	0.043	_	
92-34	18041-18046	0.493	_	
92-35	18047-18048	±	_	
92-36	18049-18054	0.048	_	
92-37	18055-18061	17.063	_	
92-38	18062-18063	<	_	
92-39	18063-18068	0.001	_	
92-40	18071-18075	PH_L	_	
92-41	18076-18081	0.709	_	
92-42	18082-18083	±	_	
92-43	18084-18089	0.049	_	
92-44	18090-18095	0.682	_	
92-45	18096-18097	±	_	
92-46	18098-18103	0.055	_	
92-47	18104-18110	11.519	_	
92-48	18111-18116	0.001	_	
92-49	18119-18124	SMA_L	_	
92-50	18125-18130	0.338	_	
92-51	18131-18132	±	_	
92-52	18133-18138	0.049	_	
92-53	18139-18144	0.330	_	
92-54	18145-18146	±	_	
92-55	18147-18152	0.056	_	
92-56	18153-18157	.726	_	
92-57	18158-18163	0.395	_	
92-58	18166-18170	Th_L	_	
92-59	18171-18176	0.553	_	
92-60	18177-18178	±	_	
92-61	18179-18184	0.067	_	
92-62	18185-18190	0.508	_	
92-63	18191-18192	±	_	
92-64	18193-18198	0.071	_	
92-65	18199-18205	17.739	_	
92-66	18206-18207	<	_	
92-67	18207-18212	0.001	_	
92-68	18215-18219	Th_R	_	
92-69	18220-18225	0.596	_	
92-70	18226-18227	±	_	
92-71	18228-18233	0.070	_	
92-72	18234-18239	0.551	_	
92-73	18240-18241	±	_	
92-74	18242-18247	0.082	_	
92-75	18248-18254	13.913	_	
92-76	18255-18256	<	_	
92-77	18256-18261	0.001	_	
92-78	18264-18269	Cal_R	_	
92-79	18270-18275	0.387	_	
92-80	18276-18277	±	_	
92-81	18278-18283	0.045	_	
92-82	18284-18289	0.353	_	
92-83	18290-18291	±	_	
92-84	18292-18297	0.047	_	
92-85	18298-18304	22.458	_	
92-86	18305-18306	<	_	
92-87	18306-18311	0.001	_	
92-88	18314-18319	IPL_L	_	
92-89	18320-18325	0.528	_	
92-90	18326-18327	±	_	
92-91	18328-18333	0.089	_	
92-92	18334-18339	0.496	_	
92-93	18340-18341	±	_	
92-94	18342-18347	0.082	_	
92-95	18348-18353	5.438	_	
92-96	18354-18359	0.021	_	
92-97	18362-18367	ITG_R	_	
92-98	18368-18373	0.611	_	
92-99	18374-18375	±	_	
92-100	18376-18381	0.077	_	
92-101	18382-18387	0.569	_	
92-102	18388-18389	±	_	
92-103	18390-18395	0.078	_	
92-104	18396-18402	14.333	_	
92-105	18403-18404	<	_	
92-106	18404-18409	0.001	_	
92-107	18412-18421	Post_CG_L	_	
92-108	18422-18427	0.448	_	
92-109	18428-18429	±	_	
92-110	18430-18435	0.055	_	
92-111	18436-18441	0.419	_	
92-112	18442-18443	±	_	
92-113	18444-18449	0.056	_	
92-114	18450-18456	11.270	_	
92-115	18457-18462	0.001	_	
92-116	18465-18474	Post_CG_R	_	
92-117	18475-18480	0.572	_	
92-118	18481-18482	±	_	
92-119	18483-18488	0.067	_	
92-120	18489-18494	0.535	_	
92-121	18495-18496	±	_	
92-122	18497-18502	0.058	_	
92-123	18503-18509	14.566	_	
92-124	18510-18511	<	_	
92-125	18511-18516	0.001	_	
92-126	18520-18523	age	_	
92-127	18524-18527	and	_	
92-128	18528-18531	sex	_	
92-129	18532-18539	effects	_	
92-130	18540-18544	were	_	
92-131	18545-18554	regressed	_	
92-132	18555-18558	out	_	
92-133	18559-18568	Decreased	_	
92-134	18569-18572	GMV	_	
92-135	18573-18576	was	_	
92-136	18577-18581	seen	_	
92-137	18582-18586	only	_	
92-138	18587-18589	in	_	
92-139	18590-18593	the	_	
92-140	18594-18603	bilateral	_	
92-141	18604-18611	frontal	_	
92-142	18611-18612	,	_	
92-143	18613-18621	parietal	_	
92-144	18621-18622	,	_	
92-145	18623-18631	temporal	_	
92-146	18631-18632	,	_	
92-147	18633-18642	occipital	_	
92-148	18643-18649	lobule	_	
92-149	18649-18650	,	_	
92-150	18651-18660	cingulate	_	
92-151	18661-18667	cortex	_	
92-152	18667-18668	,	_	
92-153	18669-18676	insular	_	
92-154	18676-18677	,	_	
92-155	18678-18686	striatum	_	
92-156	18687-18690	and	_	
92-157	18691-18699	thalamus	_	
92-158	18700-18702	in	_	
92-159	18703-18711	patients	_	
92-160	18712-18716	with	_	
92-161	18717-18730	schizophrenia	_	
92-162	18731-18732	(	_	
92-163	18732-18735	Fig	_	
92-164	18735-18736	.	_	
92-165	18736-18737	 	_	
92-166	18737-18739	3c	_	
92-167	18740-18743	and	_	
92-168	18744-18745	d	_	
92-169	18746-18749	and	_	
92-170	18750-18755	Table	_	
92-171	18755-18756	 	_	
92-172	18756-18757	3	_	
92-173	18757-18758	)	_	
92-174	18758-18759	.	_	

#Text=Associations between the spatial distributions of gFCD and GMV
#Text=As previously mentioned, increased gFCD were primarily located in subcortical regions, including the basal ganglia and some components of the limbic system and SMA.
93-1	18761-18773	Associations	_	
93-2	18774-18781	between	_	
93-3	18782-18785	the	_	
93-4	18786-18793	spatial	_	
93-5	18794-18807	distributions	_	
93-6	18808-18810	of	_	
93-7	18811-18815	gFCD	_	
93-8	18816-18819	and	_	
93-9	18820-18823	GMV	_	
93-10	18824-18826	As	_	
93-11	18827-18837	previously	_	
93-12	18838-18847	mentioned	_	
93-13	18847-18848	,	_	
93-14	18849-18858	increased	_	
93-15	18859-18863	gFCD	_	
93-16	18864-18868	were	_	
93-17	18869-18878	primarily	_	
93-18	18879-18886	located	_	
93-19	18887-18889	in	_	
93-20	18890-18901	subcortical	_	
93-21	18902-18909	regions	_	
93-22	18909-18910	,	_	
93-23	18911-18920	including	_	
93-24	18921-18924	the	_	
93-25	18925-18930	basal	_	
93-26	18931-18938	ganglia	_	
93-27	18939-18942	and	_	
93-28	18943-18947	some	_	
93-29	18948-18958	components	_	
93-30	18959-18961	of	_	
93-31	18962-18965	the	_	
93-32	18966-18972	limbic	_	
93-33	18973-18979	system	_	
93-34	18980-18983	and	_	
93-35	18984-18987	SMA	_	
93-36	18987-18988	.	_	

#Text=Decreased gFCD were primarily located in the posterior cortical regions.
94-1	18989-18998	Decreased	_	
94-2	18999-19003	gFCD	_	
94-3	19004-19008	were	_	
94-4	19009-19018	primarily	_	
94-5	19019-19026	located	_	
94-6	19027-19029	in	_	
94-7	19030-19033	the	_	
94-8	19034-19043	posterior	_	
94-9	19044-19052	cortical	_	
94-10	19053-19060	regions	_	
94-11	19060-19061	.	_	

#Text=However, in this study, only decreased GMV was observed.
95-1	19062-19069	However	_	
95-2	19069-19070	,	_	
95-3	19071-19073	in	_	
95-4	19074-19078	this	_	
95-5	19079-19084	study	_	
95-6	19084-19085	,	_	
95-7	19086-19090	only	_	
95-8	19091-19100	decreased	_	
95-9	19101-19104	GMV	_	
95-10	19105-19108	was	_	
95-11	19109-19117	observed	_	
95-12	19117-19118	.	_	

#Text=Notably, the aberrant patterns of gFCD and GMV differ between regions.
96-1	19119-19126	Notably	_	
96-2	19126-19127	,	_	
96-3	19128-19131	the	_	
96-4	19132-19140	aberrant	_	
96-5	19141-19149	patterns	_	
96-6	19150-19152	of	_	
96-7	19153-19157	gFCD	_	
96-8	19158-19161	and	_	
96-9	19162-19165	GMV	_	
96-10	19166-19172	differ	_	
96-11	19173-19180	between	_	
96-12	19181-19188	regions	_	
96-13	19188-19189	.	_	

#Text=In the caudate, thalami and hippocampus complex (HPC), gFCD increased but GMV decreased, while in the posterior cortices, decreased gFCD accompanied decreased GMV.
97-1	19190-19192	In	_	
97-2	19193-19196	the	_	
97-3	19197-19204	caudate	_	
97-4	19204-19205	,	_	
97-5	19206-19213	thalami	_	
97-6	19214-19217	and	_	
97-7	19218-19229	hippocampus	_	
97-8	19230-19237	complex	_	
97-9	19238-19239	(	_	
97-10	19239-19242	HPC	_	
97-11	19242-19243	)	_	
97-12	19243-19244	,	_	
97-13	19245-19249	gFCD	_	
97-14	19250-19259	increased	_	
97-15	19260-19263	but	_	
97-16	19264-19267	GMV	_	
97-17	19268-19277	decreased	_	
97-18	19277-19278	,	_	
97-19	19279-19284	while	_	
97-20	19285-19287	in	_	
97-21	19288-19291	the	_	
97-22	19292-19301	posterior	_	
97-23	19302-19310	cortices	_	
97-24	19310-19311	,	_	
97-25	19312-19321	decreased	_	
97-26	19322-19326	gFCD	_	
97-27	19327-19338	accompanied	_	
97-28	19339-19348	decreased	_	
97-29	19349-19352	GMV	_	
97-30	19352-19353	.	_	

#Text=These findings indicated a complex association between gFCD aberrances and GMV changes in schizophrenia.
98-1	19354-19359	These	_	
98-2	19360-19368	findings	_	
98-3	19369-19378	indicated	_	
98-4	19379-19380	a	_	
98-5	19381-19388	complex	_	
98-6	19389-19400	association	_	
98-7	19401-19408	between	_	
98-8	19409-19413	gFCD	_	
98-9	19414-19424	aberrances	_	
98-10	19425-19428	and	_	
98-11	19429-19432	GMV	_	
98-12	19433-19440	changes	_	
98-13	19441-19443	in	_	
98-14	19444-19457	schizophrenia	_	
98-15	19457-19458	.	_	

#Text=To further investigate whether gFCD correlates with GMV changes, we also performed correlation.
99-1	19459-19461	To	_	
99-2	19462-19469	further	_	
99-3	19470-19481	investigate	_	
99-4	19482-19489	whether	_	
99-5	19490-19494	gFCD	_	
99-6	19495-19505	correlates	_	
99-7	19506-19510	with	_	
99-8	19511-19514	GMV	_	
99-9	19515-19522	changes	_	
99-10	19522-19523	,	_	
99-11	19524-19526	we	_	
99-12	19527-19531	also	_	
99-13	19532-19541	performed	_	
99-14	19542-19553	correlation	_	
99-15	19553-19554	.	_	

#Text=In multiple regions, we found that although gFCD and GMV were both affected, there was no statistical correlation between gFCD and GMV either in patients with schizophrenia patients or controls (Fig. 3).
100-1	19555-19557	In	_	
100-2	19558-19566	multiple	_	
100-3	19567-19574	regions	_	
100-4	19574-19575	,	_	
100-5	19576-19578	we	_	
100-6	19579-19584	found	_	
100-7	19585-19589	that	_	
100-8	19590-19598	although	_	
100-9	19599-19603	gFCD	_	
100-10	19604-19607	and	_	
100-11	19608-19611	GMV	_	
100-12	19612-19616	were	_	
100-13	19617-19621	both	_	
100-14	19622-19630	affected	_	
100-15	19630-19631	,	_	
100-16	19632-19637	there	_	
100-17	19638-19641	was	_	
100-18	19642-19644	no	_	
100-19	19645-19656	statistical	_	
100-20	19657-19668	correlation	_	
100-21	19669-19676	between	_	
100-22	19677-19681	gFCD	_	
100-23	19682-19685	and	_	
100-24	19686-19689	GMV	_	
100-25	19690-19696	either	_	
100-26	19697-19699	in	_	
100-27	19700-19708	patients	_	
100-28	19709-19713	with	_	
100-29	19714-19727	schizophrenia	_	
100-30	19728-19736	patients	_	
100-31	19737-19739	or	_	
100-32	19740-19748	controls	_	
100-33	19749-19750	(	_	
100-34	19750-19753	Fig	_	
100-35	19753-19754	.	_	
100-36	19754-19755	 	_	
100-37	19755-19756	3	_	
100-38	19756-19757	)	_	
100-39	19757-19758	.	_	

#Text=Association between gFCD/GMV and clinical variables
#Text=We did not find any statistical correlation between gFCD or GMV and antipsychotic dose, illness duration, or any PANSS scores (negative, positive, general psychopathology, or total scores).
101-1	19759-19770	Association	_	
101-2	19771-19778	between	_	
101-3	19779-19783	gFCD	_	
101-4	19783-19784	/	_	
101-5	19784-19787	GMV	_	
101-6	19788-19791	and	_	
101-7	19792-19800	clinical	_	
101-8	19801-19810	variables	_	
101-9	19811-19813	We	_	
101-10	19814-19817	did	_	
101-11	19818-19821	not	_	
101-12	19822-19826	find	_	
101-13	19827-19830	any	_	
101-14	19831-19842	statistical	_	
101-15	19843-19854	correlation	_	
101-16	19855-19862	between	_	
101-17	19863-19867	gFCD	_	
101-18	19868-19870	or	_	
101-19	19871-19874	GMV	_	
101-20	19875-19878	and	_	
101-21	19879-19892	antipsychotic	_	
101-22	19893-19897	dose	_	
101-23	19897-19898	,	_	
101-24	19899-19906	illness	_	
101-25	19907-19915	duration	_	
101-26	19915-19916	,	_	
101-27	19917-19919	or	_	
101-28	19920-19923	any	_	
101-29	19924-19929	PANSS	_	
101-30	19930-19936	scores	_	
101-31	19937-19938	(	_	
101-32	19938-19946	negative	_	
101-33	19946-19947	,	_	
101-34	19948-19956	positive	_	
101-35	19956-19957	,	_	
101-36	19958-19965	general	_	
101-37	19966-19981	psychopathology	_	
101-38	19981-19982	,	_	
101-39	19983-19985	or	_	
101-40	19986-19991	total	_	
101-41	19992-19998	scores	_	
101-42	19998-19999	)	_	
101-43	19999-20000	.	_	

#Text=Discussion
#Text=In this study, we first used voxel-wise graph theory to investigate the spatial distribution patterns of gFCD and GMV alterations in a relatively large schizophrenic patient data set.
102-1	20001-20011	Discussion	_	
102-2	20012-20014	In	_	
102-3	20015-20019	this	_	
102-4	20020-20025	study	_	
102-5	20025-20026	,	_	
102-6	20027-20029	we	_	
102-7	20030-20035	first	_	
102-8	20036-20040	used	_	
102-9	20041-20051	voxel-wise	_	
102-10	20052-20057	graph	_	
102-11	20058-20064	theory	_	
102-12	20065-20067	to	_	
102-13	20068-20079	investigate	_	
102-14	20080-20083	the	_	
102-15	20084-20091	spatial	_	
102-16	20092-20104	distribution	_	
102-17	20105-20113	patterns	_	
102-18	20114-20116	of	_	
102-19	20117-20121	gFCD	_	
102-20	20122-20125	and	_	
102-21	20126-20129	GMV	_	
102-22	20130-20141	alterations	_	
102-23	20142-20144	in	_	
102-24	20145-20146	a	_	
102-25	20147-20157	relatively	_	
102-26	20158-20163	large	_	
102-27	20164-20177	schizophrenic	_	
102-28	20178-20185	patient	_	
102-29	20186-20190	data	_	
102-30	20191-20194	set	_	
102-31	20194-20195	.	_	

#Text=We found that gFCD and GMV were both affected in some regions of the basal ganglia, thalami, limbic system, and posterior cortices, which are the key regions contributing to the pathology of schizophrenia as indicated by several lines of evidence.
103-1	20196-20198	We	_	
103-2	20199-20204	found	_	
103-3	20205-20209	that	_	
103-4	20210-20214	gFCD	_	
103-5	20215-20218	and	_	
103-6	20219-20222	GMV	_	
103-7	20223-20227	were	_	
103-8	20228-20232	both	_	
103-9	20233-20241	affected	_	
103-10	20242-20244	in	_	
103-11	20245-20249	some	_	
103-12	20250-20257	regions	_	
103-13	20258-20260	of	_	
103-14	20261-20264	the	_	
103-15	20265-20270	basal	_	
103-16	20271-20278	ganglia	_	
103-17	20278-20279	,	_	
103-18	20280-20287	thalami	_	
103-19	20287-20288	,	_	
103-20	20289-20295	limbic	_	
103-21	20296-20302	system	_	
103-22	20302-20303	,	_	
103-23	20304-20307	and	_	
103-24	20308-20317	posterior	_	
103-25	20318-20326	cortices	_	
103-26	20326-20327	,	_	
103-27	20328-20333	which	_	
103-28	20334-20337	are	_	
103-29	20338-20341	the	_	
103-30	20342-20345	key	_	
103-31	20346-20353	regions	_	
103-32	20354-20366	contributing	_	
103-33	20367-20369	to	_	
103-34	20370-20373	the	_	
103-35	20374-20383	pathology	_	
103-36	20384-20386	of	_	
103-37	20387-20400	schizophrenia	_	
103-38	20401-20403	as	_	
103-39	20404-20413	indicated	_	
103-40	20414-20416	by	_	
103-41	20417-20424	several	_	
103-42	20425-20430	lines	_	
103-43	20431-20433	of	_	
103-44	20434-20442	evidence	_	
103-45	20442-20443	.	_	

#Text=More importantly, in our findings, decreased gFCD was found in areas primarily located in the posterior cortical regions, while increased gFCD was observed primarily in areas located in the sub-cortical and limbic system regions.
104-1	20444-20448	More	_	
104-2	20449-20460	importantly	_	
104-3	20460-20461	,	_	
104-4	20462-20464	in	_	
104-5	20465-20468	our	_	
104-6	20469-20477	findings	_	
104-7	20477-20478	,	_	
104-8	20479-20488	decreased	_	
104-9	20489-20493	gFCD	_	
104-10	20494-20497	was	_	
104-11	20498-20503	found	_	
104-12	20504-20506	in	_	
104-13	20507-20512	areas	_	
104-14	20513-20522	primarily	_	
104-15	20523-20530	located	_	
104-16	20531-20533	in	_	
104-17	20534-20537	the	_	
104-18	20538-20547	posterior	_	
104-19	20548-20556	cortical	_	
104-20	20557-20564	regions	_	
104-21	20564-20565	,	_	
104-22	20566-20571	while	_	
104-23	20572-20581	increased	_	
104-24	20582-20586	gFCD	_	
104-25	20587-20590	was	_	
104-26	20591-20599	observed	_	
104-27	20600-20609	primarily	_	
104-28	20610-20612	in	_	
104-29	20613-20618	areas	_	
104-30	20619-20626	located	_	
104-31	20627-20629	in	_	
104-32	20630-20633	the	_	
104-33	20634-20646	sub-cortical	_	
104-34	20647-20650	and	_	
104-35	20651-20657	limbic	_	
104-36	20658-20664	system	_	
104-37	20665-20672	regions	_	
104-38	20672-20673	.	_	

#Text=However, only decreased GMV was found in either the cortical or sub-cortical regions in patients with schizophrenia.
105-1	20674-20681	However	_	
105-2	20681-20682	,	_	
105-3	20683-20687	only	_	
105-4	20688-20697	decreased	_	
105-5	20698-20701	GMV	_	
105-6	20702-20705	was	_	
105-7	20706-20711	found	_	
105-8	20712-20714	in	_	
105-9	20715-20721	either	_	
105-10	20722-20725	the	_	
105-11	20726-20734	cortical	_	
105-12	20735-20737	or	_	
105-13	20738-20750	sub-cortical	_	
105-14	20751-20758	regions	_	
105-15	20759-20761	in	_	
105-16	20762-20770	patients	_	
105-17	20771-20775	with	_	
105-18	20776-20789	schizophrenia	_	
105-19	20789-20790	.	_	

#Text=In our previous study, we demonstrated for the first time that the gFCD aberrant in schizophrenia, we found increased gFCD in the bilateral striatum and hippocampus and decreased rsFCD in the bilateral sensorimotor cortices and right occipital cortex.
106-1	20791-20793	In	_	
106-2	20794-20797	our	_	
106-3	20798-20806	previous	_	
106-4	20807-20812	study	_	
106-5	20812-20813	,	_	
106-6	20814-20816	we	_	
106-7	20817-20829	demonstrated	_	
106-8	20830-20833	for	_	
106-9	20834-20837	the	_	
106-10	20838-20843	first	_	
106-11	20844-20848	time	_	
106-12	20849-20853	that	_	
106-13	20854-20857	the	_	
106-14	20858-20862	gFCD	_	
106-15	20863-20871	aberrant	_	
106-16	20872-20874	in	_	
106-17	20875-20888	schizophrenia	_	
106-18	20888-20889	,	_	
106-19	20890-20892	we	_	
106-20	20893-20898	found	_	
106-21	20899-20908	increased	_	
106-22	20909-20913	gFCD	_	
106-23	20914-20916	in	_	
106-24	20917-20920	the	_	
106-25	20921-20930	bilateral	_	
106-26	20931-20939	striatum	_	
106-27	20940-20943	and	_	
106-28	20944-20955	hippocampus	_	
106-29	20956-20959	and	_	
106-30	20960-20969	decreased	_	
106-31	20970-20975	rsFCD	_	
106-32	20976-20978	in	_	
106-33	20979-20982	the	_	
106-34	20983-20992	bilateral	_	
106-35	20993-21005	sensorimotor	_	
106-36	21006-21014	cortices	_	
106-37	21015-21018	and	_	
106-38	21019-21024	right	_	
106-39	21025-21034	occipital	_	
106-40	21035-21041	cortex	_	
106-41	21041-21042	.	_	

#Text=Our previous findings added new evidence for supporting the hypothesis that schizophrenia is a connectivity disorder from the perspective of functional connectivity density.
107-1	21043-21046	Our	_	
107-2	21047-21055	previous	_	
107-3	21056-21064	findings	_	
107-4	21065-21070	added	_	
107-5	21071-21074	new	_	
107-6	21075-21083	evidence	_	
107-7	21084-21087	for	_	
107-8	21088-21098	supporting	_	
107-9	21099-21102	the	_	
107-10	21103-21113	hypothesis	_	
107-11	21114-21118	that	_	
107-12	21119-21132	schizophrenia	_	
107-13	21133-21135	is	_	
107-14	21136-21137	a	_	
107-15	21138-21150	connectivity	_	
107-16	21151-21159	disorder	_	
107-17	21160-21164	from	_	
107-18	21165-21168	the	_	
107-19	21169-21180	perspective	_	
107-20	21181-21183	of	_	
107-21	21184-21194	functional	_	
107-22	21195-21207	connectivity	_	
107-23	21208-21215	density	_	
107-24	21215-21216	.	_	

#Text=And our findings had been confirmed by the subsequent studies.
108-1	21217-21220	And	_	
108-2	21221-21224	our	_	
108-3	21225-21233	findings	_	
108-4	21234-21237	had	_	
108-5	21238-21242	been	_	
108-6	21243-21252	confirmed	_	
108-7	21253-21255	by	_	
108-8	21256-21259	the	_	
108-9	21260-21270	subsequent	_	
108-10	21271-21278	studies	_	
108-11	21278-21279	.	_	

#Text=As previously mentioned, some cortical regions (e.g., the frontal, temporal, and parietal lobes, cingulate gyrus, cuneus, and others), limbic system (e.g., hippocampus, parahippocampus, and thalami) and basal ganglia are key regions of functional connectivity and GMV aberrances in schizophrenia.
109-1	21280-21282	As	_	
109-2	21283-21293	previously	_	
109-3	21294-21303	mentioned	_	
109-4	21303-21304	,	_	
109-5	21305-21309	some	_	
109-6	21310-21318	cortical	_	
109-7	21319-21326	regions	_	
109-8	21327-21328	(	_	
109-9	21328-21331	e.g	_	
109-10	21331-21332	.	_	
109-11	21332-21333	,	_	
109-12	21334-21337	the	_	
109-13	21338-21345	frontal	_	
109-14	21345-21346	,	_	
109-15	21347-21355	temporal	_	
109-16	21355-21356	,	_	
109-17	21357-21360	and	_	
109-18	21361-21369	parietal	_	
109-19	21370-21375	lobes	_	
109-20	21375-21376	,	_	
109-21	21377-21386	cingulate	_	
109-22	21387-21392	gyrus	_	
109-23	21392-21393	,	_	
109-24	21394-21400	cuneus	_	
109-25	21400-21401	,	_	
109-26	21402-21405	and	_	
109-27	21406-21412	others	_	
109-28	21412-21413	)	_	
109-29	21413-21414	,	_	
109-30	21415-21421	limbic	_	
109-31	21422-21428	system	_	
109-32	21429-21430	(	_	
109-33	21430-21433	e.g	_	
109-34	21433-21434	.	_	
109-35	21434-21435	,	_	
109-36	21436-21447	hippocampus	_	
109-37	21447-21448	,	_	
109-38	21449-21464	parahippocampus	_	
109-39	21464-21465	,	_	
109-40	21466-21469	and	_	
109-41	21470-21477	thalami	_	
109-42	21477-21478	)	_	
109-43	21479-21482	and	_	
109-44	21483-21488	basal	_	
109-45	21489-21496	ganglia	_	
109-46	21497-21500	are	_	
109-47	21501-21504	key	_	
109-48	21505-21512	regions	_	
109-49	21513-21515	of	_	
109-50	21516-21526	functional	_	
109-51	21527-21539	connectivity	_	
109-52	21540-21543	and	_	
109-53	21544-21547	GMV	_	
109-54	21548-21558	aberrances	_	
109-55	21559-21561	in	_	
109-56	21562-21575	schizophrenia	_	
109-57	21575-21576	.	_	

#Text=In this study, gFCD and GMV were both affected in most of these regions, but the spatial distribution pattern of gFCD and GMV differed between regions.
110-1	21577-21579	In	_	
110-2	21580-21584	this	_	
110-3	21585-21590	study	_	
110-4	21590-21591	,	_	
110-5	21592-21596	gFCD	_	
110-6	21597-21600	and	_	
110-7	21601-21604	GMV	_	
110-8	21605-21609	were	_	
110-9	21610-21614	both	_	
110-10	21615-21623	affected	_	
110-11	21624-21626	in	_	
110-12	21627-21631	most	_	
110-13	21632-21634	of	_	
110-14	21635-21640	these	_	
110-15	21641-21648	regions	_	
110-16	21648-21649	,	_	
110-17	21650-21653	but	_	
110-18	21654-21657	the	_	
110-19	21658-21665	spatial	_	
110-20	21666-21678	distribution	_	
110-21	21679-21686	pattern	_	
110-22	21687-21689	of	_	
110-23	21690-21694	gFCD	_	
110-24	21695-21698	and	_	
110-25	21699-21702	GMV	_	
110-26	21703-21711	differed	_	
110-27	21712-21719	between	_	
110-28	21720-21727	regions	_	
110-29	21727-21728	.	_	

#Text=With the exception of the SMA, in the cortical regions, gFCD and GMV consistently decreased.
111-1	21729-21733	With	_	
111-2	21734-21737	the	_	
111-3	21738-21747	exception	_	
111-4	21748-21750	of	_	
111-5	21751-21754	the	_	
111-6	21755-21758	SMA	_	
111-7	21758-21759	,	_	
111-8	21760-21762	in	_	
111-9	21763-21766	the	_	
111-10	21767-21775	cortical	_	
111-11	21776-21783	regions	_	
111-12	21783-21784	,	_	
111-13	21785-21789	gFCD	_	
111-14	21790-21793	and	_	
111-15	21794-21797	GMV	_	
111-16	21798-21810	consistently	_	
111-17	21811-21820	decreased	_	
111-18	21820-21821	.	_	

#Text=However, in the sub-cortical regions, the alterations in gFCD and GMV contrasted, with increased gFCD and decreased GMV simultaneously observed in these regions.
112-1	21822-21829	However	_	
112-2	21829-21830	,	_	
112-3	21831-21833	in	_	
112-4	21834-21837	the	_	
112-5	21838-21850	sub-cortical	_	
112-6	21851-21858	regions	_	
112-7	21858-21859	,	_	
112-8	21860-21863	the	_	
112-9	21864-21875	alterations	_	
112-10	21876-21878	in	_	
112-11	21879-21883	gFCD	_	
112-12	21884-21887	and	_	
112-13	21888-21891	GMV	_	
112-14	21892-21902	contrasted	_	
112-15	21902-21903	,	_	
112-16	21904-21908	with	_	
112-17	21909-21918	increased	_	
112-18	21919-21923	gFCD	_	
112-19	21924-21927	and	_	
112-20	21928-21937	decreased	_	
112-21	21938-21941	GMV	_	
112-22	21942-21956	simultaneously	_	
112-23	21957-21965	observed	_	
112-24	21966-21968	in	_	
112-25	21969-21974	these	_	
112-26	21975-21982	regions	_	
112-27	21982-21983	.	_	

#Text=Our results suggest that the association between anatomical changes and functional activity aberrances is complex and undefined.
113-1	21984-21987	Our	_	
113-2	21988-21995	results	_	
113-3	21996-22003	suggest	_	
113-4	22004-22008	that	_	
113-5	22009-22012	the	_	
113-6	22013-22024	association	_	
113-7	22025-22032	between	_	
113-8	22033-22043	anatomical	_	
113-9	22044-22051	changes	_	
113-10	22052-22055	and	_	
113-11	22056-22066	functional	_	
113-12	22067-22075	activity	_	
113-13	22076-22086	aberrances	_	
113-14	22087-22089	is	_	
113-15	22090-22097	complex	_	
113-16	22098-22101	and	_	
113-17	22102-22111	undefined	_	
113-18	22111-22112	.	_	

#Text=Previous studies also demonstrated that structural deficits do not have a straightforward relationship with functional abnormalities.
114-1	22113-22121	Previous	_	
114-2	22122-22129	studies	_	
114-3	22130-22134	also	_	
114-4	22135-22147	demonstrated	_	
114-5	22148-22152	that	_	
114-6	22153-22163	structural	_	
114-7	22164-22172	deficits	_	
114-8	22173-22175	do	_	
114-9	22176-22179	not	_	
114-10	22180-22184	have	_	
114-11	22185-22186	a	_	
114-12	22187-22202	straightforward	_	
114-13	22203-22215	relationship	_	
114-14	22216-22220	with	_	
114-15	22221-22231	functional	_	
114-16	22232-22245	abnormalities	_	
114-17	22245-22246	.	_	

#Text=Thus, longitudinal studies aiming to pinpoint the onset of connectivity abnormalities as schizophrenia develops will help clarify the nature of the associations between the structural deficits and functional connectivity alterations in schizophrenia.
115-1	22247-22251	Thus	_	
115-2	22251-22252	,	_	
115-3	22253-22265	longitudinal	_	
115-4	22266-22273	studies	_	
115-5	22274-22280	aiming	_	
115-6	22281-22283	to	_	
115-7	22284-22292	pinpoint	_	
115-8	22293-22296	the	_	
115-9	22297-22302	onset	_	
115-10	22303-22305	of	_	
115-11	22306-22318	connectivity	_	
115-12	22319-22332	abnormalities	_	
115-13	22333-22335	as	_	
115-14	22336-22349	schizophrenia	_	
115-15	22350-22358	develops	_	
115-16	22359-22363	will	_	
115-17	22364-22368	help	_	
115-18	22369-22376	clarify	_	
115-19	22377-22380	the	_	
115-20	22381-22387	nature	_	
115-21	22388-22390	of	_	
115-22	22391-22394	the	_	
115-23	22395-22407	associations	_	
115-24	22408-22415	between	_	
115-25	22416-22419	the	_	
115-26	22420-22430	structural	_	
115-27	22431-22439	deficits	_	
115-28	22440-22443	and	_	
115-29	22444-22454	functional	_	
115-30	22455-22467	connectivity	_	
115-31	22468-22479	alterations	_	
115-32	22480-22482	in	_	
115-33	22483-22496	schizophrenia	_	
115-34	22496-22497	.	_	

#Text=In this study, we did not found a correlation between aberrant of gFCD/GMV and antipsychotic dose, illness duration, and symptom severity, this finding is consistent with previous studies. and suggest that illness duration, symptom severity, and antipsychotic dose are not linearly related to brain functional or structural abrreant.
116-1	22498-22500	In	_	
116-2	22501-22505	this	_	
116-3	22506-22511	study	_	
116-4	22511-22512	,	_	
116-5	22513-22515	we	_	
116-6	22516-22519	did	_	
116-7	22520-22523	not	_	
116-8	22524-22529	found	_	
116-9	22530-22531	a	_	
116-10	22532-22543	correlation	_	
116-11	22544-22551	between	_	
116-12	22552-22560	aberrant	_	
116-13	22561-22563	of	_	
116-14	22564-22568	gFCD	_	
116-15	22568-22569	/	_	
116-16	22569-22572	GMV	_	
116-17	22573-22576	and	_	
116-18	22577-22590	antipsychotic	_	
116-19	22591-22595	dose	_	
116-20	22595-22596	,	_	
116-21	22597-22604	illness	_	
116-22	22605-22613	duration	_	
116-23	22613-22614	,	_	
116-24	22615-22618	and	_	
116-25	22619-22626	symptom	_	
116-26	22627-22635	severity	_	
116-27	22635-22636	,	_	
116-28	22637-22641	this	_	
116-29	22642-22649	finding	_	
116-30	22650-22652	is	_	
116-31	22653-22663	consistent	_	
116-32	22664-22668	with	_	
116-33	22669-22677	previous	_	
116-34	22678-22685	studies	_	
116-35	22685-22686	.	_	
116-36	22687-22690	and	_	
116-37	22691-22698	suggest	_	
116-38	22699-22703	that	_	
116-39	22704-22711	illness	_	
116-40	22712-22720	duration	_	
116-41	22720-22721	,	_	
116-42	22722-22729	symptom	_	
116-43	22730-22738	severity	_	
116-44	22738-22739	,	_	
116-45	22740-22743	and	_	
116-46	22744-22757	antipsychotic	_	
116-47	22758-22762	dose	_	
116-48	22763-22766	are	_	
116-49	22767-22770	not	_	
116-50	22771-22779	linearly	_	
116-51	22780-22787	related	_	
116-52	22788-22790	to	_	
116-53	22791-22796	brain	_	
116-54	22797-22807	functional	_	
116-55	22808-22810	or	_	
116-56	22811-22821	structural	_	
116-57	22822-22830	abrreant	_	
116-58	22830-22831	.	_	

#Text=Our findings suggested that aberrant gFCD and GMV maybe an independent trait characteristic of schizophrenia.
117-1	22832-22835	Our	_	
117-2	22836-22844	findings	_	
117-3	22845-22854	suggested	_	
117-4	22855-22859	that	_	
117-5	22860-22868	aberrant	_	
117-6	22869-22873	gFCD	_	
117-7	22874-22877	and	_	
117-8	22878-22881	GMV	_	
117-9	22882-22887	maybe	_	
117-10	22888-22890	an	_	
117-11	22891-22902	independent	_	
117-12	22903-22908	trait	_	
117-13	22909-22923	characteristic	_	
117-14	22924-22926	of	_	
117-15	22927-22940	schizophrenia	_	
117-16	22940-22941	.	_	

#Text=Our findings also support the hypothesis that BOLD signal alterations may better track the presence of psychosis rather than its severity or duration, and is not linearly related to the antipsychotic dose.
118-1	22942-22945	Our	_	
118-2	22946-22954	findings	_	
118-3	22955-22959	also	_	
118-4	22960-22967	support	_	
118-5	22968-22971	the	_	
118-6	22972-22982	hypothesis	_	
118-7	22983-22987	that	_	
118-8	22988-22992	BOLD	_	
118-9	22993-22999	signal	_	
118-10	23000-23011	alterations	_	
118-11	23012-23015	may	_	
118-12	23016-23022	better	_	
118-13	23023-23028	track	_	
118-14	23029-23032	the	_	
118-15	23033-23041	presence	_	
118-16	23042-23044	of	_	
118-17	23045-23054	psychosis	_	
118-18	23055-23061	rather	_	
118-19	23062-23066	than	_	
118-20	23067-23070	its	_	
118-21	23071-23079	severity	_	
118-22	23080-23082	or	_	
118-23	23083-23091	duration	_	
118-24	23091-23092	,	_	
118-25	23093-23096	and	_	
118-26	23097-23099	is	_	
118-27	23100-23103	not	_	
118-28	23104-23112	linearly	_	
118-29	23113-23120	related	_	
118-30	23121-23123	to	_	
118-31	23124-23127	the	_	
118-32	23128-23141	antipsychotic	_	
118-33	23142-23146	dose	_	
118-34	23146-23147	.	_	

#Text=Conclusion
#Text=This study provides new evidence of aberrant gFCD and decreased GMV in multiple brain regions contributing to the pathology of schizophrenia in a relatively large sample of patients with schizophrenia.
119-1	23148-23158	Conclusion	_	
119-2	23159-23163	This	_	
119-3	23164-23169	study	_	
119-4	23170-23178	provides	_	
119-5	23179-23182	new	_	
119-6	23183-23191	evidence	_	
119-7	23192-23194	of	_	
119-8	23195-23203	aberrant	_	
119-9	23204-23208	gFCD	_	
119-10	23209-23212	and	_	
119-11	23213-23222	decreased	_	
119-12	23223-23226	GMV	_	
119-13	23227-23229	in	_	
119-14	23230-23238	multiple	_	
119-15	23239-23244	brain	_	
119-16	23245-23252	regions	_	
119-17	23253-23265	contributing	_	
119-18	23266-23268	to	_	
119-19	23269-23272	the	_	
119-20	23273-23282	pathology	_	
119-21	23283-23285	of	_	
119-22	23286-23299	schizophrenia	_	
119-23	23300-23302	in	_	
119-24	23303-23304	a	_	
119-25	23305-23315	relatively	_	
119-26	23316-23321	large	_	
119-27	23322-23328	sample	_	
119-28	23329-23331	of	_	
119-29	23332-23340	patients	_	
119-30	23341-23345	with	_	
119-31	23346-23359	schizophrenia	_	
119-32	23359-23360	.	_	

#Text=More importantly, we revealed that gFCD and GMV are jointly affected in multiple regions, but that their spatial distribution patterns in the intergroup difference maps were dissociated.
120-1	23361-23365	More	_	
120-2	23366-23377	importantly	_	
120-3	23377-23378	,	_	
120-4	23379-23381	we	_	
120-5	23382-23390	revealed	_	
120-6	23391-23395	that	_	
120-7	23396-23400	gFCD	_	
120-8	23401-23404	and	_	
120-9	23405-23408	GMV	_	
120-10	23409-23412	are	_	
120-11	23413-23420	jointly	_	
120-12	23421-23429	affected	_	
120-13	23430-23432	in	_	
120-14	23433-23441	multiple	_	
120-15	23442-23449	regions	_	
120-16	23449-23450	,	_	
120-17	23451-23454	but	_	
120-18	23455-23459	that	_	
120-19	23460-23465	their	_	
120-20	23466-23473	spatial	_	
120-21	23474-23486	distribution	_	
120-22	23487-23495	patterns	_	
120-23	23496-23498	in	_	
120-24	23499-23502	the	_	
120-25	23503-23513	intergroup	_	
120-26	23514-23524	difference	_	
120-27	23525-23529	maps	_	
120-28	23530-23534	were	_	
120-29	23535-23546	dissociated	_	
120-30	23546-23547	.	_	

#Text=These findings suggest that structural and functional alterations probably contribute independently to the neurobiology of schizophrenia.
121-1	23548-23553	These	_	
121-2	23554-23562	findings	_	
121-3	23563-23570	suggest	_	
121-4	23571-23575	that	_	
121-5	23576-23586	structural	_	
121-6	23587-23590	and	_	
121-7	23591-23601	functional	_	
121-8	23602-23613	alterations	_	
121-9	23614-23622	probably	_	
121-10	23623-23633	contribute	_	
121-11	23634-23647	independently	_	
121-12	23648-23650	to	_	
121-13	23651-23654	the	_	
121-14	23655-23667	neurobiology	_	
121-15	23668-23670	of	_	
121-16	23671-23684	schizophrenia	_	
121-17	23684-23685	.	_	

#Text=However, the nature of the associations between the structural deficits and functional alterations needs clarification using longitudinal studies to pinpoint the onset of connectivity abnormalities as schizophrenia develops.
122-1	23686-23693	However	_	
122-2	23693-23694	,	_	
122-3	23695-23698	the	_	
122-4	23699-23705	nature	_	
122-5	23706-23708	of	_	
122-6	23709-23712	the	_	
122-7	23713-23725	associations	_	
122-8	23726-23733	between	_	
122-9	23734-23737	the	_	
122-10	23738-23748	structural	_	
122-11	23749-23757	deficits	_	
122-12	23758-23761	and	_	
122-13	23762-23772	functional	_	
122-14	23773-23784	alterations	_	
122-15	23785-23790	needs	_	
122-16	23791-23804	clarification	_	
122-17	23805-23810	using	_	
122-18	23811-23823	longitudinal	_	
122-19	23824-23831	studies	_	
122-20	23832-23834	to	_	
122-21	23835-23843	pinpoint	_	
122-22	23844-23847	the	_	
122-23	23848-23853	onset	_	
122-24	23854-23856	of	_	
122-25	23857-23869	connectivity	_	
122-26	23870-23883	abnormalities	_	
122-27	23884-23886	as	_	
122-28	23887-23900	schizophrenia	_	
122-29	23901-23909	develops	_	
122-30	23909-23910	.	_	

#Text=Abbreviations
#Text=FCD
#Text=Functional connectivity density
#Text=gFCD
#Text=Global functional connectivity density
#Text=GMV
#Text=Gray matter volume
#Text=PANSS
#Text=Positive and negative syndrome scale
#Text=SCID
#Text=Structural clinical interview for DSM-IV
#Text=References
#Text=Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia
#Text=Focal gray matter density changes in schizophrenia
#Text=Multivariate voxel-based morphometry successfully differentiates schizophrenia patients from healthy controls
#Text=Morphometric brain abnormalities in schizophrenia in a population-based sample: relationship to duration of illness
#Text=Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine
#Text=Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms
#Text=Antipsychotic drug effects on brain morphology in first-episode psychosis
#Text=Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia
#Text=Dysconnectivity in schizophrenia: where are we now?
123-1	23911-23924	Abbreviations	_	
123-2	23925-23928	FCD	_	
123-3	23929-23939	Functional	_	
123-4	23940-23952	connectivity	_	
123-5	23953-23960	density	_	
123-6	23961-23965	gFCD	_	
123-7	23966-23972	Global	_	
123-8	23973-23983	functional	_	
123-9	23984-23996	connectivity	_	
123-10	23997-24004	density	_	
123-11	24005-24008	GMV	_	
123-12	24009-24013	Gray	_	
123-13	24014-24020	matter	_	
123-14	24021-24027	volume	_	
123-15	24028-24033	PANSS	_	
123-16	24034-24042	Positive	_	
123-17	24043-24046	and	_	
123-18	24047-24055	negative	_	
123-19	24056-24064	syndrome	_	
123-20	24065-24070	scale	_	
123-21	24071-24075	SCID	_	
123-22	24076-24086	Structural	_	
123-23	24087-24095	clinical	_	
123-24	24096-24105	interview	_	
123-25	24106-24109	for	_	
123-26	24110-24116	DSM-IV	_	
123-27	24117-24127	References	_	
123-28	24128-24135	Mapping	_	
123-29	24136-24146	adolescent	_	
123-30	24147-24152	brain	_	
123-31	24153-24159	change	_	
123-32	24160-24167	reveals	_	
123-33	24168-24175	dynamic	_	
123-34	24176-24180	wave	_	
123-35	24181-24183	of	_	
123-36	24184-24195	accelerated	_	
123-37	24196-24200	gray	_	
123-38	24201-24207	matter	_	
123-39	24208-24212	loss	_	
123-40	24213-24215	in	_	
123-41	24216-24220	very	_	
123-42	24221-24232	early-onset	_	
123-43	24233-24246	schizophrenia	_	
123-44	24247-24252	Focal	_	
123-45	24253-24257	gray	_	
123-46	24258-24264	matter	_	
123-47	24265-24272	density	_	
123-48	24273-24280	changes	_	
123-49	24281-24283	in	_	
123-50	24284-24297	schizophrenia	_	
123-51	24298-24310	Multivariate	_	
123-52	24311-24322	voxel-based	_	
123-53	24323-24334	morphometry	_	
123-54	24335-24347	successfully	_	
123-55	24348-24362	differentiates	_	
123-56	24363-24376	schizophrenia	_	
123-57	24377-24385	patients	_	
123-58	24386-24390	from	_	
123-59	24391-24398	healthy	_	
123-60	24399-24407	controls	_	
123-61	24408-24420	Morphometric	_	
123-62	24421-24426	brain	_	
123-63	24427-24440	abnormalities	_	
123-64	24441-24443	in	_	
123-65	24444-24457	schizophrenia	_	
123-66	24458-24460	in	_	
123-67	24461-24462	a	_	
123-68	24463-24479	population-based	_	
123-69	24480-24486	sample	_	
123-70	24486-24487	:	_	
123-71	24488-24500	relationship	_	
123-72	24501-24503	to	_	
123-73	24504-24512	duration	_	
123-74	24513-24515	of	_	
123-75	24516-24523	illness	_	
123-76	24524-24531	Caudate	_	
123-77	24532-24538	nuclei	_	
123-78	24539-24546	volumes	_	
123-79	24547-24549	in	_	
123-80	24550-24563	schizophrenic	_	
123-81	24564-24572	patients	_	
123-82	24573-24580	treated	_	
123-83	24581-24585	with	_	
123-84	24586-24593	typical	_	
123-85	24594-24608	antipsychotics	_	
123-86	24609-24611	or	_	
123-87	24612-24621	clozapine	_	
123-88	24622-24633	Progressive	_	
123-89	24634-24642	striatal	_	
123-90	24643-24646	and	_	
123-91	24647-24658	hippocampal	_	
123-92	24659-24665	volume	_	
123-93	24666-24670	loss	_	
123-94	24671-24673	in	_	
123-95	24674-24683	initially	_	
123-96	24684-24703	antipsychotic-naive	_	
123-97	24703-24704	,	_	
123-98	24705-24718	first-episode	_	
123-99	24719-24732	schizophrenia	_	
123-100	24733-24741	patients	_	
123-101	24742-24749	treated	_	
123-102	24750-24754	with	_	
123-103	24755-24765	quetiapine	_	
123-104	24765-24766	:	_	
123-105	24767-24779	relationship	_	
123-106	24780-24782	to	_	
123-107	24783-24787	dose	_	
123-108	24788-24791	and	_	
123-109	24792-24800	symptoms	_	
123-110	24801-24814	Antipsychotic	_	
123-111	24815-24819	drug	_	
123-112	24820-24827	effects	_	
123-113	24828-24830	on	_	
123-114	24831-24836	brain	_	
123-115	24837-24847	morphology	_	
123-116	24848-24850	in	_	
123-117	24851-24864	first-episode	_	
123-118	24865-24874	psychosis	_	
123-119	24875-24882	Reduced	_	
123-120	24883-24888	basal	_	
123-121	24889-24896	ganglia	_	
123-122	24897-24904	volumes	_	
123-123	24905-24910	after	_	
123-124	24911-24920	switching	_	
123-125	24921-24923	to	_	
123-126	24924-24934	olanzapine	_	
123-127	24935-24937	in	_	
123-128	24938-24949	chronically	_	
123-129	24950-24957	treated	_	
123-130	24958-24966	patients	_	
123-131	24967-24971	with	_	
123-132	24972-24985	schizophrenia	_	
123-133	24986-25001	Dysconnectivity	_	
123-134	25002-25004	in	_	
123-135	25005-25018	schizophrenia	_	
123-136	25018-25019	:	_	
123-137	25020-25025	where	_	
123-138	25026-25029	are	_	
123-139	25030-25032	we	_	
123-140	25033-25036	now	_	
123-141	25036-25037	?	_	

#Text=Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
#Text=Schizophrenia: a disconnection syndrome
#Text=Functional disintegration in paranoid schizophrenia using resting-state fMRI
#Text=Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
#Text=Altered cerebral blood flow covariance network in schizophrenia
#Text=Frequency dependent alterations in regional homogeneity of baseline brain activity in schizophrenia
#Text=A multi-site resting state fMRI study on the amplitude of low frequency fluctuations in schizophrenia
#Text=Anatomical and functional brain abnormalities in drug-naive first-episode schizophrenia
#Text=Aberrant intrinsic brain activity and cognitive deficit in first-episode treatment-naive patients with schizophrenia
#Text=Amplitude of low-frequency oscillations in schizophrenia: a resting state fMRI study
#Text=Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis
#Text=Voxel-based morphometry--the methods
#Text=Classification of Different Therapeutic Responses of Major Depressive Disorder with Multivariate Pattern Analysis Method Based on Structural MR Scans
#Text=Functional connectivity density mapping
#Text=Functional connectivity hubs in the human brain
#Text=Association between functional connectivity hubs and brain networks
#Text=Mapping small-world properties through development in the human brain: disruption in schizophrenia
#Text=Functional connectivity density alterations in schizophrenia.Front
#Text=Disrupted cortical hubs in functional brain networks in social anxiety disorder
#Text=A selective review of cerebral abnormalities in patients with first-episode schizophrenia before and after treatment
#Text=Dissociation of anatomical and functional alterations of the default-mode network in first-episode, drug-naive schizophrenia
#Text=Brainnetome-wide association studies in schizophrenia: the advances and future
#Text=Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia
#Text=Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Abnormal amplitude low-frequency oscillations in medication-naive, first-episode patients with major depressive disorder: A resting-state fMRI study
#Text=Multivariate classification of social anxiety disorder using whole brain functional connectivity
#Text=Liu Feng, Wang Yifeng, Li Meiling, Wang Wenqin, Li Rong, Zhang Zhiqiang, Lu Guangming, Chen Huafu.
124-1	25038-25051	Dysconnection	_	
124-2	25052-25054	in	_	
124-3	25055-25068	schizophrenia	_	
124-4	25068-25069	:	_	
124-5	25070-25074	from	_	
124-6	25075-25083	abnormal	_	
124-7	25084-25092	synaptic	_	
124-8	25093-25103	plasticity	_	
124-9	25104-25106	to	_	
124-10	25107-25115	failures	_	
124-11	25116-25118	of	_	
124-12	25119-25134	self-monitoring	_	
124-13	25135-25148	Schizophrenia	_	
124-14	25148-25149	:	_	
124-15	25150-25151	a	_	
124-16	25152-25165	disconnection	_	
124-17	25166-25174	syndrome	_	
124-18	25175-25185	Functional	_	
124-19	25186-25200	disintegration	_	
124-20	25201-25203	in	_	
124-21	25204-25212	paranoid	_	
124-22	25213-25226	schizophrenia	_	
124-23	25227-25232	using	_	
124-24	25233-25246	resting-state	_	
124-25	25247-25251	fMRI	_	
124-26	25252-25265	Hyperactivity	_	
124-27	25266-25269	and	_	
124-28	25270-25287	hyperconnectivity	_	
124-29	25288-25290	of	_	
124-30	25291-25294	the	_	
124-31	25295-25302	default	_	
124-32	25303-25310	network	_	
124-33	25311-25313	in	_	
124-34	25314-25327	schizophrenia	_	
124-35	25328-25331	and	_	
124-36	25332-25334	in	_	
124-37	25335-25347	first-degree	_	
124-38	25348-25357	relatives	_	
124-39	25358-25360	of	_	
124-40	25361-25368	persons	_	
124-41	25369-25373	with	_	
124-42	25374-25387	schizophrenia	_	
124-43	25388-25395	Altered	_	
124-44	25396-25404	cerebral	_	
124-45	25405-25410	blood	_	
124-46	25411-25415	flow	_	
124-47	25416-25426	covariance	_	
124-48	25427-25434	network	_	
124-49	25435-25437	in	_	
124-50	25438-25451	schizophrenia	_	
124-51	25452-25461	Frequency	_	
124-52	25462-25471	dependent	_	
124-53	25472-25483	alterations	_	
124-54	25484-25486	in	_	
124-55	25487-25495	regional	_	
124-56	25496-25507	homogeneity	_	
124-57	25508-25510	of	_	
124-58	25511-25519	baseline	_	
124-59	25520-25525	brain	_	
124-60	25526-25534	activity	_	
124-61	25535-25537	in	_	
124-62	25538-25551	schizophrenia	_	
124-63	25552-25553	A	_	
124-64	25554-25564	multi-site	_	
124-65	25565-25572	resting	_	
124-66	25573-25578	state	_	
124-67	25579-25583	fMRI	_	
124-68	25584-25589	study	_	
124-69	25590-25592	on	_	
124-70	25593-25596	the	_	
124-71	25597-25606	amplitude	_	
124-72	25607-25609	of	_	
124-73	25610-25613	low	_	
124-74	25614-25623	frequency	_	
124-75	25624-25636	fluctuations	_	
124-76	25637-25639	in	_	
124-77	25640-25653	schizophrenia	_	
124-78	25654-25664	Anatomical	_	
124-79	25665-25668	and	_	
124-80	25669-25679	functional	_	
124-81	25680-25685	brain	_	
124-82	25686-25699	abnormalities	_	
124-83	25700-25702	in	_	
124-84	25703-25713	drug-naive	_	
124-85	25714-25727	first-episode	_	
124-86	25728-25741	schizophrenia	_	
124-87	25742-25750	Aberrant	_	
124-88	25751-25760	intrinsic	_	
124-89	25761-25766	brain	_	
124-90	25767-25775	activity	_	
124-91	25776-25779	and	_	
124-92	25780-25789	cognitive	_	
124-93	25790-25797	deficit	_	
124-94	25798-25800	in	_	
124-95	25801-25814	first-episode	_	
124-96	25815-25830	treatment-naive	_	
124-97	25831-25839	patients	_	
124-98	25840-25844	with	_	
124-99	25845-25858	schizophrenia	_	
124-100	25859-25868	Amplitude	_	
124-101	25869-25871	of	_	
124-102	25872-25885	low-frequency	_	
124-103	25886-25898	oscillations	_	
124-104	25899-25901	in	_	
124-105	25902-25915	schizophrenia	_	
124-106	25915-25916	:	_	
124-107	25917-25918	a	_	
124-108	25919-25926	resting	_	
124-109	25927-25932	state	_	
124-110	25933-25937	fMRI	_	
124-111	25938-25943	study	_	
124-112	25944-25955	Subcortical	_	
124-113	25956-25966	modulation	_	
124-114	25967-25969	of	_	
124-115	25970-25981	attentional	_	
124-116	25982-25989	control	_	
124-117	25990-25992	by	_	
124-118	25993-26010	second-generation	_	
124-119	26011-26025	antipsychotics	_	
124-120	26026-26028	in	_	
124-121	26029-26042	first-episode	_	
124-122	26043-26052	psychosis	_	
124-123	26053-26064	Voxel-based	_	
124-124	26065-26076	morphometry	_	
124-125	26076-26077	-	_	
124-126	26077-26078	-	_	
124-127	26078-26081	the	_	
124-128	26082-26089	methods	_	
124-129	26090-26104	Classification	_	
124-130	26105-26107	of	_	
124-131	26108-26117	Different	_	
124-132	26118-26129	Therapeutic	_	
124-133	26130-26139	Responses	_	
124-134	26140-26142	of	_	
124-135	26143-26148	Major	_	
124-136	26149-26159	Depressive	_	
124-137	26160-26168	Disorder	_	
124-138	26169-26173	with	_	
124-139	26174-26186	Multivariate	_	
124-140	26187-26194	Pattern	_	
124-141	26195-26203	Analysis	_	
124-142	26204-26210	Method	_	
124-143	26211-26216	Based	_	
124-144	26217-26219	on	_	
124-145	26220-26230	Structural	_	
124-146	26231-26233	MR	_	
124-147	26234-26239	Scans	_	
124-148	26240-26250	Functional	_	
124-149	26251-26263	connectivity	_	
124-150	26264-26271	density	_	
124-151	26272-26279	mapping	_	
124-152	26280-26290	Functional	_	
124-153	26291-26303	connectivity	_	
124-154	26304-26308	hubs	_	
124-155	26309-26311	in	_	
124-156	26312-26315	the	_	
124-157	26316-26321	human	_	
124-158	26322-26327	brain	_	
124-159	26328-26339	Association	_	
124-160	26340-26347	between	_	
124-161	26348-26358	functional	_	
124-162	26359-26371	connectivity	_	
124-163	26372-26376	hubs	_	
124-164	26377-26380	and	_	
124-165	26381-26386	brain	_	
124-166	26387-26395	networks	_	
124-167	26396-26403	Mapping	_	
124-168	26404-26415	small-world	_	
124-169	26416-26426	properties	_	
124-170	26427-26434	through	_	
124-171	26435-26446	development	_	
124-172	26447-26449	in	_	
124-173	26450-26453	the	_	
124-174	26454-26459	human	_	
124-175	26460-26465	brain	_	
124-176	26465-26466	:	_	
124-177	26467-26477	disruption	_	
124-178	26478-26480	in	_	
124-179	26481-26494	schizophrenia	_	
124-180	26495-26505	Functional	_	
124-181	26506-26518	connectivity	_	
124-182	26519-26526	density	_	
124-183	26527-26538	alterations	_	
124-184	26539-26541	in	_	
124-185	26542-26561	schizophrenia.Front	_	
124-186	26562-26571	Disrupted	_	
124-187	26572-26580	cortical	_	
124-188	26581-26585	hubs	_	
124-189	26586-26588	in	_	
124-190	26589-26599	functional	_	
124-191	26600-26605	brain	_	
124-192	26606-26614	networks	_	
124-193	26615-26617	in	_	
124-194	26618-26624	social	_	
124-195	26625-26632	anxiety	_	
124-196	26633-26641	disorder	_	
124-197	26642-26643	A	_	
124-198	26644-26653	selective	_	
124-199	26654-26660	review	_	
124-200	26661-26663	of	_	
124-201	26664-26672	cerebral	_	
124-202	26673-26686	abnormalities	_	
124-203	26687-26689	in	_	
124-204	26690-26698	patients	_	
124-205	26699-26703	with	_	
124-206	26704-26717	first-episode	_	
124-207	26718-26731	schizophrenia	_	
124-208	26732-26738	before	_	
124-209	26739-26742	and	_	
124-210	26743-26748	after	_	
124-211	26749-26758	treatment	_	
124-212	26759-26771	Dissociation	_	
124-213	26772-26774	of	_	
124-214	26775-26785	anatomical	_	
124-215	26786-26789	and	_	
124-216	26790-26800	functional	_	
124-217	26801-26812	alterations	_	
124-218	26813-26815	of	_	
124-219	26816-26819	the	_	
124-220	26820-26832	default-mode	_	
124-221	26833-26840	network	_	
124-222	26841-26843	in	_	
124-223	26844-26857	first-episode	_	
124-224	26857-26858	,	_	
124-225	26859-26869	drug-naive	_	
124-226	26870-26883	schizophrenia	_	
124-227	26884-26900	Brainnetome-wide	_	
124-228	26901-26912	association	_	
124-229	26913-26920	studies	_	
124-230	26921-26923	in	_	
124-231	26924-26937	schizophrenia	_	
124-232	26937-26938	:	_	
124-233	26939-26942	the	_	
124-234	26943-26951	advances	_	
124-235	26952-26955	and	_	
124-236	26956-26962	future	_	
124-237	26963-26973	Systematic	_	
124-238	26974-26985	meta-review	_	
124-239	26986-26989	and	_	
124-240	26990-26997	quality	_	
124-241	26998-27008	assessment	_	
124-242	27009-27011	of	_	
124-243	27012-27015	the	_	
124-244	27016-27026	structural	_	
124-245	27027-27032	brain	_	
124-246	27033-27044	alterations	_	
124-247	27045-27047	in	_	
124-248	27048-27061	schizophrenia	_	
124-249	27062-27079	Neuropathological	_	
124-250	27079-27080	,	_	
124-251	27081-27093	neurogenetic	_	
124-252	27094-27097	and	_	
124-253	27098-27110	neuroimaging	_	
124-254	27111-27119	evidence	_	
124-255	27120-27123	for	_	
124-256	27124-27129	white	_	
124-257	27130-27136	matter	_	
124-258	27137-27146	pathology	_	
124-259	27147-27149	in	_	
124-260	27150-27163	schizophrenia	_	
124-261	27164-27172	Spurious	_	
124-262	27173-27176	but	_	
124-263	27177-27187	systematic	_	
124-264	27188-27200	correlations	_	
124-265	27201-27203	in	_	
124-266	27204-27214	functional	_	
124-267	27215-27227	connectivity	_	
124-268	27228-27231	MRI	_	
124-269	27232-27240	networks	_	
124-270	27241-27246	arise	_	
124-271	27247-27251	from	_	
124-272	27252-27259	subject	_	
124-273	27260-27266	motion	_	
124-274	27267-27275	Abnormal	_	
124-275	27276-27285	amplitude	_	
124-276	27286-27299	low-frequency	_	
124-277	27300-27312	oscillations	_	
124-278	27313-27315	in	_	
124-279	27316-27332	medication-naive	_	
124-280	27332-27333	,	_	
124-281	27334-27347	first-episode	_	
124-282	27348-27356	patients	_	
124-283	27357-27361	with	_	
124-284	27362-27367	major	_	
124-285	27368-27378	depressive	_	
124-286	27379-27387	disorder	_	
124-287	27387-27388	:	_	
124-288	27389-27390	A	_	
124-289	27391-27404	resting-state	_	
124-290	27405-27409	fMRI	_	
124-291	27410-27415	study	_	
124-292	27416-27428	Multivariate	_	
124-293	27429-27443	classification	_	
124-294	27444-27446	of	_	
124-295	27447-27453	social	_	
124-296	27454-27461	anxiety	_	
124-297	27462-27470	disorder	_	
124-298	27471-27476	using	_	
124-299	27477-27482	whole	_	
124-300	27483-27488	brain	_	
124-301	27489-27499	functional	_	
124-302	27500-27512	connectivity	_	
124-303	27513-27516	Liu	_	
124-304	27517-27521	Feng	_	
124-305	27521-27522	,	_	
124-306	27523-27527	Wang	_	
124-307	27528-27534	Yifeng	_	
124-308	27534-27535	,	_	
124-309	27536-27538	Li	_	
124-310	27539-27546	Meiling	_	
124-311	27546-27547	,	_	
124-312	27548-27552	Wang	_	
124-313	27553-27559	Wenqin	_	
124-314	27559-27560	,	_	
124-315	27561-27563	Li	_	
124-316	27564-27568	Rong	_	
124-317	27568-27569	,	_	
124-318	27570-27575	Zhang	_	
124-319	27576-27584	Zhiqiang	_	
124-320	27584-27585	,	_	
124-321	27586-27588	Lu	_	
124-322	27589-27598	Guangming	_	
124-323	27598-27599	,	_	
124-324	27600-27604	Chen	_	
124-325	27605-27610	Huafu	_	
124-326	27610-27611	.	_	

#Text=Dynamic Functional Network Connectivity in Idiopathic Generalized Epilepsy with Generalized Tonic–Clonic Seizure.
125-1	27612-27619	Dynamic	_	
125-2	27620-27630	Functional	_	
125-3	27631-27638	Network	_	
125-4	27639-27651	Connectivity	_	
125-5	27652-27654	in	_	
125-6	27655-27665	Idiopathic	_	
125-7	27666-27677	Generalized	_	
125-8	27678-27686	Epilepsy	_	
125-9	27687-27691	with	_	
125-10	27692-27703	Generalized	_	
125-11	27704-27716	Tonic–Clonic	_	
125-12	27717-27724	Seizure	_	
125-13	27724-27725	.	_	

#Text=Hum Brain Mapp 2017, in press, doi:10.1002/hbm.23430.
126-1	27726-27729	Hum	_	
126-2	27730-27735	Brain	_	
126-3	27736-27740	Mapp	_	
126-4	27741-27745	2017	_	
126-5	27745-27746	,	_	
126-6	27747-27749	in	_	
126-7	27750-27755	press	_	
126-8	27755-27756	,	_	
126-9	27757-27760	doi	_	
126-10	27760-27761	:	_	
126-11	27761-27768	10.1002	_	
126-12	27768-27769	/	_	
126-13	27769-27772	hbm	_	
126-14	27772-27778	.23430	_	
126-15	27778-27779	.	_	

#Text=Shokri-Kojori E, Tomasi D, Wiers CE, Wang GJ, Volkow ND.
127-1	27780-27793	Shokri-Kojori	_	
127-2	27794-27795	E	_	
127-3	27795-27796	,	_	
127-4	27797-27803	Tomasi	_	
127-5	27804-27805	D	_	
127-6	27805-27806	,	_	
127-7	27807-27812	Wiers	_	
127-8	27813-27815	CE	_	
127-9	27815-27816	,	_	
127-10	27817-27821	Wang	_	
127-11	27822-27824	GJ	_	
127-12	27824-27825	,	_	
127-13	27826-27832	Volkow	_	
127-14	27833-27835	ND	_	
127-15	27835-27836	.	_	

#Text=Alcohol affects brain functional connectivity and its coupling with behavior: greater effects in male heavy drinkers.
128-1	27837-27844	Alcohol	_	
128-2	27845-27852	affects	_	
128-3	27853-27858	brain	_	
128-4	27859-27869	functional	_	
128-5	27870-27882	connectivity	_	
128-6	27883-27886	and	_	
128-7	27887-27890	its	_	
128-8	27891-27899	coupling	_	
128-9	27900-27904	with	_	
128-10	27905-27913	behavior	_	
128-11	27913-27914	:	_	
128-12	27915-27922	greater	_	
128-13	27923-27930	effects	_	
128-14	27931-27933	in	_	
128-15	27934-27938	male	_	
128-16	27939-27944	heavy	_	
128-17	27945-27953	drinkers	_	
128-18	27953-27954	.	_	

#Text=Mol Psychiatry. 2016;29 [Epub ahead of print].
129-1	27955-27958	Mol	_	
129-2	27959-27969	Psychiatry	_	
129-3	27969-27970	.	_	
129-4	27971-27975	2016	_	
129-5	27975-27976	;	_	
129-6	27976-27978	29	_	
129-7	27979-27980	[	_	
129-8	27980-27984	Epub	_	
129-9	27985-27990	ahead	_	
129-10	27991-27993	of	_	
129-11	27994-27999	print	_	
129-12	27999-28000	]	_	
129-13	28000-28001	.	_	

#Text=High-resolution functional connectivity density: hub locations, sensitivity, specificity, reproducibility, and reliability
#Text=Temporal changes in local functional connectivity density reflect the temporal variability of the amplitude of low frequency fluctuations in gray matter
#Text=Functional disconnection between the visual cortex and the sensorimotor cortex suggests a potential mechanism for self-disorder in schizophrenia
#Text=Functional connectivity dynamics: modeling the switching behavior of the resting state
#Text=DISC1 Ser704Cys impacts thalamic-prefrontal connectivity
#Text=Schizophrenia, neuroimaging and connectomics
#Text=Emerging evidence of connectomic abnormalities in schizophrenia
#Text=Thalamocortical dysconnectivity in schizophrenia
130-1	28002-28017	High-resolution	_	
130-2	28018-28028	functional	_	
130-3	28029-28041	connectivity	_	
130-4	28042-28049	density	_	
130-5	28049-28050	:	_	
130-6	28051-28054	hub	_	
130-7	28055-28064	locations	_	
130-8	28064-28065	,	_	
130-9	28066-28077	sensitivity	_	
130-10	28077-28078	,	_	
130-11	28079-28090	specificity	_	
130-12	28090-28091	,	_	
130-13	28092-28107	reproducibility	_	
130-14	28107-28108	,	_	
130-15	28109-28112	and	_	
130-16	28113-28124	reliability	_	
130-17	28125-28133	Temporal	_	
130-18	28134-28141	changes	_	
130-19	28142-28144	in	_	
130-20	28145-28150	local	_	
130-21	28151-28161	functional	_	
130-22	28162-28174	connectivity	_	
130-23	28175-28182	density	_	
130-24	28183-28190	reflect	_	
130-25	28191-28194	the	_	
130-26	28195-28203	temporal	_	
130-27	28204-28215	variability	_	
130-28	28216-28218	of	_	
130-29	28219-28222	the	_	
130-30	28223-28232	amplitude	_	
130-31	28233-28235	of	_	
130-32	28236-28239	low	_	
130-33	28240-28249	frequency	_	
130-34	28250-28262	fluctuations	_	
130-35	28263-28265	in	_	
130-36	28266-28270	gray	_	
130-37	28271-28277	matter	_	
130-38	28278-28288	Functional	_	
130-39	28289-28302	disconnection	_	
130-40	28303-28310	between	_	
130-41	28311-28314	the	_	
130-42	28315-28321	visual	_	
130-43	28322-28328	cortex	_	
130-44	28329-28332	and	_	
130-45	28333-28336	the	_	
130-46	28337-28349	sensorimotor	_	
130-47	28350-28356	cortex	_	
130-48	28357-28365	suggests	_	
130-49	28366-28367	a	_	
130-50	28368-28377	potential	_	
130-51	28378-28387	mechanism	_	
130-52	28388-28391	for	_	
130-53	28392-28405	self-disorder	_	
130-54	28406-28408	in	_	
130-55	28409-28422	schizophrenia	_	
130-56	28423-28433	Functional	_	
130-57	28434-28446	connectivity	_	
130-58	28447-28455	dynamics	_	
130-59	28455-28456	:	_	
130-60	28457-28465	modeling	_	
130-61	28466-28469	the	_	
130-62	28470-28479	switching	_	
130-63	28480-28488	behavior	_	
130-64	28489-28491	of	_	
130-65	28492-28495	the	_	
130-66	28496-28503	resting	_	
130-67	28504-28509	state	_	
130-68	28510-28515	DISC1	_	
130-69	28516-28525	Ser704Cys	_	
130-70	28526-28533	impacts	_	
130-71	28534-28553	thalamic-prefrontal	_	
130-72	28554-28566	connectivity	_	
130-73	28567-28580	Schizophrenia	_	
130-74	28580-28581	,	_	
130-75	28582-28594	neuroimaging	_	
130-76	28595-28598	and	_	
130-77	28599-28611	connectomics	_	
130-78	28612-28620	Emerging	_	
130-79	28621-28629	evidence	_	
130-80	28630-28632	of	_	
130-81	28633-28644	connectomic	_	
130-82	28645-28658	abnormalities	_	
130-83	28659-28661	in	_	
130-84	28662-28675	schizophrenia	_	
130-85	28676-28691	Thalamocortical	_	
130-86	28692-28707	dysconnectivity	_	
130-87	28708-28710	in	_	
130-88	28711-28724	schizophrenia	_	
